State-of-the-Art Ammonia Reforming Technology from Amogy Verified by ABS

(HOUSTON) ABS has issued New Technology Qualification (NTQ) for an innovative ammonia-to-electrical power system from Amogy. The Amogy ammonia-to-electrical power system splits, or “cracks,” liquid ammonia into its base elements of hydrogen and nitrogen, funneling the hydrogen into a fuel cell generating high-performance power. The technology represents a sustainable, clean energy solution tailored for industries such as maritime shipping and power generation. ABS assessed the integrated reactor system transforming ammonia into hydrogen resulting in pure hydrogen gas that can be utilized for fuel cells. “Amogy’s new technology is another example of the rapid development of innovation around alternative fuels for maritime use. Cracking ammonia to produce hydrogen for fuel cells is one that has the potential to accelerate the energy transition in the maritime industry, supporting global decarbonization goals,” said Patrick Ryan, ABS Senior Vice President and Chief Technology Officer. “We are honored to receive this Technology Qualification letter from ABS,” said Seonghoon Woo, CEO at Amogy. “This achievement marks a significant milestone on our path toward broader industry adoption of our technology, highlighting the safety, viability, and maturity of our ammonia-powered solution. We are excited to further collaborate with ABS as we advance through the new technology qualification process.” ABS NTQ services offer guidance and certification on early adoption and efficient implementation of new technologies – demonstrating level of maturity – and that potential risks have been systematically reviewed. Learn more here . ABS is leading the maritime industry in comprehensive decarbonization and sustainability solutions. Learn more here . Photo Caption (L to R): While attending the International Partnering Forum (IPF) in New Orleans, Anastasija Kuprijanova, Amogy Director of Maritime Business Development, and Keegan Plaskon, ABS Director of Business Development, met for a presentation of the ABS NTQ Statement of Maturity.

Jumpgate AB resolves to carry out a rights issue of ca 28.6 MSEK, fully covered by subscription commitments, subscription intents and guarantee commitments

The Board of Directors of Jumpgate AB (”Jumpgate” or the ”Company”) has today, 9 May 2024, pursuant to an authorization from an extraordinary general meeting on 27 June 2023, resolved to carry out a new issue of shares raising gross proceeds of ca 28.6 MSEK with preferential rights for existing shareholders (the ”Rights Issue”). Furthermore, the Board of Directors intends to propose an extraordinary general meeting, planned for the end of May 2024, to resolve to carry out a directed conversion issue of shares of ca 7.2 MSEK (the ”Conversion Issue”). Notice of the extraordinary general meeting will be announced through a separate press release. Because of the Rights Issue, the Board of Directors has resolved to change the announcement date for the Company´s quarterly report for the first quarter of 2024 to 22 May 2024. Jumpgate has received a strong interest for participation in the Rights Issue, with subscription commitments and subscription intents comprising 6.5 MSEK in total, equivalent of ca 22.7 percent of the Rights Issue, has been received from current investors with significant industry experience, including Jimmy Jönsson, Susana Meza Graham (through company), F1 Funds AS, F2 Funds AS and Infundo AB (controlled by Viktor Modigh and Marcus Jacobs). Furthermore, a number of current shareholders and external investors, including Jimmy Jönsson, Alexander Ivarsson, F2 Funds AS and Nowo Global Fund, have made guarantee commitments comprising ca 22.1 MSEK, equivalent of ca 77.3 percent of the Rights Issue. The guarantee commitments consist of a bottom guarantee of 16.4 MSEK, equivalent of ca 57.3 percent of the Rights Issue (the ”Bottom Guarantee”), and a top guarantee of ca 5.7 MSEK, equivalent of ca 20 percent of the Rights Issue (”Top Guarantee”). The Rights Issue is thus covered 100 percent by subscription commitments, subscription intents and guarantee commitments. Summary of the Rights Issue · A person who on the record date of 20 May 2024 is registered as a shareholder of Jumpgate in the share register kept by Euroclear Sweden AB will receive one (1) subscription right for each share held in the Company. One hundred (100) subscription rights entitle the holder to subscribe for ninety-nine (99) new issued shares. · The Rights Issue entails an issue of maximum 476 464 626 shares at a subscription price of 0.06 SEK per share. · Fully subscribed, the Rights Issue will contribute ca 28.6 MSEK to Jumpgate before transaction costs. · The final day of trading in the Company´s shares with the right to receive subscription rights is 16 May 2024, and the first day of trading in the Company´s shares without the right to receive subscription rights is 17 May 2024. · The subscription period for the Rights Issue runs from 22 May 2024 until and including 5 June 2024. · Subscription rights that are not exercised during the subscription period become invalid and lose their value. Trading in subscription rights takes place on NGM Nordic SME during the period 22 May 2024 to 31 May 2024. · Trading in paid and subscribed shares (”BTA”) takes place on NGM Nordic SME during the period from 22 May 2024 until the Rights Issue has been registered with Bolagsverket, expected to happen around week 26, 2024. · The Rights Issue is 100 percent covered by subscription commitments, subscription intents, and guarantee commitments. Subscription commitments and subscription intents comprise ca 6.5 MSEK, equivalent of ca 22.7 percent of the Rights Issue, The Bottom Guarantee comprises ca 16.4 MSEK, equivalent of ca 57.3 percent of the Rights Issue, and the Top Guarantee comprises ca 5.7 MSEK, equivalent of 20 percent of the Rights Issue. · Full terms and conditions for the Rights Issue as well as other information about the Company will be described in the Information Memorandum, which is expected to be published around 22 May 2024 (the ”Memorandum”). · Current shareholders in the Company who do not subscribe for shares in the Rights Issue will get their shareholding diluted. Fully subscribed, the Rights Issue provides a dilution equivalent of ca 50 percent, based on the number of shares in the Company after the Rights Issue. Background and reason for the Rights Issue Jumpgate is an independent gaming group active on the global market. The Company develops and publishes its own games as well as developing games for external companies (so called work-for-hire). With the goal to create a leading group of developing studios with first class partners, the Company has during the last year continued its strategic shift from mobile games to an increased focus on premium PC and console games with a good return profile. As part of the new strategy, Jumpgate announced on 5 April 2023 the acquisition of the German company Nukklear GmbH. The acquisition of Nukklear has so far contributed a significant annualised increase of revenue of approximately 5 MEUR, expected to increase with additional game projects expected during 2024. As an additional part of the new strategy, Jumpgate announced on 3 May 2024 that the portfolio company Tivola Games divests its free-to-play mobile game portfolio for ca 8.2 MSEK, with proceeds mainly to be used to amortize debt and strengthen the balance sheet of the Company.    With the purpose of financing the final part of the consideration for the acquisition of Nukklear, to enable the amortization of a part of the Company´s interest bearing debt and to strengthen the Company´s Working Capital the Board of Directors have resolved to carry out the Rights Issue. The proceeds from the Rights Issue in combination with the sale of the free-to-play mobile game portfolio is partly intended to be used for reducing the Company´s debt level significantly and the interest bearing debt is calculated to amount to 11 MSEK following the Rights Issue. Fully subscribed, the Rights Issue contributes ca 28.6 MSEK in gross proceeds to Jumpgate, before transaction costs estimated at ca 1.2 MSEK. The Company mainly intends to use the expected net proceeds of ca 27.4 MSEK for the following purposes given in order of priority, with an estimated allocation of the proceeds given in percent: · Additional consideration for the acquisition of Nukklear (52 %) · Amortization of interest-bearing debt (10 %) · Working Capital such as development, sales, marketing and production (38 %) Harald Riegler, CEO for Jumpgate ”We see continued great potential in our strategy to build a stable base of revenue based on co-development and work-for-hire, where we add significant upside at successful launches in a number of game projects. Despite very challenging market conditions during 2023 and the beginning of 2024, we have, in addition to cost effectivization, also focused on developing the Company and positioning ourselves for a turnaround in the market. Now, we have already signed several important agreements during 2024 and we see positive tendences signalling a normalization of the gaming market. We are proud and happy over the support from current as well as incoming owners. Through the financing, we are able to fulfil our obligations related to the Nukklear acquisition and strengthen our balance sheet significantly. With reduced financial risk, lowered capital costs and additional working capital, we are in a considerably better position to execute the Company´s growth plan. We are hoping that as many as possible of our current shareholders participate in the share issue and look forward to follow up with additional important steps forward in the coming months”. Subscription commitments, subscription intents and guarantee commitments Jumpgate has received subscription commitments, subscription intents and guarantee commitments comprising ca 28.6 MSEK in total, equivalent of 100 percent of the Rights Issue. Subscription commitments and subscription intents comprising ca 6.5 MSEK have been received from a number of current shareholders. Additionally, a number of current shareholders and external investors have contributed with guarantee commitments comprising ca 22.1 MSEK, equivalent of ca 77.3 percent of the Rights Issue. The guarantee commitments consist of the Bottom Guarantee comprising ca 16.4 MSEK, equivalent of ca 57.3 percent of the Rights Issue, as well as the Top Guarantee comprising ca 5.7 MSEK, equivalent of 20 percent of the Rights Issue. Through the Bottom Guarantee, provided that subscription takes place for an amount at least corresponding to the subscription commitments and subscription intents, 80 percent of the proceeds of the Rights Issue is secured. Furthermore, a number of current shareholders and external investors have entered into agreements for a Top Guarantee comprising ca 5.7 MSEK, equivalent of 20 percent of the Rights Issue. Through the Top Guarantee, provided that subscription takes place for an amount at least corresponding to the subscription commitments, subscription intents and the Bottom Guarantee, 100 percent of the proceeds of the Rights Issue is secured. For the Bottom Guarantee, there is a guarantee fee of fourteen (14) percent of the guaranteed amount paid in new issued shares in the Company. For the Top Guarantee, there is a guarantee fee of twenty (20) percent of the guaranteed amount paid in new issued shares in the Company. No fee is attributable to subscription commitments or subscription intents. Neither the subscription commitments, subscription intents or guarantee commitments are secured by bank guarantee, escrow funds, pledging or similar arrangements. Preliminary time plan for the Rights Issue 16 May 2024 Last trading day including the right to receive subscription rights17 May 2024 First trading day excluding the right to receive subscription rights20 May 2024 Record date for participation in the Rights Issue22 May – 31 May 2024 Trading in subscription rights at NGM Nordic SME22 May – 5 June 2024 Subscription period22 May 2024 – until registration at Trading with paid and subscribedthe Swedish Companies Registration shares ”BTA” will take place at NGMOffice Nordic SME from 22 May until the Rights Issue has been registered at the Swedish Companies Registration Office, expected to take place around week 26 2024.10 June 2024 Publication of preliminary outcome of the Rights Issue Background and reason for the Conversion Issue To secure the Company´s need for liquidity and to continue the development of current game projects, Jumpgate has ahead of the Rights Issue, taken up bridge loans with total claims comprising 3.6 MSEK from Infundo AB (controlled by chairman Viktor Modigh and director Marcus Jacobs), director Andras Vajlok and Jimmy Jönsson. Furthermore, Jumpgate has debt amounting to ca 3.6 MSEK including consideration to the sellers of Funatics, due variable remuneration to executives in Jumpgate and due board fees. Because of the above, the board of directors of Jumpgate intends to, with the purpose of additionally strengthening the Company´s balance sheet, propose an extraordinary general meeting, planned for the end of May 2024, to resolve on a directed conversion issue of shares equivalent of ca 7.2 MSEK. The Conversion Issue comprises 120 478 888 shares at a subscription price of 0,06 SEK per share, equivalent to the subscription price in the Rights Issue. The subscription price in the Conversion Issue has been negotiated with the subscribers at arms´ length terms and the board of directors consider it to be in accordance with market conditions.   The Board of Directors reason for deviating from the shareholders´ preferential rights Ahead of the Conversion Issue, the Company´s board of directors have done an analysis of different financing options and as part of this have contemplated carefully the possibility to raise additional capital through the Rights Issue. The conclusion of this analysis is that the Conversion Issue, objectively, is the most advantageous alternative for the Company and its shareholders. The reasons for this, and why the deviation from the shareholders´ preferential rights, is the following: i. A Rights Issue for an amount over 2.5 MEUR had required a prospectus to be issued, adding additional complexity, demanded more time from the Company and provided increased costs. Furthermore, such a rights issue would not have been possible to carry out until after the summer, providing a risk that a negative share price development during the process, especially given the current volatile and challenging market conditions.ii. Repaying the debt with the liquidity from the Rights Issue would have hindered the Company from executing the activities fully that the proceeds are allocated to.iii. The main part of the Conversion Issue is subscribed for by directors, executives, larger shareholders and persons engaged with Jumpgate. A conversion of the debt will further strengthen their long-term engagement with the Company and increase their incentive while strengthening the shareholder base further. Based on the above, the board of directors is of the opinion that, after weighing the alternatives, the Conversion Issue is the most advantageous option for further strengthening the Company´s balance sheet while retaining the most value in Jumpgate and being the most beneficial for the Company´s shareholders. Extraordinary general meeting Some of the person eligible for subscribing in the Conversion Issue are subject to chapter 16 of the Swedish Companies Act (the so called Leo-legislation) meaning that the Conversion Issue is subject to approval by a general meeting with a majority of at least nine tenths of the given votes as well as the shares represented at the general meeting. Notice to the extraordinary general meeting will be announced through a separate press release. Change of share capital, number of shares and dilution The Rights Issue entails that the number of shares in Jumpgate will increase by a maximum of 476 464 626 shares, from the current 481 277 445 to 957 742 071 and the share capital increases by a maximum of SEK 13 121 726,0632033 from the current SEK 13 254 269,99 to SEK 26 375 996,0532033. For current shareholders who don´t participate in the Rights Issue, this means that, provided that the Rights Issue is fully subscribed, there is a dilution effect of ca 49.7 percent of the votes and share capital in the Company. Provided that the Rights Issue is fully subscribed and the Conversion Issue is carried out, the number of shares in Jumpgate will increase with 120 478 888 shares, from 957 742 071 shares to 1 078 220 959 shares and the share capital will increase with 3 317 960,82745363 SEK, from 26 375 996,0532033 to 29 693 956,8806569 SEK. The Conversion Issue entails, provided that the Rights Issue is fully subscribed, an additional dilution effect of ca 12.6 percent of the votes and share capital in the Company. Changed announcement date for the Company´s quarterly report for the first quarter of 2024 Because of the coming Rights Issue, the Board of Directors of Jumpgate have resolved to announce the quarterly report for the first quarter of 2024 on 22 May 2024 instead of 23 May 2024 as previously communicated. Advisors Nordicap Corporate Finance AB (www.nordicap.se) is a financial advisor to Jumpgate in connection with the Rights Issue and the Conversion Issue. Aqurat Fondkommission AB (www.aqurat.se) is issue institute. Important Information Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Jumpgate in any jurisdiction, either from Jumpgate or from anyone else. This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 ("the Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. An information memorandum will be prepared by the Company and published on the Company's website. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation. Forward-looking statements This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or NGM Nordic SME´s rules for issuers. Potential investors should not put undue faith in the forward looking information herein, and potential investors are strongly encouraged to read the parts of the information memorandum including a more detailed description of factors that may impact the Company´s activities and the market where the Company operates. For additional information Harald Riegler CEO, Jumpgate AB Phone: +46 (0)705 - 54 73 33 E-mail: harald@jumpgategames.se About the Company Jumpgate AB is an independent group of game development companies founded in 2011, comprising five game studios: Nukklear (Hannover), Tivola Games (Hamburg), gameXcite (Hamburg), Funatics (Düsseldorf) and Tableflip Entertainment (Visby). The group develops and publishes its own games as well as developing games and other digital products for external companies. The companies in the group have established collaborations with strong industry partners and exciting product portfolios with large potential. The group is engaged in the global market, distributing games on a worldwide basis and has a large international network. For more information: www.jumpgategames.se This information is such information Jumpgate AB (publ) is obliged to make public in accordance with the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-09 19:30 CEST.

Autoliv Declares Quarterly Dividend

To holders of record on the close of business on Thursday, May 23, the dividend will be payable on: · Wednesday, June 12, 2024, to holders of Autoliv common stock listed on the New York Stock Exchange (Common Stock); and · Thursday, June 13, 2024, to holders of Autoliv Swedish Depository Receipts listed on Nasdaq Stockholm (SDRs). The ex-date will be Wednesday, May 22, 2024, for holders of Common Stock and SDRs. Inquiries:  Investors & Analysts: Anders Trapp, Tel +46 (0)8 587 206 71Investors & Analysts: Henrik Kaar, Tel +46 (0)8 587 206 14 Media: Gabriella Etemad, Tel +46 (0)8 587 206 02 This information is information that Autoliv, Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 05:20 p.m. (ET) on May 9, 2024. About Autoliv  Autoliv, Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world as well as mobility safety solutions, such as pedestrian protection, connected safety services and safety solutions for riders of powered two wheelers. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2023, our products saved 35,000 lives and reduced more than 450,000 injuries. Our  70,000 associates in 25 countries are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. We drive innovation, research, and development at our 14 technical centers, with their 20 test tracks. Sales in 2023 amounted to US $ 10.5 billion. For more information go to www.autoliv.com. Safe Harbor Statement This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including general economic conditions and fluctuations in the global automotive market. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

Seabras Secures New Contracts for 6 PLSVs, Bolstering Backlog by $1.8 Billion

Hamilton, Bermuda, May 10, 2024 - Paratus Energy Services Ltd. (“Paratus” or the “Company”) is pleased to announce that certain wholly owned entities of Seabras Sapura Holding GmbH and Seabras Sapura Participações S.A. (collectively, “Seabras” or “JV”) have successfully been awarded contracts for its full fleet of six multi-purpose pipe-laying support vessels (“PLSV”) as part of a competitive Petrobras tender process. This achievement is set to bolster Seabras’ backlog by approximately $1.8 billion. Following the award of these contracts, Seabras’ backlog stands at approximately $2.1 billion[1]. The contract awards represent a meaningful improvement to dayrates, reflecting the positive industry momentum and the growing demand for PLSVs in Brazil. This achievement is a testament to Seabras’ unwavering commitment to operational excellence, safety, and customer satisfaction. Since commencing operations in 2014, the vessels have maintained an average technical utilization of approximately 98%. "We are delighted to announce this significant milestone" said Rogerio Salbego, CEO of Seabras. "This success demonstrates the strength of our fleet, our strong long-term relationship with Petrobras, and our track record of delivering value to our clients.” The contracts, each with a three-year term, will commence on different mobilization dates between May 2024 and June 2025 according to the current contract schedule for each of the PLSVs, with the longest dated contract going through 2028. The awards will provide longer-term revenue visibility, and will continue to support Seabras’ strong cash flow and enable the JV to continue returning capital to its long-term shareholders. “We are pleased with the outcome of Petrobras’ recent tender and are confident that this will pave the way for ongoing success”, said Robert Jensen, Executive Director of Paratus. “We remain confident that Seabras’ long-term cash flow visibility will further strengthen the overall financial flexibility of Paratus and its ability to return cash to its shareholders.” About Seabras Seabras is a leading subsea services company, with a fleet of six multi-purpose PLSVs with capabilities for subsea engineering, installation, and other services. All of Seabras’ vessels are currently operating under contract in Brazil. Seabras is headquartered in downtown Rio de Janeiro, with additional support offices in Rio das Ostras and Vienna. Seabras is a 50/50 joint venture between Paratus and Sapura Energy Berhad, a global integrated energy services and solutions provider. For further information about Seabras visit www.sapura.com.br/en About Paratus Paratus Energy Services Ltd. is an investment holding company of a group of leading energy services companies. The Paratus Group is primarily comprised of its ownership of SeaMex and a 50/50 JV interest in Seabras. SeaMex is an offshore drilling company with a fleet of five high-specification jack-up rigs working under contracts in Mexico. Seabras is a leading subsea services company, with a fleet of six multi-purposes PLSVs under contracts in Brazil. In addition, Paratus is the largest shareholder in Archer Ltd, a global oil services company, listed on the Oslo Stock Exchange. For further information visit www.paratus-energy.com For further information, please contact: Hawthorn Advisors      paratus@hawthornadvisors.com          +44 (0)203 7454960 Paratus -- Forward-Looking Statements This release includes forward-looking statements. Such statements are generally not historical in nature, and specifically include statements about the Company’s and / or the Paratus Group’s (including any member of the Paratus Group) plans, strategies, business prospects, changes and trends in its business and the markets in which it operates. These statements are based on management’s current plans, expectations, assumptions and beliefs concerning future events impacting the Company and / or the Paratus Group and therefore involve a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, which speak only as of the date of this news release. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, management’s reliance on third party professional advisors and operational partners and providers, the Company’s ability (or inability) to control the operations and governance of certain joint ventures and investment vehicles, oil and energy services and solutions market conditions, subsea services market conditions, and offshore drilling market conditions, the cost and timing of capital projects, the performance of operating assets, delay in payment or disputes with customers, the  ability to successfully employ operating assets, procure or have access to financing, ability to comply with loan covenants, liquidity and adequacy of cash flow from operations of its subsidiaries and investments, fluctuations in the international price of oil or alternative energy sources, international financial, commodity or currency market conditions, including, in each case, the impact of pandemics and related economic conditions, changes in governmental regulations, including in connection with pandemics, that affect the Paratus Group, increased competition in any of the industries in which the Paratus Group operates, the impact of global economic conditions and global health threats, including in connection with pandemics, our ability to maintain relationships with suppliers, customers, joint venture partners, professional advisors, operational partners and providers, employees and other third parties and our ability to maintain adequate financing to support our business plans, factors related to the offshore drilling, subsea services, and oil and energy services and solutions markets, the impact of global economic conditions, our liquidity and the adequacy of cash flows for our obligations, including the ability of the Company’s subsidiaries and investment vehicles to pay dividends, political and other uncertainties, the concentration of our revenues in certain geographical jurisdictions, limitations on insurance coverage, our ability to attract and retain skilled personnel on commercially reasonable terms, the level of expected capital expenditures, our expected financing of such capital expenditures, and the timing and cost of completion of capital projects, fluctuations in interest rates or exchange rates and currency devaluations relating to foreign or U.S. monetary policy, tax matters, changes in tax laws, treaties and regulations, tax assessments and liabilities for tax issues, legal and regulatory matters, customs and environmental matters, the potential impacts on our business resulting from climate-change or greenhouse gas legislation or regulations, the impact on our business from climate-change related physical changes or changes in weather patterns, and the occurrence of cybersecurity incidents, attacks or other breaches to our information technology systems, including our rig operating systems. Consequently, no forward-looking statement can be guaranteed. Neither the Company nor any member of the Paratus Group undertakes any obligation to update any forward-looking statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict all of these factors. Further, we cannot assess the impact of each such factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. [1] Reflected pro forma as of March 31, 2024

Skanska builds new building at Rice University in Houston, Texas, USA, for USD 48M, about SEK 500M

The 10,400 square meter building for the Jones Graduate School of Business at Rice University will consist of new classrooms, including two 120-seat classrooms, two 65-seat classrooms, two hybrid technology classrooms, Ph.D. student office space, and various breakout and meeting spaces. It will also include a large event space, courtyard enclosure and cafe, along with the rework of the West Quad landscape. Construction is slated to begin in May 2024 and expected to reach completion in February 2026.

Fortaco sells its heavy project business in Hungary

Fortaco has signed an agreement to sell its heavy project business in Jászberény, Hungary to Cyclus GmbH (50%) and Ask US Management s.r.o. (50%). The current Managing Director, Mr. Uwe Sträter to continue as Managing Director and one of the owners. The transaction is part of the strategic evaluation of Fortaco’s marine, energy, and heavy project businesses announced on 28 February 2024. The business offerings include the whole steel fabrication process from ready-to-weld parts, welded, machined, and painted high-strength steel structures for the heavy off-highway equipment industries like mining, construction equipment, as well as marine and energy industries. The original company, Apritógépgyár was founded in 1951 and it was acquired by Fortaco in 2013. In 2023, the company’s net sales were EUR 23 million and the business was loss-making. The company employs 250 people. “The selling of heavy project business in Hungary is the first step of our strategic evaluation announced on 28 February this year. I’m happy that we have founda goodnew home for the business. I trust the new owners have the needed capabilities to expand thebusinessoutside of Fortaco’s strategic off-highway industry.Fortaco, as a responsible owner, hands over the business with re-settled financial terms to secure a smooth continuation for the new owners. I wish all the best to the Jászberény team and new owners to develop the business onwards,” says Lars Hellberg, President & CEO of Fortaco. “Fortaco Zrt. is well-known for its high-quality products as well as for talented and highly skilled employees. I am more than happy we could agree with Fortaco on this transaction that combines an experienced ownership structure with a stable financial base for developing the business. This will enable us to expand our product portfolio and business also outside of our traditional customer base,” says Uwe Sträter, Managing Director. The transaction is subject to the approval of Fortaco’s bondholders and some customary closing conditions, and it is expected to be closed by the end of June 2024. Fortaco expects to complete the strategic evaluation of its marine and energy businesses during the first half of 2024. Further InformationLars Hellberg, President & CEO+358 40 572 9488lars.hellberg@fortacogroup.com

TF Bank: Monthly statistics April 2024

The total loan portfolio amounted to SEK 19,545 million at the end of April. Compared to April 2023, the loan portfolio has increased by 20 % in local currencies.  Month Apr-24 Apr-23 ChangeConsumer Lending   New lending, SEK million 383 547 -30 %Credit Cards   New lending, SEK million 1,401 713 96 %Ecommerce Solutions   Transaction volume*, SEK million 1,189 1,170 2 %  Cumulative for the year Jan-Apr 24 Jan-Apr 23 ChangeConsumer Lending   New lending, SEK million 1,534 2,163 -29 %Credit Cards   New lending, SEK million 4,600 2,675 72 %Ecommerce Solutions   Transaction volume*, SEK million 4,047 4,031 0 % *The sum of all purchases that go through TF Bank’s payment solutions All figures for April 2024 are preliminary. For further information, please contact:Mikael Meomuttel, CFO and Head of Investor Relations +46 (0) 70 626 95 33 The information was provided for publication on May 10, 2024 at 08.30 CET. TF Bank in briefTF Bank was founded 1987 and is a digital bank offering consumer banking services and e-commerce solutions through a proprietary IT platform with a high degree of automation. Deposit and lending activities are conducted in Sweden, Finland, Norway, Denmark, Estonia, Latvia, Lithuania, Poland, Germany, Austria, Spain, Ireland and the Netherlands through subsidiary, branch or cross-border banking with the support of the Swedish banking license. The operations are divided into three segments: Consumer Lending, Credit Cards and Ecommerce Solutions. TF Bank is listed on Nasdaq Stockholm.

Scania at IFAT 2024 in Munich: Offering the means for sustainable cities

• Scania comes to IFAT with its vast experience of urban solutions • Electrification or renewable fuels? Scania offers every alternative • It has never been easier to choose solutions for true de-carbonisation • Sustainable, smart and safe solutions for municipalities • Charging does not need to be an issue – ask Scania for guidance. “For many years now our approach has been that there is no one-size-fits-all uni­versal solution available, and it will never come,” says Stefan Dorski, Senior Vice President, Head of Scania Trucks. “This belief is truly mirrored in our offer, which might be the broadest in the industry. We have all the relevant propulsion alter­natives, in combina­tion with a wide range of cabs, bodybuilder friendliness, and all the core power take off variants.”   What Scania is bringing to IFAT 2024 certainly bears witness to this philosophy: the stand (FM 709/15) is brimming with examples of the diversity of solutions that Scania offers for municipalities. And Scania’s ambitions do not stop with the hard­­ware. Safety and driver environments that are ideal for municipality applications where good, direct vision from the cab is an absolute necessity are also on display, to­gether with Scania’s take on how these vehicles shall connect and com­municate in a productive and driver-friendly way via apps and Scania’s Smart Dash display.     “We know from decades of experience how important the complete solution and the adaptation to the surrounding ecosystem are for the outcome,” says Mikael Schuer, Product Manager, Scania Trucks. “These solutions must fit effortlessly with the many different interfaces in the urban ecosystem. That means performing above average and frictionless in everything from getting the job done to protecting the driver, ped­estrians, cyclists and other, vulnerable road users.”  Scania applies an ‘eyes on the road and hands on the wheel’-approach when deve­loping its solutions. The interface between the driver and the truck must offer the kind of integration and ergonomics that makes the manoeuvring of the truck itself and its different capabilities effortless and natural.  Increased digitalisation and the use of cameras are of course supporting this, but the value of direct vision, cross-cab access and the feeling of being in control can never be replaced. It is also vital to avoid these digital solutions creating a cognitive overload or, perhaps even worse, over-reliance and complacency.   Electrification without worriesAlthough many in the industry are looking into start using battery-electric vehicles in their daily operations, charging is still often cited as an issue. A lack of knowledge and experience tend to create hurdles that slow down the transformation to electrification. However, Scania offers charging solutions for depots that include everything from consultancy and hardware for charging stations, to financing and repair and maintenance, all seamlessly paired via premium digital services. These charging solutions are complemented by Scania Charging Access, a new charging service that is also available for mixed fleets, which offers seamless access to a Europe-wide network of charging points that are suitable for trucks and buses. Scania Charging Access offers predict­able costs via a con­­venient in­voicing system with no hidden fees.  “We see it as our obligation as a leading manu­facturer to guide our customers on their transformation journeys,” says Dorski. “Regardless if their optimal solution is electric or based on renewable fuels, we are ready to support them in the best possible way in a true partnership. This is of course nothing new for Scania – we have only broadened the scope of what we offer.”  The following vehicles will be exhibited at Scania’s stand (FM 709/15): Bio-Methane | Alternative fuelsRefuse collector (chassis only): L 280 B6x2*4, biogas-powered truck with tanks for compressed gas. BEV | Electrification Scania 40 R B6x2*4, battery-electric truck with 400 kW e-machine. Will be joined by a suitable charging station from Kempower.  BEV | ElectrificationA rigid truck without body-build. It displays Scania’s latest battery packs, the e-machine and its installation. Features Scania Smart Dash.  ICE | Fuel-efficient truck Vacuum truck chassis: 420 P B 6X2*4. Chassis adapted for bodybuilders with the Super-based power­train, including the G25 Scania Opticruise gearbox.

Ericsson announces change to the Executive Team

Börje Ekholm, President and CEO of Ericsson, says: “Fadi has contributed immensely to Ericsson with his deep knowledge of our industry, customer focus, business acumen and leadership skills. I wish him all the best in his future endeavors.” Fadi Pharaon says: “It has been a true honor to be part of Ericsson’s Executive Team and to head Market Area Middle East & Africa alongside all the talented colleagues at Ericsson. I am very passionate about the Company and grateful for all the opportunities it offered me. I will be following Ericsson as it continues to progress and execute on our strategy to strengthen leadership in mobile networks, drive a focused expansion in enterprise, and pursue cultural transformation.” NOTES TO EDITORS: FOLLOW US: Subscribe to Ericsson press releases here Subscribe to Ericsson blog posts here https://twitter.com/ericssonhttps://www.facebook.com/ericssonhttps://www.linkedin.com/company/ericsson MORE INFORMATION AT:Ericsson Newsroom media.relations@ericsson.com  (+46 10 719 69 92)investor.relations@ericsson.com  (+46 10 719 00 00) ABOUT ERICSSON:Ericsson enables communications service providers and enterprises to capture the full value of connectivity. The company’s portfolio spans the following business areas: Networks, Cloud Software and Services, Enterprise Wireless Solutions and Global Communications Platform. It is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson’s innovation investments have delivered the benefits of mobility and mobile broadband to billions of people globally. Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com

MEKO strengthens its position in Poland through strategic acquisition

Currently, MEKO holds about a 5 percent market share in Poland following the acquisition of Inter-Team in 2018. By acquiring Elit Polska, this share will increase to approximately 8 percent, positioning MEKO as the third-largest player in the independent automotive aftermarket in Poland, a country with around 38 million inhabitants and over 26 millioncars. Elit Polska complements MEKO's existing operations well. The company is a long-established wholesaler of auto parts, consumables, and workshop equipment with two warehouses and 49 branches across the country. In 2023, Elit Polska had a turnover of 429 million Polish zloty, equivalent to approximately 1.159 billion Swedish kronor. MEKO is acquiring all shares in Elit Polska, where the company’s 485 employees will join MEKO’s organization, enabling an even stronger offering to Polish customers. "Elit Polska is a strategic, tailor-made addition for MEKO where we now gain broader geographic coverage in one of the EU's largest markets. Together with Elit Polska, we can position ourselves to take advantage of opportunities such as improved purchasing terms and coordination gains within our respective distribution networks. This will benefit our customers, strengthen our growth in Poland, and enhance our financial strength over time," says Pehr Oscarson, President and CEO of MEKO. Andy Hamilton, President and Executive Managing Director, LKQ Europe, says: “This transaction follows a long-term strategic review of our operations in Poland and extensive consultations with relevant stakeholders. We believe that MEKO is the right business to take Elit Polska forward and to continue to support our customers moving forward.” The acquisition will not materially affect MEKO's debt or cash flow. During 2024 and 2025, certain initial costs will arise to enable annual synergies with full effect from 2026, assuming that the combined operations then contribute to increased profitability for MEKO. Elit Polska is currently owned by LKQ Corporation, MEKO's largest shareholder, which also has representation on MEKO's board. Therefore, the acquisition process was managed by an independent board at MEKO without representatives from LKQ Corporation. Additionally, the independent board engaged Lenner & Partners CorporateFinance AB for an independent assessment of the transaction's valuation. Lenner & Partners concluded in their analysis that the financial valuation of the transaction is fair. The transaction is subject to customary approvals from relevant authorities. Terms of the transaction were not disclosed. For further information, please contact: Pehr OscarsonPresident and CEO, MEKOPhone: +46 (0)8-464 00 00Email: pehr.oscarson@meko.com Christer JohanssonCFO, MEKOPhone: +46 (0)8-464 00 00Email: christer.johansson@meko.com Anders OxelströmDirector of Communications, MEKOPhone: + 46 73 522 52 42Email: anders.oxelstrom@meko.com

Gaming Innovation Group - Issue of new shares

Gaming Innovation Group Inc. (GiG) has today issued 2,176,941 new shares of its common stock. The new shares are issued by the Board of Directors under the Company's 150,000,000 authorized shares, and the Company confirms that the new shares have been duly authorized by all necessary corporate actions and that the new shares have been fully paid and validly issued. The Company’s share capital has increased from USD 129,003,161 to USD 131,180,102, and the number of outstanding shares has increased from 129,003,161 to 131,180,102 (par value USD 1.00). In addition, a total of 1,432,500 options are outstanding as of today. The 2,176,941 new shares were distributed as follows: 823,897 new shares have been issued in connection with the acquisition of KaFe Rocks Ltd., ref. announcements from GiG on 7 November 2023 and 21 December 2023. Under the Share Purchase Agreement, GiG were obligated to issue EUR 2.5 million in shares to the sellers, pending specific operational cost savings targets being met by year-end 2023. The targets were met, and the sellers are entitled to extra payment, where the number of shares is based on a 30-day VWAP of the GiG share at the time of closing (NOK 30.11).  982,694 new shares have been issued in connection with the option program entered into in connection with the acquisition of Sportnco Gaming SAS (“Sportnco”), ref.  Exemption Document dated 13 July 2022., whereby key employees in Sportnco, contingent on continued employment, will receive shares in the Company at EUR 2.11 (NOK 24.80) per share.   370,350 new shares have been issued in connection with exercise of options, whereof 319,000 shares at a share price of NOK 15.00 and 51,350 at a share price of NOK 22.00 per share.  For further information, please contact:Tore Formo, Group CFO, tore@gig.com, +47 91668678 About Gaming Innovation Group (GiG)Gaming Innovation Group is a leading iGaming technology company, providing solutions, products and services to iGaming Operators. Founded in 2012, Gaming Innovation Group’s vision is ‘To be the industry leading platform, sportsbook and media provider delivering world class solutions to our iGaming partners and their customers.  GiG’s mission is to drive sustainable growth and profitability of our partners through product innovation, scalable technology and quality of service. Gaming Innovation Group operates out of Malta and is dual-listed on the Oslo Stock Exchange under the ticker symbol GIG and on Nasdaq Stockholm under the ticker symbol GIGSEK. www.gig.com

SciBase announces outcome in rights issue of units

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT. "I am grateful for the support we have from our existing owners and also welcome our new owners to SciBase. We are in a very interesting position as we now can continue to deliver on our strategy. With our profitable growth in Germany as a base and our significant progress in the US, we are now well positioned to establish Nevisense as the new standard of care and contribute to saving lives. The US is developing according to our plans and in recent quarters we have gained several new customers who have already started using Nevisense. I look with confidence on our continued development”, says Pia Renaudin, CEO of SciBase. Outcome in the Rights IssueThe Rights Issue was comprised of 35,949,429 Units, of which 13,264,074 Units, corresponding to approximately 37 percent of the Rights Issue, have been subscribed for with support of unit rights. Additionally, 8,493,194 Units have been subscribed for without support of unit rights, corresponding to approximately 24 percent of the Rights Issue. Consequently, the Rights Issue was subscribed to approximately 61 percent with and without support of unit rights. The Rights Issue will provide the Company with proceeds of approximately SEK 9 million before deduction of costs related to the Rights Issue. Upon full exercise of all warrants of series TO 2 from the Rights Issue, at the determined subscription price of SEK 0.42, the Company is expected to raise additional proceeds of approximately SEK 46 million before deduction of costs related to the warrants. The last day of trading in paid subscribed units (Sw. BTU) is expected to 27 May 2024. Thereafter, paid subscribed units will be converted into shares and warrants of series TO 2. First day of trading shares and warrants of series TO 2 issued through the Rights Issue is expected to 31 May 2024. Number of shares and share capital Following registration of the Rights Issue with the Swedish Companies Registration Office (Swe. Bolagsverket), the Company's share capital will increase by SEK 1,087,863.40 through issuance of 21,757,268 new shares. The number of shares thereby increases from 119,831,437 to 141,588,705. Shareholders who have not participated in the Rights Issue will be diluted by approximately 15.4 percent. In case all warrants of series TO 2 are exercised to subscribe for shares, the number of shares will further increase by 108,786,340 to 250,375,045 shares and the share capital will further increase by a maximum of SEK 5,439,317.00 resulting in an additional dilution effect of approximately 43.4 percent. Notice of allotment Those who have subscribed for Units without the support of unit rights will be allocated units in accordance with the principles set out in the prospectus published by the Company on 19 April 2024. Notice of allotment is provided by means of a contract note, which is distributed to each subscriber. Units shall be paid for in accordance with the instructions on the contract note. Nominee registered shareholders receive notice of allotment in accordance with the procedures of the respective nominee. Only those who will receive allotment will be informed. Advisors Vator Securities is the financial advisor and Advokatfirman Schjødt is the legal advisor to SciBase in connection with the Rights Issue. For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: pia.renaudin@scibase.com The information was submitted for publication, through the agency of the contact persons set out above, at 13.00 CEST on 10 May 2024. Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: ca@vatorsec.se About SciBase: SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The Company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases Important information Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Any acquisition of Units in SciBase in the Rights Issue should only be made on the basis of the information contained in the formal prospectus issued in connection with the Rights Issue, which was approved by the Swedish Financial Supervisory Authority on 19 April 2024. This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act") and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation. Forward-looking statements This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.

Kährs science-based targets validated and approved by SBTi

Kährs has made a public commitment to near-term and net-zero targets with the Science Based Target initiative (SBTi) Net-Zero standard, including FLAG emissions and removals. These targets have now been approved by the SBTi. “I am proud of this validation, which is an important milestone for Kährs towards reaching our sustainability goals. It is confirmation that we are on the right path for the future. SBTi provides a common, robust, and science-based understanding of net-zero, which clarifies and gives us confidence that our targets are aligned with climate science”, says Therése Gerdman, Sustainability Manager at Kährs Group. “Since we announced our carbon neutral goal for 2030, we have made dedicated efforts, with a low-carbon transition plan in place, outlining the steps we need to take to reach our goals. Our customers can trust that we will match their ambitions and targets, and that we together can take action and responsibility.” Overall Net-Zero Target: Kährs Holding AB (Kährs Group) commits to reach net-zero greenhouse gas emissions across the value chain by 2040. Near-Term Targets: Kährs Group commits to reduce absolute scope 1 and 2 GHG emissions 95% by 2030 from a 2020 base year.* Kährs Group also commits to increase active annual sourcing of renewable electricity from 74.5% in 2022 to 100% by 2030. Kährs Group further commits to reduce scope 3 GHG emissions 42% by 2030 from a 2020 base year.* Long-Term Targets: Energy & Industry: Kährs Group commits to maintain a minimum of 95% absolute scope 1 and 2 GHG emissions from 2030 through 2040 from a 2020 base year.* Kährs Group also commits to reduce scope 3 GHG emissions 90% by 2040 from a 2020 base year.* *Target boundary includes biogenic land-related emissions and removals from bioenergy feedstocks. FLAG: Kährs Group commits to reduce absolute scope 3 FLAG GHG emissions 72% by 2040 from a 2020 base year (includes FLAG emissions and removals). Kährs Group’s targets will be available on the SBTi’s target dashboard from 6 June 2024 https://sciencebasedtargets.org/target-dashboard About SBTiThe Science Based Targets initiative (SBTi) is a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. They develop standards, tools and guidance which allow companies to set greenhouse gas (GHG) emissions reductions targets in line with what is needed to keep global heating below catastrophic levels and reach net-zero by 2050 at latest.  The SBTi is incorporated as a charity, with a subsidiary which will host its target validation services. Their partners are CDP, the United Nations Global Compact, the We Mean Business Coalition, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). About SBTi FLAGThe world’s Forest, Land and Agriculture (FLAG) sector are one of the industries at highest risk from the impact of climate change. But it is also a significant source of emissions. It represents nearly a quarter of global greenhouse gas (GHG) emissions - the largest emitting sector after energy, but it also has the potential to absorb a significant amount of existing emissions from the atmosphere. To address this gap in emission accounting and reduction, the Science Based Target initiative (SBTi) introduced new FLAG guidance in April 2023 that requires SBTi committed companies to account for their FLAG emissions and provide pathways for decarbonization in line with the 1.5 degrees Celsius scenario. GHG accounting criteria and recommendations on FLAG emissions have been historically poorly addressed and there has been no framework on target setting for these emissions. Only a few companies have been accounting for and reporting these emissions at some level. The reason for this is lack of data and methodology, resulting in around 22% of global emissions from the land sector not being accounted for appropriately in corporate carbon footprint calculations. The SBTi’s FLAG Guidance provides the world’s first standard method for companies in land-intensive sectors to set science-based targets that include land-based emission reductions and removals. Learn more about FLAG: https://sciencebasedtargets.org/sectors/forest-land-and-agriculture Read more about Kährs sustainability work in our Sustainability Report 2023 .   

atNorth Shortlisted for Datacloud Global Awards, The Energy Awards and The Women in Green Business Awards

Reykjavík, Iceland – May 10[th],  2024 – atNorth , the leading Nordic colocation, high-performance computing, and artificial intelligence service provider, today announced widespread industry recognition including shortlisting’s in the ‘Excellence in Data Centre Europe Award 2024’ category at the Datacloud Global Awards  and the ‘Energy Efficient Partnership of the Year’ category at the Energy Awards , The Datacloud Global Awards celebrate excellence in the data center and cloud industry, recognizing outstanding achievements, innovation, and leadership across various categories. From pioneering technology solutions to sustainable practices, these awards highlight the trailblazers and visionaries driving the digital transformation landscape forward. atNorth’s continuous commitment to developing the most advantageous solutions for its clients has led the business to be recognized for its efforts in energy efficiency, data center excellence and as a leader in the data center industry. Additionally, atNorth’s CFO & Deputy CEO, Eva Sóley Guðbjörnsdóttir has been shortlisted in the ‘Diversity and Inclusion Champion of the Year’ category at the Women in Green Business Awards , illustrating the commendable ethos of atNorth’s business as a whole, as it champions fairness and the greater good – both internally and at the core of its service provision. “We are delighted to be acknowledged in a variety of categories across multiple awards,” says Eva Sóley Guðbjörnsdóttir, CFO & Deputy CEO, at atNorth. “As we remain committed to our vision of ‘more compute for a better world’, this recognition inspires us to continue to advocate for best practice within our business and the industry as a whole. The news follows atNorth’s recognition in TechRound’s Sustainability60  campaign, at the UK Green Business Awards  and the Tech Capital Awards . The business has also recently announced Anna Kristín Pálsdóttir as Chief Development Officer  and Jörgen Larsson as Director of Hyperscale Operations  as the business continues to scale to meet the increasing demand for its services. About atNorth atNorth is a leading Nordic data center services company that offers sustainable, cost-effective, scalable colocation and high-performance computing services trusted by industry-leading organizations. The business acquired leading High-Performance Computing (HPC) provider, Gompute, in 2023 enabling a compelling full stack offering tailored to AI and other critical high-performance workloads.  With sustainability at its core, atNorth's data centers run on renewable energy resources and support circular economy principles. All atNorth sites leverage innovative design, power efficiency, and intelligent operations to provide long-term infrastructure and flexible colocation deployments. The tailor-made solutions enable businesses to calculate, simulate, train and visualize data workloads in an efficient, cost-optimized way. atNorth is headquartered in Reykjavik, Iceland and operates seven data centers in strategic locations across the Nordics, with additional sites to open in Helsinki, Finland and in Denmark in Q4 2024, as well as its tenth site ready for operation in Kouvola, Finland in 2025. For more information, visit atNorth.com or follow atNorth on LinkedIn  or Facebook . Press Contact: Caroline Brunton Kite Hill PR for atNorth +44 (0) 7796 274 416 caroline@kitehillpr.com

Mandatum plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (Altor Fund Manager AB)

Mandatum Plc, Stock exchange release, 10 May 2024 at 2:30 p.m. EEST Mandatum plc (Business ID 3355142-3) has received a notification, pursuant to Chapter 9, Section 5 of the Finnish Securities Markets Act, that the breakdown of Altor Fund Manager AB’s (registration number 556962-9149, Sweden) and its funds’ direct or indirect holding of the shares and votes in Mandatum plc has changed. Total positions of Altor Fund Manager AB, and its funds subject to the notification: +----------------+----------+------------------+------+----------------------+| |%of shares|% of shares and |Total |Total number of shares|| |and |voting rights |of |and voting rights of || |voting |through financial |both |issuer || |rights |instruments (total|in % | || |(total |of B) |(A+B) | || |of A) | | | |+----------------+----------+------------------+------+----------------------+|Resulting |10.00% |6.61% |16.62%|501,796,752 ||situation on the| | | | ||date on | | | | ||which threshold | | | | ||was crossed or | | | | ||reached | | | | |+----------------+----------+------------------+------+----------------------+|Positions of |9.98% |6.63% |16.62%| ||previous | | | | ||notification | | | | ||(if applicable) | | | | |+----------------+----------+------------------+------+----------------------+ Notified details of the resulting situation on the date on which the threshold was crossed:A: Shares and voting rights +----------+--------------+-----------------+-------------+-------------+|Class/type|Number of |% of shares ||of shares |shares and |and voting || |voting rights |rights ||ISIN code | | |+----------+--------------+-----------------+-------------+-------------+| |Direct |Indirect |Direct |Indirect || | |(SMA 9:6 and 9:7)|(SMA 9:5) |(SMA 9:6 and || |(SMA 9:5) | | |9:7) |+----------+--------------+-----------------+-------------+-------------+| |50,200,000 |50,200,000 (Altor|10.00% (Altor|10.00% (Altor|| |(Altor In-vest|Fund Manager AB) |Invest 8 AS) |Fund Manager || |8 AS) | | |AB) |+----------+--------------+-----------------+-------------+-------------+|SUBTOTAL A|50,200,000 |10.00% |+----------+--------------+-----------------+-------------+-------------+ B: Financial instruments according to SMA 9:6a +----------+----------+--------------+-----------+-----------------+-----------+|Type of |Expiration|Exercise/Conve|Physical or|Number of shares |% of shares||financial |date |rsion Period |cash |and voting rights|and voting ||instrument| | |settlement | |rights |+----------+----------+--------------+-----------+-----------------+-----------+|Swap |13.2.2025 |13.2.2025 |Physical |33,178,580 |6.61% || | | |settlement | | |+----------+----------+--------------+-----------+-----------------+-----------+| | | | | | |+----------+----------+--------------+-----------+-----------------+-----------+| | | |SUBTOTAL B |33,178,580 |6.61% |+----------+----------+--------------+-----------+-----------------+-----------+ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: +------------+-----------+-----------------------------+-------------+|Name |% of shares|% of shares and voting rights|Total of both|| |and voting |through financial instruments| || |rights | | |+------------+-----------+-----------------------------+-------------+|Altor Fund |0.00 |0.00 |0.00 ||Manager AB | | | |+------------+-----------+-----------------------------+-------------+|Altor Fund |0.00 |0.00 |0.00 ||VI (No. 1) | | | ||AB | | | |+------------+-----------+-----------------------------+-------------+|Altor Fund |0.00 |0.00 |0.00 ||VI (No. 2) | | | ||AB | | | |+------------+-----------+-----------------------------+-------------+|Altor Invest|10.00 |6.61 |16.62 ||8 AS | | | |+------------+-----------+-----------------------------+-------------+ Additional information:Altor Invest 8 AS will have no voting rights in relation to the shares underlying the financial instruments until physical settlement. Additional informationInvestor enquiries: Lotta BorgströmVP, Investor RelationsTel. +358 50 022 1027lotta.borgstrom(a)mandatum.fi Media enquiries:Niina RiiheläSVP, Communications, brand and sustainabilityTel. +358 40 728 1548niina.riihela(a)mandatum.fi   Mandatum in briefMandatum is a major financial services provider that combines expertise in wealth management and life insurance.Mandatum offers clients a wide array of services covering asset and wealth management, savings and investment, compensation and rewards as well as pension plans and personal risk insurance. Mandatum offers services to corporate, retail, institutional and wealth management clients.At the centre of Mandatum's success are highly skilled personnel, a strong brand as well as a proven investment track record. mandatum.fi/en/group  Distribution: Nasdaq Helsinki Financial Supervisory Authority The principal media www.mandatum.fi 

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

Uppsala, Sweden – May 10, 2024. On March 28, 2024, Orexo AB (publ), (“Orexo” or the “Company”) (STO:ORX) (OTCQX:ORXOY) successfully issued senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years (the “Bonds”). Pursuant to the terms and conditions for the Bonds, Orexo has undertaken to apply for admission to trading of the Bonds on the sustainable bond list of Nasdaq Stockholm. For this purpose, the Company has prepared a listing prospectus, which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The prospectus is available at the Company’s website www.orexo.com and at the Swedish Financial Supervisory Authority’s website www.fi.se. The application for admission to trading has been submitted and the first day of trading of the Bonds is estimated to be around May 14, 2024. For further information please contact: Nikolaj Sørensen, President and CEO Fredrik Järrsten, EVP and CFO Lena Wange, IR & Communications Director Tel: +46 (0)18780 88 00 E-mail: ir@orexo.com About Orexo Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US. For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube. The information was sent for publication, through the agency of the contact person set out above, on May 10, 2024, at 1.30 pm CET.

RMD sensors to Brazil

Railway Metrics & Dynamics has received an order for a fully paid, wide-scale demonstration deployment of their train performance monitoring and derailment detection equipment in Brazil. This will be the first deployment of such high-tech train monitoring equipment in South America. RMD’s system performs real-time monitoring of rolling stock dynamics for the purposes of analyzing track conditions, changes to the track geometry, rolling stock conditions like flat wheels, asset tracking, instant derailment detection, and more. This advanced and real-time warning system is a game-changer for railroad safety and performance monitoring. The Brazilian railroad system, known as the Ferrovia Brasileira, plays a crucial role in the country's transportation infrastructure. Brazil has one of the largest railway networks in the world, covering thousands of kilometers across the country. The network is primarily used for freight transportation, including commodities such as soybeans, iron ore, and agricultural products – with passenger services largely concentrated in urban areas. The Brazilian railway system faces several challenges, including infrastructure limitations, old equipment, and competition from other modes of transportation. Also, the country's vast size and diverse terrain present logistical challenges for railway operations. In recent years, Brazil has made efforts to modernize and expand its railway infrastructure. This includes investments in new tracks, signaling systems, and rolling stock. The government has also promoted the construction of new railway lines to connect key economic regions and facilitate trade. The Brazil deployment will begin in 2024 and will allow RMD to offer product performance demonstrations to railroad clients in the South American market. RMD’s performance monitoring system is applicable to both freight and passenger rail, including metros, urban trains, and high-speed rail. The RMD system builds a connected network of Performance Monitoring Units (PMU) which communicate with each other, the locomotive, central train control, and anyone designated for reception of the real-time and recorded data. Urgent messages are relayed to the train driver through an easy to use “dashboard” on any connected device. – This is very exciting, says Jan Lindqvist, CEO of Railway Metrics and Dynamics. This once again proves how scalable our platform is. This project will showcase our solutions to railroad clients in the South American market - using the same components, IT solutions, and workflows as in Europe. RMD is proud to add Brazil to its list of customers and markets.

Mandatory notification of trade – primary insider

Tore Sjursen, director in Multiconsult ASA has, through Bonao Invest AS on 10 May 2024, purchased 1 800 shares in Multiconsult ASA at an average price of NOK 149.50 per share. After the transaction Tore Sjursen, through Bonao Invest AS, holds 2 715 shares in Multiconsult. Mr. Sjursen owns 100 per cent of the shares in Bonao Invest AS For further information, please contact: Investor relations:   Pål-Sverre Jørgensen, Group Treasurer & Investor Relations Officer   Phone: +47 416 11 161   E-mail: ir@multiconsult.no / psmj@multiconsult.no Media:   Gaute Christensen, VP Communications   Phone: +47 911 70 188   E-mail: gaute.christensen@multiconsult.no This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Dolphin Drilling AS – update on Blackford Dolphin and earlier announced notice of contract termination in Nigeria

Oslo, 10 May 2024 Dolphin Drilling AS (the "Company") (ticker code: DDRIL) refers to the announcement on 30 April 2024 regarding the termination of the drilling contract in Nigeria. Further to the notice of termination to General Hydrocarbons Limited (“GHL”), a Nigerian oil and gas company, in respect of a contract for the Blackford Dolphin rig, the Company has filed a Request for Arbitration to pursue the recovery of sums remaining due by GHL. The termination of the contract is disputed by GHL. GHL have also filed a Request for Arbitration and, additionally, have made an application to the Nigerian courts for an interim injunction seeking to maintain status quo, pending the appointment of an arbitrator. The Company is, together with its external counsel in Nigeria, immediately taking steps to oppose the interim injunction before the Nigerian courts. The Company will continue to update the market on any material developments in the arbitration and court processes. For further information, please contact: Ingolf Gillesdal, Corporate Finance and Investor Relations, tel: +47 920 45 320 Stephen Cox, CFO, tel: +44 7800 612 130

Stora Enso Oyj: Notification of Change in Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act (9 May 2024)

Stora Enso Oyj has received a notificationpursuant to chapter 9, section 5 of the Securities Market Act fromBlackRock, Inc on 10 May 2024. On 9 May 2024, BlackRock's holding in Stora Enso’s shares increased above the 5 percent threshold. +----------------+--------------+-----------------------------+---------------+| |% of shares |% of shares and voting rights|Total of both || |and voting |through financial instruments|in % (7.A + || |rights |(total of 7.B) |7.B) || |(total of 7.A)| | |+----------------+--------------+-----------------------------+---------------+|Resulting |5.04% shares |0.11% shares |5.16% shares ||situation on the| | | ||date on |Below 5% |Below 5% voting rights |Below 5% voting||which threshold |voting rights | |rights ||was crossed or | | | ||reached | | | |+----------------+--------------+-----------------------------+---------------+|Position of |4.93% shares |0.12% shares |5.05% shares ||previous | | | ||notification |Below 5% |Below 5% voting rights |Below 5% voting||(if applicable) |voting rights | |rights |+----------------+--------------+-----------------------------+---------------+ A: Shares andvotingrightsClass/type of Number of % ofshares shares and shares voting and votingISIN code (if rights rightspossible)Direct Indirect Direct Indirect (SMA 9:5) (SMA 9:6 (SMA 9:5) (SMA 9:6 and 9:7) and 9:7)FI0009005961 39,825,270 5.04% shares shares Below 5% Below voting 5% rights voting rightsSUBTOTAL A 39,825,270 5.04% shares shares Below 5% Below 5% voting voting rights rights B: FinancialInstrumentsaccordingto SMA 9:6aType of Expiration Exercise/ Physical Number % offinancial date Conversion or of sharesinstrument Period cash shares and settlement and voting voting rights rightsAmerican N/A N/A Physical 490,080 0.06%Depositary shares sharesReceipt(US86210M1062) Below 5% Below 5% voting voting rights rightsSecurities N/A N/A Physical 56,840 0.00%Lent shares shares Below 5% Below 5% voting voting rights rightsCFD N/A N/A Cash 346,480 0.04% shares shares Below 5% Below 5% voting voting rights rights SUBTOTAL B 893,400 0.11% shares shares Below 5% Below 5% voting voting rights rights Stora Enso has two series of shares. Each A share and every ten R shares carry one vote. Stora Enso has 175,979,614 A shares and 612,640,373 R shares in issue. The company does not hold its own shares. The total number of Stora Enso shares is 788,619,987 and the total number votes at least 237,243,651.Full chain of controlled undertakings through which the voting rights and financial instruments are effectively held starting with the ultimate controlling natural person or legal entity is presented in the enclosed annex. Investor enquiries:Anna-Lena ÅströmSVP Investor Relationstel. +46 70 210 7691 Part of the global bioeconomy, Stora Enso is a leading provider of renewable products in packaging, biomaterials and wooden construction, and one of the largest private forest owners in the world. We create value with our low-carbon and recyclable fiber-based products, through which we support our customers in meeting the demand for renewable sustainable products. Stora Enso has approximately 20,000 employees and our sales in 2023 were EUR 9.4 billion. Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded in OTC Markets (OTCQX) in the USA as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors STORA ENSO OYJ

SaltX and SMA Minerals' concept for production of fossil-free lime (ZEQL) delivers CO2 for the manufacturing of e-Fuels

The agreement means that SMA Mineral, which will operate and own the ZEQL facility in Mo i Rana, can utilize the CO2 that SaltX's Electric Arc Calciner (EAC) technology separates in the electric manufacturing process of quicklime. The facility will now be expanded to include the production of e-Fuels for the aviation industry in partnership with the American company Infinium. Svante Fielding, CEO of SMA Mineral: "Through our expertise in sustainable quicklime production in collaboration with SaltX and our agreement with Infinium, SMA Mineral is prepared to play a significant role in reducing the carbon footprint of sectors vital to the European economy." SMA Mineral and SaltX have been collaborating since the spring of 2022 and have actively sought alternative solutions for how the collected carbon dioxide should be managed most effectively. Carl-Johan Linér, CEO of SaltX, explains: "The fact that our technology lays the foundation for this expanded and unique initiative is very exciting and important for us and for reducing CO2 emissions globally. This is a project of 'mega-factory' magnitude that will generate significant interest, and we are proud to contribute to a more sustainable quicklime and aviation industry." For more information about Infinium's technology for producing e-Fuels, click here. For more information, please contact:Carl-Johan Linér, CEO SaltX Technology, +46 705-32 08 08Svante Fielding, CEO SMA Mineral, +46 738-03 46 78 About SaltX TechnologySaltX is a Swedish Greentech company that develops and markets sustainable technology that will benefit customers, the climate, and society. The company operates within the electrification of emission-intensive industries such as the lime and cement industries. SaltX Technology's share is listed on the Nasdaq First North Premier Growth Market. For more information, visit www.saltxtechnology.com. About SMA MineralSMA Mineral is one of the largest lime producers in the Nordic region, supplying lime to the steel, paper, and pulp industries, as well as many other applications. Since its inception in 1980, SMA has been at the forefront of extraction, processing, and distribution of products based primarily on calcium carbonate and dolomite. With a constant commitment to sustainability and environmentally responsible methods, SMA's minerals are crucial components in various industries including steel, paper, and water and flue gas purification. For more information, visit www.smamineral.se. About ZEQLZEQL [sequel] is an industrial partnership for electrified production of quicklime jointly owned by SMA Mineral and SaltX Technology. The manufacturing method and factory concept involve new innovative electrification technology with built-in CO2 separation. The first factory is planned to be operational by 2025. www.zeql.com About InfiniumInfinium is a supplier of electrofuels with a mission to decarbonize the world. Electrofuels are a new type of synthetic fuel manufactured using renewable energy and carbon dioxide, not petroleum or resources needed for food production. Infinium's electrofuels can be used in existing trucks, airplanes, and ships, significantly reducing harmful carbon dioxide emissions compared to fossil-based fuels. In addition to helping the transportation industry achieve carbon dioxide reduction goals, Infinium's electrofuels are a lower carbon dioxide emission alternative for chemical processing, including plastic production. Learn why Amazon and other leading cleantech investors have chosen Infinium at www.infiniumco.com.

Lucara Reports Voting Results From Annual Meeting

VANCOUVER, BC, May 10, 2024 /CNW/ - (LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm) Lucara Diamond Corp. (“Lucara” or the “Company”) held its Annual General and Special Meeting of shareholders in Vancouver, British Columbia today. Shareholders voted as follows on the matters before the meeting: Board Members Shareholders elected the following 7 board members with shareholders represented at the meeting voting in favour of individual directors as follows: +--------------------+-----------+-----------+----------+----------------+|Director |Votes |% Votes For|Votes |% Votes Withheld|| | | | | || |For | |Withheld | |+--------------------+-----------+-----------+----------+----------------+|Sheila Colman |168,104,342|77.54% |48,685,353|22.46% |+--------------------+-----------+-----------+----------+----------------+|Paul Conibear |165,804,491|76.48% |50,985,204|23.52% |+--------------------+-----------+-----------+----------+----------------+|David Dicaire |212,797,320|98.16% |3,992,375 |1.84% |+--------------------+-----------+-----------+----------+----------------+|Ian Gibbs |213,012,431|98.26% |3,777,264 |1.74% |+--------------------+-----------+-----------+----------+----------------+|William Lamb |212,492,282|98.02% |4,297,413 |1.98% |+--------------------+-----------+-----------+----------+----------------+|Adam Lundin |216,457,252|99.85% |332,443 |0.15% |+--------------------+-----------+-----------+----------+----------------+|Peter J. O’Callaghan|153,988,015|71.03% |62,801,680|28.97% |+--------------------+-----------+-----------+----------+----------------+ The Company would like to acknowledge the contributions of Catherine McLeod-Seltzer and Marie Inkster, who did not stand for re-election as Directors of the Company. In addition to serving as a long-standing Director, Catherine also played a role in founding the Company. Paul Conibear, Chair of the Board said, “Both Catherine and Marie have been valuable members of the Board for many years, and on behalf of the Company, shareholders and my fellow Board members, we would like to express gratitude to both Catherine and Marie for their guidance and contribution to the Company.” Appointment of Auditors Shareholders re-appointed PricewaterhouseCoopers LLP as Lucara’s auditors with 95.77% of shareholders voting in favour. Ordinary Resolutions for the Share Issuance Disinterested shareholders passed an ordinary resolution to authorize and approve the issuance of up to 1,125,000 common shares of the Company to Nemesia S.à.r.l., pursuant to the terms of a debenture agreement, as required pursuant to the rules of the Toronto Stock Exchange. This resolution passed with 97.34% of votes cast in favour. Advisory Resolution on Executive Compensation Management’s approach to executive compensation, also disclosed in Lucara’s management proxy circular dated April 5, 2024 was approved with 97.79% of shares represented at the meeting voting in favour. Following the meeting, Paul Conibear will continue to serve as Chairman of the Board.  On behalf of the Board, William Lamb President and Chief Executive Officer Follow Lucara Diamond on Facebook , Instagram , and LinkedIn  The information in this release is accurate at the time of distribution but may be superseded or qualified by subsequent news releases. The information was submitted for publication, through the agency of the contact person set out above, on May 10, 2024 at 3:30 p.m. Pacific Time.  Please view PDF version 

Noble Corporation plc publishes its quarterly report for the first quarter of 2024

SUGAR LAND, TEXAS, May 10, 2024 /PRNewswire/ - With reference to the announcement published on May 6, 2024 containing the results of Noble Corporation plc ("Noble") (CSE: NOBLE, NYSE: NE) for the quarterly period ended March 31, 2024, Noble hereby announces the publication of its quarterly report on Form 10-Q for the quarter ended March 31, 2024 (the "Quarterly Report"). The Quarterly Report has today been filed with the U.S. Securities and Exchange Commission and is available at https://bit.ly/4dAxC1h. IMPORTANT INFORMATION This announcement is for information purposes only and does not constitute or contain any invitation, solicitation, recommendation, offer or advice to any person to subscribe for or otherwise acquire or dispose of any securities of Noble. Certain statements in this announcement, including any attachments hereto, may constitute forward-looking statements. Forward-looking statements are statements (other than statements of historical fact) relating to future events and Noble and its subsidiaries (collectively, the "NobleGroup") anticipated or planned financial and operational performance. The words "targets", "believes", "continues", "expects", "aims", "intends", "plans", "seeks", "will", "may", "might", "anticipates", "would", "could", "should", "estimates", "projects", "potentially" or similar expressions or the negatives thereof, identify certain of these forward-looking statements. The absence of these words, however, does not mean that the statements are not forward-looking. Other forward-looking statements can be identified in the context in which the statements are made. Although Noble believes that the expectations reflected in these forward-looking statements are reasonable as of the date of this announcement, such forward-looking statements are based on Noble's current expectations, estimates, forecasts, assumptions and projections about the Noble Group's business and the industry in which the Noble Group operates and/or which has been extracted from publications, reports and other documents prepared by the Noble Group and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other important factors beyond the Noble Group's control that could cause the Noble Group's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Any forward-looking statements included in this announcement, including any attachment hereto, speak only as of today. Noble does not intend, and does not assume, any obligations to update any forward-looking statements contained herein, except as may be required by law or the rules of the New York Stock Exchange or Nasdaq Copenhagen. All subsequent written and oral forward-looking statements attributable to Noble or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements referred to above and contained in this announcement, including any attachment hereto. View PDF Version 

Lundin Mining Announces Annual Meeting Voting Results

VANCOUVER, BC, May 10, 2024 /CNW/ - (TSX: LUN; Nasdaq Stockholm: LUMI) Lundin Mining Corporation (“Lundin Mining” or the “Company”) today announced the voting results from its 2024 Annual and Special Meeting of Shareholders (the “Meeting”). A total of 610,859,421 common shares were voted at the Meeting, representing 78.81% of the votes attached to all outstanding common shares as of the record date March 22, 2024. Shareholders voted in favour of all items of business considered at the Meeting, as follows: % For % AgainstDirector NomineesAdam I. Lundin 93.67% 6.33%C. Ashley Heppenstall 90.66% 9.34%Donald K. Charter 97.38% 2.62%Juliana L. Lam 99.39% 0.61%Jack O. A. Lundin 98.62% 1.38%Dale C. Peniuk 96.10% 3.90%Maria Olivia Recart 95.23% 4.77%Natasha N.D. Vaz 99.88% 0.12% % For % WithholdAppointment of Auditors 98.13% 1.87% PricewaterhouseCoopers LLP % For % Against % AbstainAdvisory Vote on the Company’s 94.37% 5.56% 0.07%Approach to ExecutiveCompensation. % For % WithholdAn amendment to the articles of amalgamation of Lundin 99.97% 0.03%Mining the Corporation (as amended) (the "Articles") tochange the province of the registered office of LundinMining the Corporation  from Ontario to British Columbia. % For % WithholdAn amendment to the Articles to remove one special share 99.96% 0.04%from Lundin Mining's authorized share capital. Chair of the Board, Lead Director, and Board Committee Appointments The Board of Directors (the “Board”) is pleased to announce the reappointment of Mr. Adam Lundin as the Chair of the Board and Mr. Ashley Heppenstall as Lead Director. The Board is also pleased to announce the composition of the Board Committees and each Committee Chair as noted in the table below: Audit Corporate Governance Human Resources / Safety, SustainabilityCommittee and Nominating Compensation and Technical Committee Committee CommitteeDale C. Dale C. Peniuk (Chair) Donald K. Charter Natasha N.D. VazPeniuk (Chair) (Chair)(Chair)C. Ashley C. Ashley Heppenstall C. Ashley Donald K. CharterHeppenstall HeppenstallJuliana L. Juliana L. Lam Dale C. Peniuk Adam I. LundinLam Maria Olivia Recart The information in this release is subject to the disclosure requirements of Lundin Mining under the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out below on May 10, 2024 at 18:00 Pacific Time. Detailed voting results for the Meeting are available on SEDAR+ at www.sedarplus.com. View PDF Version 

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

“We are pleased that Cevira continues to advance toward market approval in China, as it can serve an important non-invasive option to treat pre-cervical cancer without the complications of surgical intervention,” said Dan Schneider,” President and CEO of Photocure. “Asieris continues to be a valued partner to Photocure, with solid execution on both programs that it has licensed from us. We look forward to further announcements on the regulatory progress of Cevira as well as Asieris’ pending NDA for Hexvix in China.” The Asieris media release states: “APL-1702 is a first-in-class, non-surgical treatment for cervical HSIL with its efficacy proven in an international phase III trial. It heralds a potential paradigm shift in the treatment of precancerous cervical lesions, with the clinical focus moving from excision to long-term disease management. Emphasis lies in optimizing the delicate balance between treatment risks and benefits, striving to minimize or delay invasive procedures while effectively reversing the progression of the disease.” Read Asieris’ full media release here: https://asieris.com/asieris-announces-nmpa-acceptance-of-nda-for-apl-1702-a-non-surgical-therapy-for-treating-cervical-hsil/ Note to editors: All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. About Cevira[®]Cevira[®] (APL-1702) is a photodynamic drug-device combination product in development. Based on the principles of photodynamic therapy, the Cevira product aims to use a photosensitizer in combination with light activation to produce a therapeutic effect as a non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL) in patients aged 18 years and above, excluding carcinoma in situ.Photocure developed Cevira through Phase I and Phase II trials, and the global rights for development and commercialization were out-licensed to Asieris Meditech Co., Ltd in 2019. In November 2020 Asieris initiated the phase III clinical trial for APL-1702 (Cevira) which achieved its primary endpoint in September 2023, Clinical trial number: NCT04484415 . About Photocure ASAPhotocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com About AsierisAsieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.

ZINZINO AB (PUBL): Zinzino acquires assets in Xelliss – strategic reinforcement in southern Europe and in the microalgae spirulina

Zinzino, the global health and wellness brand from Scandinavia, has acquired, through a business asset acquisition, the rights to the distributor database and associated customer register, inventory, and intellectual property of the Luxembourg-based direct sales company Xelliss. This is a further strategically important step in Zinzino's growth plans, focusing on improving personal health and well-being on a global level with innovative biotechnology and a groundbreaking product portfolio marketed through direct sales. Xelliss is a global direct sales company based in Luxembourg. Its brand portfolio offers a range of natural and innovative products in wellness, nutrition, and cosmetics, based on the microalgae spirulina produced in-house. A visionary mindset, a tech-first approach, test-based nutrition at the cellular level, and a strong position to take advantage of current trends will shape the foundation of the partnership with Xelliss. Since the acquisition of VMA Life in 2020, Enhanzz in 2022, and the strategic cooperation with ACN at the start of 2024, Zinzino has been looking for additional powerful investments to maintain its sustainable, profitable growth, strengthen its distribution power, expand into new markets, and utilize its product portfolio in new consumer areas. -Individual advising and customized solutions are the future, not only in health and wellness, says Dag Bergheim Pettersen, CEO of Zinzino, and Jean-Michel Larré, CEO and founder of Xelliss. Together, we have many years of combined industry experience and everything required to drive the modern, personal shopping experience through direct sales. Zinzino acquires Xelliss's distributor organization as well as inventory and IP rights to the product lines. The operation, which had a turnover of approximately 8 million EUR last year, is expected to generate strong growth through the synergies created in the joint networks. The operation's gross margins are good, and profitability will therefore be able to develop very well by utilizing Zinzino's existing technical platform and organization. At the time of entry, Zinzino will pay a fixed purchase price of 2 million EUR, divided into 50% cash and 50% newly issued Zinzino shares. In addition, conditional additional purchase prices based on sales development generated by the acquired distributor organization during the period 2024–2029 will apply. The total additional purchase prices are estimated to amount to 4.0 million EUR but could reach up to 8.0 million EUR at maximum outcome and will be regulated entirely with newly issued Zinzino shares. The cash portion of the purchase price is financed with own cash. For more information:Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.comFredrik Nielsen CFO Zinzino +46 707 900 174, fredrik.nielsen@zinzino.com Pictures for publication free of charge:marketing@zinzino.com Certified Adviser: Carnegie Investment Bank AB (publ)

Kongsberg Automotive updates its long-term financial ambitions

Zurich, May 12, 2024: Kongsberg Automotive’s (KA) Board of Directors, along with the CEO and Executive Management, have updated its long-term financial goals and established new ambitions for the year 2028. In the recent months, the Board of Directors, the CEO and Executive Management, have made a thorough analysis of the company’s operational and financial prospects. The current short-term focus is to reduce structural costs and increase KA’s operational efficiency. The objective is to secure positive earnings and positive cash flow. The guidance for 2024 is that KA will deliver earnings growth, absolute positive earnings, and positive cash flow despite flat revenues. This guidance was given on March 12 when the annual report was published and reiterated on May 8 when the Q1 results 2024 were published. Going beyond 2024 the focus is on organic growth and improved profitability.  KA has successfully won numerous long-term contracts with well-reputed automotive brand names. This portfolio of contracts ensures that we have a platform for growth. Albeit our Driveline business – now labelled “non-core” – is set to decrease, we are confident that KA will deliver sustained organic growth in its core business. Once a solid earnings platform has been established KA may consider bolt-on acquisitions as a means to further enhance its growth. By 2028 we expect that min 70% of our revenues will be linked to commercial vehicles. At the same time our non-core business will be insignificant in terms of revenue. Continued focus on cost control, optimised operational footprint, and higher sales will lead to improved earnings performance. The ambition is to lift the EBIT-margin to at least 8.5 % bringing KA in line with best-in-class suppliers to the automotive industry. The long-term financial ambitions towards 2028 are as follows (replacing all previous financial goals that were given at the Capital Markets Day in 2021): · Revenues, above EUR 1.0bn · By organic growth, representing a double-digit % CAGR for the core-business: this being higher than the expected industry growth.  · EBIT margin at or above 8.5% · Annually improve our earnings performance to reach and maintain an EBIT-margin of at least 8.5 %.  “KA is seeking to become a technology and market leader within its core business areas, offering its customers world-class mobility solutions for the future, creating lasting value for all stakeholders” says KA’s President & CEO Linda Nyquist-Evenrud, adding, “we are optimizing our operations for a more effective and cost-efficient structure to best serve our customers and to build a more competitive position in areas we excel.  Media and communications contact:Therese Sjöborg Skurdal – Director Corporate Communicationstherese.skurdal@ka-group.com+47 982 14 059 Investor Relations contact:Mads Langaard – Head of Investor Relationsmads.langaard@ka-group.com+47 905 81 264 About Kongsberg Automotive ASAKongsberg Automotive provides cutting-edge technology to the global vehicle industry. We drive the global transition to sustainable mobility by putting engineering, sustainability, and innovation into practice. Our product portfolio includes driver and motion control systems, fluid assemblies, and industrial driver interface products. Find more information at: kongsbergautomotive.com 

Circio presents pre-clinical proof-of-concept data for its circVec gene therapy platform at the ASGCT 2024 meeting

Oslo, Norway, 13 May 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing circular RNA-based gene therapy, today announces that it has presented two posters that demonstrate in vivo proof-of-concept for its powerful and differentiated circVec platform approach to gene therapy. The two posters were presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting 7-11 May in Baltimore, USA “Circio has generated results demonstrating that the circVec 2.1 design performs very well in vitro. We have now confirmed this in vivo with statistically significant higher expression level and durability for circVec 2.1 DNA vectors compared to standard linear mRNA-based expression. These results provide an important technical proof-of-concept for Circio´s technology platform in an animal model. We now have confirmation for our expectation that this could translate into improved gene therapies for patients in the future,” said Dr. Thomas B Hansen, CTO at Circio. “In recent experiments, Circio has observed up to four months circVec durability in vivo. This substantially outperforms mRNA vector expression. Following these results, we can rapidly advance to design and test circVec in several AAV and DNA-based vectors. This will validate these very promising data in therapeutically relevant formats.”   At ASGCT, Circio also presented the dual-function ‘remove-&-replace’ concept for Alpha-1-antitrypsin deficiency (AATD). This genetic disease causes severe symptoms in the lung and liver. There are currently no satisfactory therapeutic options available for this indication and AATD still represents a major unmet medical need. There are over 200,000 AATD patients affected in the USA and EU alone. With the technologically differentiated circVec remove-&-replace format, Circio has developed a unique gene therapy concept that can deal with both the lung and liver-associated symptoms in one single therapeutic.  “AATD is a challenging genetic disease to treat. This is in part due to the two distinct pathologies in the liver and lung,” said Dr. Victor Levitsky, CSO at Circio. “We have now established and technically validated circVec constructs that can both replenish functional wild-type AAT and specifically remove more than 90% of the mutated protein. This is challenging to achieve because the functional and mutant forms are very similar. By using circular RNA-based AAT expression, Circio is uniquely able to separate the two species for mutant-specific knockdown, thereby solving two problems with one single product.” Optimization and In Vivo Performance of circVec, a Vector-Based Circular RNA Expression Platform;   O´Leary et al. ASGCT 2024 Expressing AAT from circular RNA-encoding vectors as a promising gene therapy approach for Alpha 1-antitrypsin deficiency; O´Leary et al. ASGCT 2024

Volvo Cars has completed the distribution of 62.7 percent of its Polestar shareholding to its shareholders and commences the conversion period of SDRs into Polestar Class A ADSs

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS DOCUMENT. THIS DOCUMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION AND SHALL NOT FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR THE SOLICITATION OF AN OFFER OR COMMITMENT TO BUY OR SUBSCRIBE FOR ANY SECURITIES TO ANY PERSON WHATSOEVER IN ANY JURISDICTION. Volvo Car AB (publ) (“Volvo Cars”) announces that the company, in accordance with the previously communicated final terms and timetable, has completed the distribution of 62.7percent of its shareholding in Polestar Automotive Holding UK PLC (“Polestar”) to Volvo Cars’ shareholders in the form of Swedish Depositary Receipts (“SDRs”). Polestar has American Depository Shares (“Polestar Class A ADSs”), which represent the underlying Class A shares in Polestar, listed on Nasdaq New York, and holders of SDRs may apply for conversion of SDRs into Polestar Class A ADSs during the conversion period which commences today. The SDRs will be distributed today to the shareholders’ securities accounts, nominee accounts or equivalent. The SDRs will not be admitted to trading in Sweden or elsewhere. During the period 13May up to and including 13 August 2024 (the “Conversion Period”), holders of SDRs may, free of charge, apply for conversion of SDRs into Polestar Class A ADSs, which can be traded on Nasdaq New York. Polestar Class A ADSs will be delivered to SDR holders who applies for conversion during the Conversion Period on a bi-weekly basis. The SDR-program is a temporary solution that will be terminated in connection with the expiry of the Conversion Period on 13 August 2024. Upon termination, all holders of SDRs who have not yet converted their SDRs into Polestar Class A ADSs, will automatically have their SDRs redeemed by Skandinaviska Enskilda Banken, as agreed with Volvo Cars, whereby the Polestar Class A ADSs that the SDRs represent will be sold on Nasdaq New York, at prevailing market terms at that point in time. The sale will take place as soon as practicable after the termination of the SDR-program. The payment of the proceeds from the sale of Polestar Class A ADSs will be paid pro rata to the previous holders of such SDRs. Such payment is expected to take place on or around 27 August 2024. Depending on whether the SDR holder’s holding is directly or nominee registered, different measures are required in order to participate in the conversion of SDRs into Polestar Class A ADSs. If your SDRs are nominee registered, follow the instructions you receive from your nominee to participate in the conversion of SDRs into Polestar Class A ADSs. Please note that Polestar Class A ADSs cannot be distributed to directly registered holders of SDRs. Consequently, directly registered holders of SDRs must open a custody account, an investment savings account (Sw. investeringssparkonto) or an endowment insurance (Sw.kapitalförsäkring) and transfer the SDRs to that account to participate in the conversion of SDRs into Polestar Class A ADSs. After opening of such account, follow the instructions from your nominee to participate in the conversion of SDRs into Polestar Class A ADSs. The Swedish Tax Agency will issue recommendations for determination of the allocation of the acquisition cost of the original Volvo Cars shares of series B between the redemption shares and the original Volvo Cars shares, the redemption share disposal value and the acquisition cost for distributed SDRs and the dividend value for withholding tax purposes. The recommendations will be made available on Volvo Cars’ website, https://investors.volvocars.com/en/the-share/polestar (subject to certain confirmations), and the Swedish Tax Agency’s website, www.skatteverket.se on or around 20 May 2024. An information brochure with further information and detailed instructions on the conversion from SDRs to Polestar Class A ADSs as well as the general terms and conditions for the SDRs, are available on Volvo Cars’ website, https://investors.volvocars.com/en/the-share/polestar (subject to certain confirmations). An information video relating to the disitribution and a shareholder Q&A has also been prepared and made available on Volvo Cars’ website and can be accessed via the same link. For information regarding Polestar, as well as the Polestar Class A ADSs, please refer to Polestar’s website, https://investors.polestar.com/. -------------------------------- Volvo Cars in 2023 For the full year 2023, Volvo Car Group recorded a record-breaking core operating profit of SEK 25.6 billion. Revenue in 2023 amounted to an all-time high of SEK 399.3 billion, while global sales reached a record 708,716 cars. About Volvo Car Group Volvo Cars was founded in 1927. Today, it is one of the most well-known and respected car brands in the world with sales to customers in more than 100 countries. Volvo Cars is listed on the Nasdaq Stockholm exchange, where it is traded under the ticker “VOLCAR B”. "For life. To give people the freedom to move in a personal, sustainable and safe way." This purpose is reflected in Volvo Cars' ambition to become a fully electric car maker by 2030 and in its commitment to an ongoing reduction of its carbon footprint, with the ambition to be a climate-neutral company by 2040. As of December 2023, Volvo Cars employed approximately 43,400 full-time employees. Volvo Cars' head office, product development, marketing and administration functions are mainly located in Gothenburg, Sweden. Volvo Cars' production plants are located in Gothenburg, Ghent (Belgium), South Carolina (US), Chengdu, Daqing and Taizhou (China). The company also has R&D and design centres in Gothenburg and Shanghai (China). For further information please contact: Volvo Cars Media Relations +46 31-59 65 25media@volvocars.com Volvo Cars Investor Relations +46 31-793 94 00 investors@volvocars.com -------------------------------- Disclaimer / Forward Looking Statements The information contained in this document is for background information only and does not purport to be full or complete. This document does not constitute or form part of any invitation or inducement to engage in investment activity, nor does it constitute an offer or invitation to buy any securities in any jurisdiction or a recommendation in respect of buying, holding or selling any securities. This document is not an offer to sell, or solicitation of an offer to buy, acquire or subscribe for, or otherwise invest in, any securities to any person in any jurisdiction. Volvo Car AB (publ) (the“Company”) has not made and does not intend to make any offer of securities in any jurisdiction. The proposed corporate events and securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state of the United States and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable state or local securities law. This document is not for publication or distribution, directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The distribution of this document may be restricted by laws in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Nothing in this document constitutes legal, financial, tax or other advice and each shareholder should consult an independent adviser as to the possible application of legal (including on national security and investment regulations, foreign direct investment regulations and/or similar laws or regulations), financial, tax or other advice in relation to the corporate events described herein. In the United Kingdom, this document has not been approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. Accordingly, such document is not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to, and may only be acted upon by, those persons in the United Kingdom falling within Article 43 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”) (which includes the existing shareholders of the Company) or any other persons to whom it may otherwise lawfully be made available to under the Financial Promotion Order. This document may include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms “believe”, “expect”, ”anticipate”, “intend”, “estimate”, “project”, “will”, “may”, “target”, “should” and similar expressions, or, in each case, their negative or other variations or comparable terminology, or by discussions of strategies, plans, objectives, goals, future events or intentions. Any forward-looking statements reflect the Company’s current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company’s business, financial position, liquidity, prospects, growth and strategies. Forward-looking statements speak only as of the date they are made and are subject to change. To the fullest extent permitted under applicable laws, the Company and its affiliates expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in this document whether as a result of new information, future developments or otherwise. None of the Company or any of its affiliates, or any of the Company’s or its affiliates' directors, officers, employees, advisors or agents, accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this document (or whether any information has been omitted from the document) or that any transaction has been or may be effected on the terms or in the manner stated herein or as to the achievement or reasonableness of future projections, estimates or prospects, if any, or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the document or its contents or otherwise arising in connection therewith. The timing of the proposed corporate events described herein may be influenced by a variety of factors which include market conditions. Past performance is not a guide to future performance. Information in this document cannot be relied upon as a guide to future performance.

New Study: The price tag of phasing-out coal

Coal phase-out is necessary to solve climate change, but can have negative impacts on workers and local communities dependent on coal for their livelihoods. Researchers at Chalmers University of Technology in Sweden and Central European University in Austria have studied government plans for coal phase-out around the world and discovered that more than half of such plans include monetary compensation to affected parties. This planned compensation globally amounts to USD 200 billion, but it excludes China and India, the two largest users of coal that currently do not have phase-out plans. The study shows that if China and India decide to phase out coal as fast as needed to reach the Paris climate targets and pay similar compensation, it would cost upwards of USD 2 trillion. To slow global warming, coal use needs to end. Many governments, mostly in Europe, have begun to phase-out coal, but these policies can harm companies, risk unemployment, and lead to economic hardship for coal-dependent regions. In response, some countries have adopted what are known as ‘just transition’ strategies, where governments support negatively impacted companies, workers, and regions. Germany for example, has pledged over EUR 40 billion to support those affected by coal phase-out. “Previously, coal phase out has often been blocked by the interests opposing it. Many countries have put money on the table through ‘just transition’ strategies which has made coal phase-out politically feasible,” says Jessica Jewell, Associate Professor at Chalmers University of Technology, and one of the authors of the study. The researchers have studied all countries with coal phase-out plans around the world and found that those with the most coal power production and with plans for rapid phase-out, have compensation policies in place. In total, these 23 countries with 16 percent of the world’s coal power plants have pledged about USD 209 billion in compensation. This may sound like a lot of money, but the researchers point out that it equates to roughly 6 gigatons of avoided CO\2\ emissions and the cost of compensation for coal phase-out per tonne of avoided CO\2\ emissions (USD 29-46 per tonne) is actually well below recent carbon prices in Europe (~USD 64-80  per tonne). “So far these ‘just transition’ policies are consistent with, or lower than, the carbon prices within the EU, which means they make sense in terms of climate change. But more funding is likely needed if we want to reach the Paris climate target,” says Jewell. This is because achieving the goals of the Paris climate agreement will not be possible without participation of the world’s major coal consumers, China and India, which have more than half of the world’s coal plants, but no phase-out plans currently in place. The study finds that, for China and India to adopt compensation policies similar to those already in place, the estimated compensation amount for both countries would be USD 2.4 trillion for the 2°C target and USD 3.2 trillion for the 1.5°C target. “The estimated compensation for China and India is not only larger in absolute terms, but would also be more expensive compared to their economic capacities”, says Lola Nacke, a doctoral student at Chalmers University of Technology, and one of the authors of the study. A big question thus is where such large sums of money would come from. Today about half of all compensation is funded from international sources such as Just Energy Transition Partnerships* supporting coal phase-out in Vietnam, Indonesia and South Africa. International finance might also be needed to support future coal phase-out compensation in major coal consuming countries. However, the researchers point out that the estimated amounts of compensation for China and India alone are comparable to the entire international climate finance pledged in Paris, and larger than current international development aid to these countries. “Discussions about the cost of climate change mitigation often focus on investments in renewable energy technologies – but we also see it’s essential to address social implications of fossil fuel decline to enable rapid transitions”, says Lola Nacke. Fact Box: *Just Energy Transition Partnerships  –  Just Energy Transition Partnerships (JETPs) are new multi-lateral structures for accelerating the phase-out of fossil fuels. These intergovernmental partnerships coordinate financial resources and technical assistance from countries in the Global North to a recipient country to help it in this regard. JETPs related to coal phase-out are currently in place for Vietnam, Indonesia and South Africa. EU Just Transition Fund  –  The fund is the first pillar of the Just Transition Mechanism. The Commission provides support to Member States having identified the territories expected to be the most negatively impacted by the transition towards climate-neutrality. The Just Transition Fund supports the economic diversification and reconversion of the territories concerned.  Paris Climate Agreement  –  To tackle climate change and its negative impacts, world leaders at the UN Climate Change Conference (COP21) in Paris reached a breakthrough on 12 December 2015: the Paris Agreement. The Agreement sets long-term goals to guide all nations to: · substantially reduce global greenhouse gas emissions to hold global temperature increase to well below 2°C above pre-industrial levels and pursue efforts to limit it to 1.5°C above pre-industrial levels, recognising that this would significantly reduce the risks and impacts of climate change. · provide financing to developing countries to mitigate climate change, strengthen resilience and enhance abilities to adapt to climate impacts. More about the research: The research is presented in the paper: "Compensating affected parties necessary for rapid coal phase-out but expensive if extended to major emitters ", published in the journal Nature Communications. The researchers involved in the study are Lola Nacke, Vadim Vinichenko, Aleh Cherp, Avi Jakhmola and Jessica Jewell, and they are active at Chalmers University of Technology, Sweden; Central European University, Austria; Lund University, Sweden; University of Bergen, Norway and International Institute for Applied Systems Analysis, Austria. For more information, please contact:  Lola Nacke , Doctoral Student, Division of Physical Resource Theory, Department of Space, Earth and Environment, Chalmers University of Technology, Sweden, lolan@chalmers.se Jessica Jewell , Associate Professor, Division of Physical Resource Theory, Department of Space, Earth and Environment, Chalmers University of Technology, Sweden, jewell@chalmers.se, +46 31 772 61 06  The contact persons speak English and are available for live and pre-recorded interviews. At Chalmers, we have podcast studios and broadcast filming equipment on site and would be able to assist a request for a television, radio or podcast interview. NOTE TO THE EDITOR - IMAGES: The Chalmers Press portal can be accessed here  and you can search for any images or videos.  We kindly request credit to be given in the following format where possible: Image/Graphic/Illustration: Chalmers University of Technology | Name Surname Images provided in Chalmers University of Technology press releases are, unless specified otherwise, free for download and publication as long as credit is given to the University and the individual creator. Cropping and rescaling of the images is permitted when required for adaptation to the publication’s format, but modifications that would influence the message and content of the original are not. The material is primarily intended for journalistic and informative use, to assist in communication and coverage of Chalmers’ research and education. Commercial usage, for example the marketing of goods and services, is not permitted.

Tobii Dynavox enters into an agreement to acquire Link Assistive, gaining direct presence in Australia and New Zealand

Tobii Dynavox AB (publ) (“Tobii Dynavox”), the world leader in assistive communication, today has entered into an agreement to acquire all business activities and assets of its reselling partner Link Assistive Pty Ltd and Link Assistive New Zealand Limited (the “Transaction”). The Transaction brings Tobii Dynavox closer to its customers in the Australian and New Zealand markets, supporting people with disabilities to communicate more effectively. The Transaction is expected to be completed during the second half of 2024. Background and reason for the acquisitionLink Assistive  is the leading supplier of communication aid solutions and services to customers in Australia and New Zealand.  Link Assistive has grown over the past decade to currently 21 employees and is headquartered in Adelaide, Australia, with a local sales office in Perth and remotely operating staff in several other locations in Australia and New Zealand. Tobii Dynavox’s solutions comprise the majority of Link Assistive’s revenue, as the companies have a long-standing partnership. Link Assistive’s turnover in 2023 was over AU$8 million with an adjusted EBIT margin of 10%. Tobii Dynavox pays the seller AU$8 million in cash at closing, with a potential additional consideration after a period of two years. The seller and founder, Bas Tijdhof, will be the CEO of Tobii Dynavox Pty Ltd doing business as Link Assistive for a period of at least two years. After closing completion of the Transaction, approximately 40% of Link Assistive’s revenue and 100% of its profits will contribute to Tobii Dynavox’s consolidated result. “I am delighted to welcome Link Assistive to the Tobii Dynavox family,” said Nils Normell, President, Tobii Dynavox, Europe & Rest of the World.  “Our collaboration over the past decade has been very strong and I am consistently impressed with the commitment and growth of the Link Assistive team.  Our recent reseller acquisitions in Ireland  and Denmark  have effectively supported more people who need communication aids.  As Australia is one of the strongest assistive communication markets, we will be positioned to realize the market potential and empower more people with a voice by collaborating more closely.” “For many years Link Assistive and Tobii Dynavox have partnered in order to bring a voice to people in Australia and New Zealand,” said Bas Tijdhof, founder and CEO of Link Assistive.  “When I founded Link Assistive in 2008, my goal was to provide people with disabilities access to high quality communication devices.  A natural progression of this partnership is for Link Assistive to become part of the Tobii Dynavox family so that we can assist even more Australians and New Zealanders with outstanding service and high-quality assistive technologies.  I am excited to be part of the growing Tobii Dynavox global team that is committed to providing communication aids to those who need a voice.”  Transaction detailsThe upfront consideration of AU$8 million will be paid in cash and financed with Tobii Dynavox’s own cash but mainly through an existing revolving credit facility. Additionally, a potential earn-out consideration of up to AU$5 million in cash may be paid to the seller based on the financial performance during a period of two years after completion of the Transaction. Completion of the Transaction is subject to relevant regulatory approvals and other customary conditions. Completion is expected to occur in the second half of 2024. This information is inside information that Tobii Dynavox AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CEST on May 13, 2024. 

EQT INFRASTRUCTURE VI, THROUGH OTELLO BIDCO AB, ANNOUNCES A RECOMMENDED CASH OFFER OF SEK 60 PER SHARE TO THE SHAREHOLDERS OF OX2 AB (PUBL)

EQT Infrastructure VI[1], through Otello BidCo AB[2] (“Otello BidCo”), hereby announces a recommended public offer to the shareholders of OX2 AB (publ) (“OX2” or the “Company”) to tender all their shares at a price of SEK 60 in cash per share (the “Offer”). The shares in OX2 are admitted to trading on Nasdaq Stockholm, Large Cap. The Company’s founder and largest shareholder Peas Industries AB (“Peas Industries”), representing approximately 45.56 percent of the shares and votes in OX2, has irrevocably undertaken to accept the Offer. The independent bid committee of the Board of Directors of OX2 has unanimously resolved to recommend that shareholders accept the Offer.[3] Key highlights and summary of the Offer · Otello BidCo offers SEK 60 in cash per OX2 share (the “Offer Price”). The total value of the Offer is approximately SEK 16,351 million. · The Offer Price represents a premium of: · · approximately 43.4 percent compared to the closing price of SEK 41.8 of OX2 shares on Nasdaq Stockholm on 10 May 2024, which was the last trading day prior to the announcement of the Offer; · · approximately 45.8 percent compared to the volume-weighted average trading price of SEK 41.1 of OX2 shares on Nasdaq Stockholm during the last 30 trading days prior to the announcement of the Offer; and · · approximately 29.2 percent compared to the volume-weighted average trading price of SEK 46.4 of OX2 shares on Nasdaq Stockholm during the last 90 trading days prior to the announcement of the Offer. · The independent bid committee of the Board of Directors of OX2 unanimously recommends that the Company’s shareholders accept the Offer. The recommendation is supported by a fairness opinion provided by Ernst & Young AB (“EY”). · The Company’s founder and largest shareholder Peas Industries, representing approximately 45.56 percent of the shares and votes in OX2, has entered into an undertaking to accept the Offer, irrespective of whether a higher competing offer is made. · The Offer is conditional upon the Offer being accepted to such extent that Otello BidCo becomes the owner of shares representing more than 50 percent of the total number of shares in OX2. In addition, the Offer is made on the terms and subject to the conditions (ii)–(vii) set out below in this announcement. · The acceptance period is expected to commence on or around 25 June 2024 and expire on or around 14 October 2024 to allow for receipt of customary regulatory approvals. Otello BidCo reserves the right to extend the acceptance period, one or several times, as well as to postpone the time for settlement. If customary regulatory approvals are received in such time that the acceptance period can be closed before 14 October 2024, Otello BidCo may announce an earlier end date of the acceptance period, provided that such announcement can be made not less than two weeks prior to the new date of expiry of the acceptance period. Christoph Balzer, Partner at EQT Partners and Investment Advisor to EQT Infrastructure VI, says: “EQT is impressed by the growth of OX2, which has become one of Europe’s main renewable energy developers under the leadership of its founders and management team. The renewables industry is supported by strong underlying trends and expected to grow substantially over the coming period. To unlock OX2’s full potential, we believe it would benefit from a transition to a more long-term, sustainable business model and becoming an integrated renewables developer and asset owner. EQT is well-suited to partner with the Company during this next phase, offering the necessary capital and deep industry expertise to accelerate its growth journey.” Johan Ihrfelt, CEO of Peas Industries, says: “This has been an emotional decision to take. Still, as OX2’s founder and main shareholder, we believe that to take our vision even further, the Company will be well positioned under EQT’s ownership as it looks to undertake the next phase of its development. With EQT’s extensive experience and expertise in acquiring and managing businesses, particularly within the renewable energy sector, coupled with a proven track record of navigating capital-intensive transitions, we have full confidence that EQT will serve as the ideal partner to support OX2’s future growth.” Background to and reasons for the Offer OX2, founded in 2004, is a leading renewable energy platform with a large and diverse project portfolio across all major renewable energy technologies (onshore and offshore wind, solar, and storage) and is today one of the largest developers of onshore wind in Europe. Headquartered in Stockholm, Sweden, the Company is currently present in 11 markets across Europe and since 2023, also in Australia. During the past years, OX2 has grown into a leading independent renewable energy developer in Europe and beyond, with a strong operational and financial track record as well as a robust set of capabilities across the value chain, including development, construction, and management. Recent market conditions, such as higher interest rates, long development timelines, and supply chain disruptions have put some short-term pressures on OX2. To maintain and grow its market position, capitalize on emerging opportunities and strengthen its presence within renewable energy in the long-term, OX2 would benefit from evolving its business model from a pure developer to an integrated renewables developer and asset owner, while retaining its ability to sell projects. EQT is a global investment organization with an active ownership approach. For more than 15 years, EQT Infrastructure has partnered with its portfolio companies to help build strong, resilient businesses for the future. It has invested over €12bn in the energy transition. EQT believes it is well positioned to become a good owner of OX2, bringing extensive experience investing in the renewables sector and in the energy transition broadly. EQT plans to provide additional investment in OX2’s pipeline while using its industry expertise to support its transformation. EQT is pleased that Peas Industries, the founder of OX2, has entered into an undertaking to accept the Offer, irrespective of whether a higher competing offer is made. EQT’s ambition is to obtain 90 percent ownership and delist the Company, as EQT believes that the possibilities to accelerate the strategy will be better in a private setting. However, to ensure a responsible change of ownership, the Offer is conditioned by Otello BidCo reaching an acceptance level over 50 percent of the shares, showcasing its commitment to owning OX2 and continue to invest in its future development, whether in a private or public setting. Management and employees Otello BidCo is fully supportive of the current management team and safeguards employee positions. There are currently no decisions on any material changes that may impact OX2’s employees and management or the existing organization and operations, including the terms of employment and locations of the business. Furthermore, there are no employees in Otello BidCo, which means that the Offer does not entail any changes for the management and employees in Otello BidCo. Otello BidCo will offer, and has received the consent of the independent bid committee of the Board of Directors of OX2 to offer, a management incentive plan for certain key employees of OX2, including the CEO. Whereas the CEO has committed to participating, the remainder of the participants will receive the offer to participate following completion of the Offer. The incentive plan, which is subject to completion of the Offer, is designed for the purpose of ensuring the continued long-term commitment by key employees and will be offered to key employees regardless of whether they currently own shares in OX2. The terms are customary in the private equity industry and include transfer and leaver provisions, and participation requires an investment in shares in a holding entity within the Otello BidCo group. While the final size of the incentive plan depends on the final number of participants and their respective investment levels, the participants’ aggregate ownership share in a holding company within the Otello BidCo group is expected to be approximately five percent, assuming the Otello BidCo group will acquire 100 percent of OX2. Otello BidCo has obtained a statement from the Swedish Securities Council (Sw. Aktiemarknadsnämnden) (Ruling 2024:29) confirming that the management incentive plan is compatible with the Swedish Stock Market Self-Regulation Committee’s Takeover rules for Nasdaq Stockholm and Nordic Growth Market NGM (the “Takeover Rules”). The Offer Consideration Otello BidCo offers SEK 60 in cash per OX2 share. Should OX2, prior to settlement of the Offer, distribute dividends or in any other way distribute or transfer value to its shareholders, the Offer Price will be reduced accordingly. The total value of the Offer is approximately SEK 16,351 million.[4] No commission will be charged in connection with settlement of the Offer. The Offer Price represents a premium of: · approximately 43.4 percent compared to the closing price of SEK 41.8 of OX2 shares on Nasdaq Stockholm on 10 May 2024, which was the last trading day prior to the announcement of the Offer; · approximately 45.8 percent compared to the volume-weighted average trading price of SEK 41.1 of OX2 shares on Nasdaq Stockholm during the last 30 trading days prior to the announcement of the Offer; and · approximately 29.2 percent compared to the volume-weighted average trading price of SEK 46.4 of OX2 shares on Nasdaq Stockholm during the last 90 trading days prior to the announcement of the Offer. Otello BidCo’s shareholding in OX2 Neither Otello BidCo nor any closely related companies or closely related parties own any shares or other financial instruments in OX2 that give financial exposure to OX2 shares at the time of this announcement, nor has Otello BidCo acquired or agreed to acquire any OX2 shares or any financial instruments that give financial exposure to OX2 shares during the six months preceding the announcement of the Offer. Otello BidCo may acquire, or enter into agreements to acquire, shares in OX2 (or any securities that are convertible into, exchangeable for or exercisable for such shares) outside the Offer, but in any event, at a price per share not more than the Offer Price. Any purchases made or agreed will be in accordance with Swedish law and the Takeover Rules and will be disclosed in accordance with applicable rules. Statement from the independent bid committee of the Board of Directors of OX2 and fairness opinion The independent bid committee of the Board and Directors of OX2 unanimously recommends the shareholders of OX2 to accept the Offer. The bid committee has further obtained a fairness opinion from EY, according to which the Offer is assessed to be fair for OX2’s shareholders from a financial perspective, based on the assumptions and considerations included in the statement. The independent bid committee of the Board of Directors of OX2 consists of the board members Niklas Midby, Malin Persson and Ann Grevelius. The board members Johan Ihrfelt, Thomas von Otter and Anna-Karin Eliasson Celsing are also board members of the Company’s largest shareholder Peas Industries, which has entered into an undertaking to accept the Offer (through its wholly-owned subsidiary Peas Industries Invest AB) (please see “Undertakings from shareholders of OX2” below). Consequently, Johan Ihrfelt, Thomas von Otter and Anna-Karin Eliasson Celsing are deemed to have a conflict of interest pursuant to Rule II.18 of the Takeover Rules and they have for this reason not participated in the resolution to recommend the shareholders of OX2 to accept the Offer. The Company’s CEO, Paul Stormoen, is a shareholder in Peas Industries and is therefore also deemed to have a conflict of interest pursuant to Rule II.18 of the Takeover Rules. Undertakings from shareholders of OX2 Otello BidCo has obtained an irrevocable undertaking to accept the Offer from the Company’s founder and largest shareholder Peas Industries through its wholly-owned subsidiary Peas Industries Invest AB. Peas Industries has undertaken to tender 124,168,572 shares (45.56 percent of the shares and votes in OX2). The irrevocable undertaking applies irrespective of whether a higher competing offer is made. The irrevocable undertaking will terminate if the Offer is not declared unconditional on or before 3 February 2025. Conditions for completion of the Offer The completion of the Offer is conditional upon: i. the Offer being accepted to such an extent that Otello BidCo becomes the owner of shares in OX2 representing more than 50 percent of the total number of shares in OX2 (on a fully diluted basis); ii. the receipt of all regulatory, governmental or similar clearances, approvals and decisions that are necessary for the Offer and the acquisition of OX2, including from competition authorities and authorities for foreign direct investments (FDI), in each case on terms which, in Otello BidCo’s opinion, are acceptable; iii. no circumstances having occurred which could have a material adverse effect or could reasonably be expected to have a material adverse effect on OX2’s financial position, prospects or operations, including OX2’s sales, results, liquidity, equity ratio, equity or assets; iv. neither the Offer nor the acquisition of OX2 being rendered wholly or partially impossible or significantly impeded as a result of legislation or other regulation, any decision of a court or public authority, or any similar circumstance; v. OX2 not taking any action that is likely to impair the prerequisites for making or completing the Offer; vi. no information made public by OX2 or disclosed by OX2 to Otello BidCo being materially inaccurate, incomplete or misleading, and OX2 having made public all information which should have been made public by OX2; and vii. no other party announcing an offer to acquire shares in OX2 on terms more favorable to the shareholders of OX2 than the Offer. Otello BidCo reserves the right to withdraw the Offer in the event that it becomes clear that any of the above conditions is not satisfied or cannot be satisfied. However, with regard to conditions (ii)–(vii) above, the Offer may only be withdrawn where the non-satisfaction of such condition is of material importance to Otello BidCo’s acquisition of OX2 or if otherwise approved by the Swedish Securities Council. Otello BidCo reserves the right to waive, in whole or in part, one or more of the conditions above, including, with respect to condition (i) above, to complete the Offer at a lower level of acceptance. Information about Otello BidCo and EQT Otello BidCo is a newly established Swedish limited liability company (with corporate registration number 559479-1856, domiciled in Stockholm, Sweden), indirectly owned by EQT Infrastructure VI. Otello BidCo was founded on 20 March 2024 and registered with the Swedish Companies Registration Office on 10 April 2024. Otello BidCo has never conducted, and at present does not conduct, any business, and its sole business purpose is to make the Offer. EQT is a purpose-driven global investment organization focused on active ownership strategies. With a Nordic heritage and a global mindset, EQT has a track record of almost three decades of developing companies across multiple geographies, sectors and strategies. EQT has investment strategies covering all phases of a business’ development, from start-up to maturity. EQT has EUR 242 billion in total assets under management (EUR 132 billion in fee-generating assets under management), within two business segments - Private Capital and Real Assets. With its roots in the Wallenberg family’s entrepreneurial mindset and philosophy of long-term ownership, EQT is guided by a set of strong values and a distinct corporate culture. EQT manages and advises funds and vehicles that invest across the world with the mission to future-proof companies, generate attractive returns and make a positive impact with everything EQT does. EQT has offices in more than 25 countries across Europe, Asia and the Americas and has more than 1,800 employees. For more information about EQT, please see EQT’s website: www.eqtgroup.com. Financing of the Offer The Offer is not subject to any financing conditions. The cash consideration payable in respect of the Offer is financed in full by funds available to Otello BidCo by way of an equity commitment letter issued by EQT Infrastructure VI EUR SCSp and EQT Infrastructure VI USD SCSp. Due diligence in connection with the Offer Otello BidCo has, in connection with the preparations of the Offer, conducted a due diligence review of OX2. With the exception of information that was subsequently included in OX2’s Q1 report for 2024, OX2 has confirmed that Otello BidCo has not been provided with any inside information regarding OX2 in connection with the due diligence review. Preliminary timetable Publication of the offer document 24 June 2024Acceptance period 25 June 2024–14 October 2024Commencement of settlement 21 October 2024 As set out above, the completion of the Offer is conditional upon, inter alia, the receipt of all regulatory, governmental or similar clearances, approvals and decisions that are necessary for the Offer and the acquisition of OX2. Such clearances, approvals and decisions are expected to have been received by the end of the acceptance period for the Offer. If all relevant clearances, approvals and decisions are received in such time that the acceptance period can be closed before 14 October 2024, Otello BidCo may announce an earlier end date of the acceptance period, provided that such announcement can be made not less than two weeks prior to the new date of expiry of the acceptance period. Otello BidCo further reserves the right to extend the acceptance period for the Offer, one or several times, as well as to postpone the time for settlement. Otello BidCo has been granted an exemption from the Swedish Securities Council (Ruling 2024:43) permitting that the initial acceptance period for the Offer is longer than ten weeks (up to 16 weeks) to enable Otello BidCo to obtain necessary regulatory clearances within that period. Compulsory redemption proceedings and delisting If Otello BidCo, whether in connection with the Offer or otherwise, acquires shares representing more than 90 percent of the total number of shares in OX2, Otello BidCo intends to commence compulsory redemption proceedings under the Swedish Companies Act (2005:551) to acquire all remaining shares in OX2 and to promote delisting of OX2’s shares from Nasdaq Stockholm. Governing law and disputes The Offer and the agreements entered into between Otello BidCo and OX2’s shareholders in relation to the Offer, shall be governed by and be interpreted in accordance with Swedish law. Disputes concerning, or arising in connection with the Offer, shall be settled exclusively by Swedish courts, with the Stockholm District Court as first instance. The Takeover Rules and the Swedish Securities Council’s rulings and statements on the interpretation and application of the Takeover Rules are applicable to the Offer. Otello BidCo has undertaken to Nasdaq Stockholm to comply with the Takeover Rules and to submit to any sanctions that can be imposed on Otello BidCo by Nasdaq Stockholm in the event of a breach of the Takeover Rules. Advisors Otello BidCo and EQT Infrastructure VI have retained Rothschild & Co Nordic AB as lead financial advisor, Carnegie Investment Bank AB as financial advisor and Advokatfirman Vinge KB and Simpson Thacher & Bartlett LLP as legal advisors in connection with the Offer. Otello BidCo The Board of Directors Information about the Offer Information about the Offer is made available at: www.sustainable-energy-offer.com The information was submitted for publication on 13 May 2024, 07.30 CEST. For enquiries, please contact: EQT Press Office +46 8 506 55 334, press@eqtpartners.com Fogel & Partners, Frida Malm +46 730 653 885, otellobidco@fogelpartners.se Important information This press release has been published in Swedish and English. In the event of any discrepancy in content between the two language versions, the Swedish version shall prevail. This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law (the “Restricted Jurisdictions”). The release, publication or distribution of this press release in or into jurisdictions other than Sweden may be restricted by law and therefore any persons who are subject to the laws of any jurisdiction other than Sweden should inform themselves about, and observe any applicable requirements. In particular, the ability of persons who are not resident in Sweden to accept the Offer may be affected by the laws of the relevant jurisdictions in which they are located. Any failure to comply with the applicable restrictions may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies and persons involved in the Offer disclaim any responsibility or liability for the violation of such restrictions by any person. This announcement has been prepared for the purpose of complying with Swedish law, the Takeover Rules and the Swedish Securities Council’s rulings regarding interpretation and application of the Takeover Rules and the information disclosed may not be the same as that which would have been disclosed if this press release had been prepared in accordance with the laws of jurisdictions other than Sweden. Unless otherwise determined by Otello BidCo or required by Swedish law, the Takeover Rules and the Swedish Securities Council’s rulings regarding interpretation and application of the Takeover Rules, and permitted by applicable law and regulation, the Offer will not be made available, directly or indirectly, in, into or from a Restricted Jurisdiction or any other jurisdiction where to do so would violate the laws in that jurisdiction and no person may accept the Offer by any use, means or instrumentality (including, but not limited to, facsimile, e-mail or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or of any facility of a national, state or other securities exchange of any Restricted Jurisdiction or any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction and the Offer may not be capable of acceptance by any such use, means, instrumentality or facilities. Accordingly, copies of this press release and any formal documentation relating to the Offer are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or into or from any Restricted Jurisdiction or any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction and persons receiving such documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send them in or into or from any Restricted Jurisdiction or any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction. The availability of the Offer to shareholders of OX2 who are not resident in and citizens of Sweden may be affected by the laws of the relevant jurisdictions in which they are located or of which they are citizens. Persons who are not resident in or citizens of Sweden should inform themselves of, and observe, any applicable legal or regulatory requirements of their jurisdictions. The Offer, the information and documents contained in this press release are not being made and have not been approved by an authorized person for the purposes of section 21 of the UK Financial Services and Markets Act 2000 (the “FSMA”). Accordingly, the information and documents contained in this press release are not being distributed to, and must not be passed on to, the general public in the United Kingdom, unless an exemption applies. The communication of the information and documents contained in this press release is exempt from the restriction on financial promotions under section 21 of the FSMA on the basis that it is a communication by or on behalf of a body corporate which relates to a transaction to acquire day to day control of the affairs of a body corporate; or to acquire 50 percent or more of the voting shares in a body corporate, within article 62 of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and other effects of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, “estimates”, “plans”, “will be” or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Actual results and developments may differ materially from those expressed in, or implied or projected by these forward-looking statements due to many factors, many of which are outside the control of Otello BidCo. Forward-looking statements appear in a number of places throughout this announcement and the information incorporated by reference into this announcement and may include statements regarding the intentions, beliefs or current expectations of Otello BidCo or OX2 concerning, amongst other things: (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (ii) business and management strategies, the expansion and growth of Otello BidCo’s or OX2’s business operations and potential synergies resulting from the Offer; and (iii) the effects of government regulation and industry changes on the business of Otello BidCo or OX2. Any forward-looking statements made herein speak only as of the date on which they are announced. Except as required by the Takeover Rules or applicable law or regulations, Otello BidCo expressly disclaims any obligation or undertaking to publicly announce updates or revisions to any forward-looking statements contained in the offer document to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. The reader should, however, consult any additional disclosures that Otello BidCo or OX2 have made or may make. Important notice to shareholders in the United States of America The Offer described in this press release is made for the issued and outstanding shares of OX2, a company incorporated under Swedish law, and is subject to Swedish disclosure and procedural requirements, which may be different from those of the United States. The Offer is made in the United States pursuant to Section 14(e) of the U.S. Securities Exchange Act of 1934, as amended (the “U.S. Exchange Act”) and Regulation 14E thereunder (“Regulation 14E”), to the extent applicable, and subject to exemptions provided by Rule 14d-1 under the U.S. Exchange Act, and otherwise in compliance with the disclosure and procedural requirements of Swedish law, including with respect to withdrawal rights, the Offer timetable, notices of extensions, announcements of results, settlement procedures (including as regards to the time when payment of the consideration is rendered) and waivers of conditions, which may be different from requirements or customary practices in relation to U.S. domestic tender offers. The offeror’s ability to waive the conditions to the Offer (both during and after the end of the acceptance period) and the shareholders’ ability to withdraw their acceptances, may not be the same under a tender offer governed by Swedish law as under a tender offer governed by U.S. law. Holders of the shares of OX2 domiciled or resident in the United States (the “U.S. Holders”) are encouraged to consult with their own advisors regarding the Offer. OX2’s financial statements and all financial information included herein, or any other documents relating to the Offer, have been or will be prepared in accordance with IFRS and may not be comparable to the financial statements or financial information of companies in the United States or other companies whose financial statements are prepared in accordance with U.S. generally accepted accounting principles. The Offer is made to the U.S. Holders on the same terms and conditions as those made to all other shareholders of OX2 to whom the offer is being made. Any information documents, including the offer document, are being disseminated to U.S. Holders on a basis comparable to the method pursuant to which such documents are provided to OX2’s other shareholders. U.S. Holders should note that OX2 is not listed on a United States securities exchange, is not subject to the periodic requirements of the U.S. Exchange Act and is not required to, and does not, file any reports with the United States Securities and Exchange Commission. The U.S. Holders should consider that the price for the Offer is being paid in SEK and that no adjustment will be made based on any changes in the exchange rate. It may be difficult for U.S. Holders to enforce their rights and any claims they may have arising under the U.S. federal or state securities laws in connection with the Offer, since OX2 is located in another country other than the United States, and some or all of its officers and directors may be residents of countries other than the United States. U.S. Holders may not be able to sue OX2 or Otello BidCo or their respective officers or directors in a non-U.S. court for violations of U.S. securities laws. Further, it may be difficult to compel OX2 or Otello BidCo and/or their respective affiliates to subject themselves to the jurisdiction or judgment of a U.S. court. To the extent permissible under applicable law or regulations, Otello BidCo and its affiliates or its brokers and its brokers’ affiliates (acting as agents for Otello BidCo or its affiliates, as applicable) may from time to time and during the pendency of the Offer, and other than pursuant to the Offer, directly or indirectly purchase or arrange to purchase shares of OX2 outside the United States in reliance on applicable exemptions from the requirements of Regulation 14E (or any securities that are convertible into, exchangeable for or exercisable for such shares). These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices, but in any event, at a price per share not more than the Offer Price, and information about such purchases will be disclosed by means of a press release or other means reasonably calculated to inform U.S. Holders of such information. In addition, affiliates to the financial advisors to Otello BidCo may also engage in ordinary course trading activities in securities of OX2, which may include purchases or arrangements to purchase such securities as long as such purchases or arrangements are in compliance with applicable law and regulation. Any information about such purchases will be announced in Swedish and in a non-binding English translation available to the U.S. Holders through relevant electronic media if, and to the extent, such announcement is required under applicable Swedish or U.S. law, rules or regulations. The receipt of cash pursuant to the Offer by a U.S. Holder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each shareholder is urged to consult an independent professional advisor regarding the tax consequences of accepting the Offer. Neither Otello BidCo nor any of its affiliates and their respective directors, officers, employees or agents or any other person acting on their behalf in connection with the Offer shall be responsible for any tax effects or liabilities resulting from acceptance of this Offer. NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE OFFER, PASSED ANY COMMENTS UPON THE MERITS OR FAIRNESS OF THE OFFER, PASSED ANY COMMENT UPON THE ADEQUACY OR COMPLETENESS OF THIS PRESS RELEASE OR PASSED ANY COMMENT ON WHETHER THE CONTENT IN THIS PRESS RELEASE IS CORRECT OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES. Rothschild & Co Nordic AB (“Rothschild & Co”) is financial advisor to Otello BidCo and EQT Infrastructure VI and no one else in connection with the Offer. Rothschild & Co is not responsible to anyone other than Otello BidCo and EQT Infrastructure VI for providing protections afforded to clients of Rothschild & Co nor for providing advice in relation to the Offer. The information contained herein does not constitute an offer to sell, nor a solicitation of an offer to buy, any security, and may not be used or relied upon in connection with any offer or solicitation. Any offer or solicitation in respect of EQT Infrastructure VI will be made only through a confidential private placement memorandum and related documents which will be furnished to qualified investors on a confidential basis in accordance with applicable laws and regulations. The information contained herein is not for publication or distribution to persons in the United States of America. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold without registration thereunder or pursuant to an available exemption therefrom. Any offering of securities to be made in the United States would have to be made by means of an offering document that would be obtainable from the issuer or its agents and would contain detailed information about the issuer of the securities and its management, as well as financial information. The securities may not be offered or sold in the United States absent registration or an exemption from registration. [1] The fund known as EQT Infrastructure VI, comprising of EQT Infrastructure VI EUR SCSp, a Luxembourg special limited partnership (société en commandite spéciale) with its registered office at 51A, Boulevard Royal, L-2449 Luxembourg, Grand Duchy of Luxembourg, registered with the Luxembourg trade and companies register (Registre de Commerce et des Sociétés, Luxembourg) under number B267825, and EQT Infrastructure VI USD SCSp, a Luxembourg special limited partnership (société en commandite spéciale) with its registered office at 51A, Boulevard Royal, L-2449 Luxembourg, Grand Duchy of Luxembourg, registered with the Luxembourg trade and companies register (Registre de Commerce et des Sociétés, Luxembourg) under number B267826, both acting by their manager (gérant) EQT Fund Management S.à r.l., a Luxembourg limited liability company (société à responsabilité limitée), with its registered office at 51A, Boulevard Royal, L-2449 Luxembourg, Grand Duchy of Luxembourg, registered with the Luxembourg Trade and Companies Register (Registre de Commerce et des Sociétés, Luxembourg) under number B167972. [2] A newly established Swedish private limited liability company (Sw. privat aktiebolag) controlled by EQT Infrastructure VI, with corporate registration number 559479-1856 and under name change from Goldcup 35136 AB. [3] The OX2 board members Johan Ihrfelt, Thomas von Otter and Anna-Karin Eliasson Celsing, as well as the Company’s CEO, Paul Stormoen, have not participated in the OX2 Board of Directors’ evaluation of or discussions regarding the Offer due to a conflict of interest (please see also “Statement from the independent bid committee of the Board of Directors of OX2 and fairness opinion” below). [4] Based on 272,517,586 shares in OX2.

Autoliv Announces Results of 2024 Annual General Meeting of Stockholders

Annual General Meeting of Stockholders The Company’s 2024 Annual General Meeting of Stockholders (AGM) voted for approval of the following proposals: · The election of Mikael Bratt, Laurie Brlas, Jan Carlson, Hasse Johansson, Leif Johansson, Franz-Josef Kortüm, Frédéric Lissalde, Xiaozhi Liu, Gustav Lundgren, Martin Lundstedt, and Thaddeus “Ted” Senko as directors of the Board for a one-year term ending at the 2025 AGM; · The non-binding, advisory resolution to approve the Company’s 2023 executive compensation for its named executive officers; and · The ratification of the appointment of Ernst & Young AB as the Company’s independent auditing firm for the fiscal year ending December 31, 2024. Committees of the Board At the Board meeting, the Board approved the membership of its standing committees as follows: · Audit and Risk Committee: Ted Senko (Chair), Laurie Brlas, Hasse Johansson, and Gustav Lundgren   · Leadership Development and Compensation Committee: Frédéric Lissalde (Chair), Leif Johansson, Xiaozhi Liu, and Martin Lundstedt  · Nominating and Corporate Governance Committee: Leif Johansson (Chair), Laurie Brlas, Franz-Josef Kortüm, and Frédéric Lissalde Chairman The Board resolved that Jan Carlson continues to serve as the Chairman of the Board. Inquiries: Investors & Analysts: Anders Trapp, Tel +46 (0)8 587 206 71 Investors & Analysts: Henrik Kaar, Tel +46 (0)8 587 206 14 Media: Gabriella Etemad, Tel +46 (0)70 612 64 24  About Autoliv Autoliv, Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world as well as mobility safety solutions, such as pedestrian protection, connected safety services and safety solutions for riders of powered two wheelers. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2023, our products saved 35,000 lives and reduced more than 450,000 injuries. Our 70,000 associates in 25 countries are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. We drive innovation, research, and development at our 14 technical centers, with their 20 test tracks. Sales in 2023 amounted to US $ 10.5 billion. For more information go to www.autoliv.com. Safe Harbor Statement This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including general economic conditions and fluctuations in the global automotive market. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

Norse Atlantic more than doubles YoY passenger numbers with strong increases in ASK and RPK for April.

April 2024 flying increased substantially compared to the same period in 2023 with passenger numbers more than doubling during the month. Year on year positive increases across all key figures. The month saw an average load factor of 79 per cent, representing an increase of 12 percentage points (p.p.) year on year. During April, Norse Atlantic Airways had 98,542 passengers across 398 flights, including 61 charter flights. 81 per cent of flights arrived within 15 minutes of their scheduled arrival time with a completion rate of 100 per cent. "April represented another strong month for Norse as we ramped up the number of flights as part of our summer schedule, load factor also increased by 12 percentage points to 79%, however, some negative effect was expected due to Easter falling in March compared to the previous year. In addition, we welcomed more than double the number of passengers compared to the same period last year and look forward to a busy summer ahead. We completed a record high of 61 charter operations throughout the month, as we now move to increase flying on our own network during the summer season, I am pleased to note that we are already well positioned for longer term charter agreements for next winter," said Bjorn Tore Larsen, CEO and Founder Norse Atlantic Airways. Key traffic figures for April are attached. Contacts: Investors: CFO, Anders Hall Jomaas, Anders.Jomaas@flynorse.com Media: SVP Communications, Philip Allport, philip.allport@flynorse.com Norse Atlantic Airways is an airline that offers affordable fares on long-haul flights, primarily between Europe and the United States. The company was founded by CEO and major shareholder Bjørn Tore Larsen in March 2021. Norse has a fleet of 15 modern, fuel-efficient and more environmentally friendly Boeing 787 Dreamliners that serve destinations including New York, Las Vegas, Los Angeles, Orlando, Miami, Cape Town, Bangkok, Oslo, Athens, London, Berlin, Rome and Paris. The company's first flight took off from Oslo to New York on June 14, 2022.

Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck

Maria Alfaiate will be responsible for strengthening corporate strategic functions and enhancing global marketing efforts. Her focus will be on optimizing Lundbeck’s ability to capitalize on both present and future opportunities. Maria brings significant experience from the life science and pharmaceutical sectors globally. Her expertise in developing strategic plans and executing programs to deliver state-of-the-art solutions for patients across diverse markets will play a pivotal role in shaping Lundbeck’s future growth. “I am delighted to welcome Maria to Lundbeck. Her impressive track record in strategic commercial leadership is a great asset to our company. Her ability to design and execute innovative plans, coupled with her deep understanding of global markets, will undoubtedly strengthen our corporate strategic functions, and support the success of therapies as they become available to patients,” says President and CEO Charl van Zyl. “Embarking on this new journey, I am fueled by the possibilities ahead and the opportunity to be impactful. I am joining a remarkable group of individuals devoted to helping patients suffering from neurological or psychiatric conditions. The vision of making a positive contribution to people and society resonates tremendously at a personal level,” says Maria Alfaiate. Maria joins Lundbeck from Bayer where she recently served as Senior Vice President and Global Head of New Products Commercialization and Portfolio Strategy. Prior to this, Maria has held positions at AstraZeneca and MSD/ Merck, in global teams but also at country level. Maria is of Portuguese nationality and holds a Master of Clinical Psychology from Universidade de Coimbra, Portugal. Contacts Thomas Mikkel Mortensen Palle Holm OlesenMedia Relations Lead, Corp. Communication Vice President, Investor RelationsTHMR@lundbeck.com PALO@lundbeck.com (PALO@lundbeck.com)+45 30 83 30 24 +45 30 83 24 26 About H. Lundbeck A/SLundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases. As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options. Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.  For additional information, we encourage you to visit our corporate site www.lundbeck.com  and connect with us via LinkedIn .

Bravida Finland strengthens its position in western Finland

Vesi-Vasa Oy was founded in 1984 and works with installation, service and maintenance of heating and plumbing systems, industrial pipes and fire extinguishing systems. The company offers services for both small projects, such as houses, and larger industrial projects.“We are very pleased to welcome Vesi-Vasa and their skilled employees to Bravida. With this acquisition, we are gaining expertise that meets the needs of both real estate and industrial customers in the Satakunta region. The expansion is fully in line with Bravida's strategy of growing in Finland, and strengthens our range of services for customers,” comments Marko Holopainen, Head of Division for Bravida Finland.Jani Vainio, CEO of Vesi-Vasa Oy, comments:“The growth of our business activities and a changing world will require strong expertise in the industry in the future, and as part of Bravida we will be able to meet these demands. We will be able to provide even better service to our customers and continue to be an attractive employer for our staff.”Bravida is expected to take over as the new owner in June 2024.For further information, please contact: Liselotte StrayHead of Group Communicationsliselotte.stray@bravida.se+46 76 852 38 11

Alleima expands its production capacity for the Industrial Heating segment in Japan

The total investment of approximately SEK 100 million includes the development of a new facility near the Kanthal division’s current premises in Sakura, Japan. The expansion will increase production capacity of electrical heating solutions to the Industrial Heating segment in Japan by approximately 60%, with ramp up starting in 2025.  The global growth in lithium-ion batteries and semiconductors is a driver for an increased demand for Kanthal’s solutions for the Industrial Heating segment. In addition, a broad range of industries, such as steel and automotive, are looking to convert heating processes from fossil fuel to electric solutions, making the production more energy efficient whilst also lowering CO2 emissions. The aim is to capture mid- and long-term market growth in Asia. “We invest in further capacity to cater to the growing demand of the Asian Industrial Heating customers. This investment aligns perfectly with our strategy for profitable growth”, says Göran Björkman, President and CEO of Alleima. The investment will be carried out during a two-year period and capex guidance of approximately SEK 950 million for full year 2024 remains unchanged. Sandviken, May 13, 2024 Alleima AB (publ) Contact details Emelie Alm, Head of Investor RelationsEmelie.alm@alleima.comPhone: +46 (0) 79060 87 17 Yvonne Edenholm, Press and Media Relations ManagerYvonne.edenholm@alleima.comPhone: +46 (0) 72145 23 42 About AlleimaAlleima, is a global manufacturer of high value-added products in advanced stainless steels andspecial alloys as well as solutions for industrial heating. Based on long-term customer partnerships and leading materials technology, we develop products for the most demanding applications and industries. Our offering includes products likeseamless steel tubes for the energy, chemical and aerospace industries, precision strip steel for white goods compressors, air conditioners and knife applications, based on more than 900 active alloy recipes. It also includes ultra-fine wires for medical and micro-electronic devices, industrial electric heating technology and coated strip steel for fuel cell technology for cars, trucks, and hydrogen production. Our fully integrated value chain, from R&D to end-product, ensures industry-leading technology, quality, sustainability, and circularity. Alleima, with headquarter in Sandviken, Sweden, had approximately 6,500 employees and revenues of about 21 billion SEK in about 80 countries in 2023. The Alleima share was listed on Nasdaq Stockholm’s Large Cap list on August 31, 2022 under the ticker ‘ALLEI’. Learn more atwww.alleima.com .

Bulletin from the extraordinary general meeting in SciBase Holding AB (publ)

Amendment of the articles of associationThe general meeting resolved, in accordance with the board of directors' three proposals, to amend §§ 4-5 of the articles of association, entailing: · that the articles of association shall be amended so that the share capital shall be not less than SEK 10,065,000 and not more than SEK 40,260,000 and that the number of shares shall be not less than 201,300,000 and not more than 805,200,000, · that the articles of association shall be amended so that the share capital shall be not less than SEK 10,780,000 and not more than SEK 43,120,000 and that the number of shares shall be not less than 215,600,000 and not more than 862,400,000, and · that the articles of association shall be amended so that the share capital shall be not less than SEK 11,500,000 and not more than SEK 46,000,000 and that the number of shares shall be not less than 230,000,000 and not more than 920,000,000. The general meeting further resolved, in a accordance with the board of directors' proposal,  to authorize the board of directors to register with the Swedish Companies Registration Office the above resolution to amend the Articles of Association, the limits of which for the minimum and maximum number of shares in the Company are consistent with the total number of shares in the Company after the rights issue announced on 5 April 2024 and the directed issues of units that the board of directors resolved upon on 5 April 2024 (that were conditional upon the subsequent approval of the general meeting). Directed issues The general meeting resolved, in accordance with the board of directors' proposal, to approve the resolution made by the board of directors on 5 April 2024, on a new issue of a maximum of 74,136,510 units to Ribbskottet AB, Per Olof Ejendal AB, Kåre Gilstring, Robert Molander, MLJK Konsult AB, Klintemar Konsult AB, Jesper Hoiland, Fredrik Mattsson, Stefan Hansson, Theodor Invest AB, Ulti AB, Van Herk Investments B.V., Morningside Group AB, Viktor Drvota and Eric Terhaerdt. The subscription price for each unit is SEK 0.42, corresponding to a subscription price of SEK 0.42 per share. Warrants of series TO 2 are issued free of charge. The issue results in an increase in the number of shares in the Company of a maximum of 74,136,510 shares, entailing a maximum increase of the share capital of SEK 3,706,825.50, and a new issue of a maximum of 370,682,550 warrants of series TO 2 entitling to subscription of 370,682,550 shares in the Company, whereby the share capital may increase by an additional maximum of SEK 18,534,127.50 if all issued warrants of series TO 2 are exercised. In total, the share capital may increase by a maximum of SEK 22,240,953.00. The general meeting further resolved in accordance with the board of directors' proposal to approve the resolution made by the board of directors on 5 April 2024, on a new issue of a maximum of 3,755,259 units to Matt Leavitt. The subscription price for each unit is SEK 0.42, corresponding to a subscription price of SEK 0.42 per share. Warrants of series TO 2 are issued free of charge. The issue results in an increase in the number of shares in the Company of a maximum of 3 755 259 shares, entailing a maximum increase of the share capital of SEK 187,762.95, and a new issue of a maximum of 18,776,295 warrants of series TO 2 entitling to subscription of 18,776,295 shares in the Company, whereby the share capital may increase by an additional maximum of SEK 938,814.75 if all issued warrants of series TO 2 are exercised. In total, the share capital may increase by a maximum of SEK 1,126,577.70. For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: pia.renaudin@scibase.com Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: ca@vatorsec.se About SciBase: SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The Company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases

Ratos Company Aibel and Hitachi Energy sign framework agreement with RWE to accelerate offshore wind integration

Under the global framework agreements, RWE has contracted Aibel and Hitachi Energy in a split contract model. The framework agreement stipulates how the three projects, and potentially additional projects in the future, will be handled. It allows Aibel and Hitachi Energy to manage resources such as securing supply chain, hiring workforce, allocating engineering and manufacturing capacity, and ordering materials ahead of time.“The success story in Aibel continues at a high and steady pace. It is very pleasing that this contract now is in place. It gives both the opportunity to invest even more in the future and to do so in a sustainable way. The importance of Aibel and its partners in the transition towards a more energy efficient and sustainable future is significant – in this project part of the scale and speed needed to be even more successful are secured,” says Christian Johansson Gebauer, board member of Aibel and President, Business Area Construction & Services, Ratos.“The agreement with RWE confirms that we have a competitive concept developed in collaboration with Hitachi Energy, and a reliable common delivery model with a balanced risk-reward profile. The capacity reservation provides predictability and further strengthens our position as a leading supplier to the offshore wind market,” says Mads Andersen, President and CEO of Aibel.Securing the capacity early and the signing of CRA demonstrates RWE's intent to accelerate the pace at which offshore energy can be integrated to the grids. The new framework agreement has the potential to deliver other possible projects worldwide.The three projects are the latest of several jointly undertaken by Aibel and Hitachi Energy since the two companies announced their strategic partnership in 2016. Key offshore wind projects won by the two companies include converter stations for Dogger Bank A, B, and C and Hornsea 3 Link 1 and Link 2 in the UK, as well as Dolwin 5 in Germany.About AibelAibel builds and maintains critical infrastructure for the energy sector and is one of the largest supplier companies in Norway. In the last five years, the company has provided products and services worth NOK 50 billion to the Norwegian Continental Shelf and is also the largest supplier of solutions within the area of electrification of offshore installations and onshore facilities. Currently, Aibel has five deliveries to offshore wind parks in Germany and the UK sector with a total contract value of more than NOK 15 billion and is the largest Norwegian supplier of infrastructure for the offshore wind industry. More than 4,950 employees work at the company’s offices in Norway, Thailand and Singapore and the company owns modern offshore yards in Haugesund, Norway, and Laem Chabang and Map Ta Phut, Thailand, with significant prefabrication and construction capacity. The Ratos holding in Aibel is 32%.For more information, please contact:Josefine Uppling, VP Communication, Ratos, +46 76114 54 21About RatosRatos is a Swedish business group focusing on technological and infrastructure solutions, consisting of 17 companies divided into three business areas: Construction & Services, Industry and Consumer. The companies have approximately SEK 34 billion in net sales (LTM). We have a distinct corporate culture and strategy – everything we do is based on our core values: Simplicity, Speed in execution and It’s All About People. We enable independent subsidiaries to excel by being part of something larger. People, leadership, culture and values are key focus areas.

Redsense Medical Spotlight presentation at the 61[st] ERA Congress in Stockholm

Redsense Medical will exhibit at the 61[st] ERA (European Renal Association) Congress in Stockholm, May 23-26, 2024. The Redsense blood loss security systems will be showcased at booth F.320, including the upcoming Clamp that is expected to be commercially launched during 2024. The company was also allotted one of four Spotlight presentation slots, which is a novelty to this year’s programme and described as “Designed to showcase cutting-edge industry innovations and insights alongside scientific content”. Redsense has invited high-profile hemodialysis physicians Dr. Christopher Chan from UHN Toronto, Canada, and Dr. Joachim Beige from KfH Kuratorium Leipzig, Germany, to present and lead discussion at the session titled “An examination of adverse vascular access bleeding events: solving the unmet gap”. The session will be held on Friday May 24 at 14:50 – 15:10 CEST on “the square” Spotlight Stage in the Exhibition area. “It is an exceptional opportunity to have two physicians of this caliber presenting their data supporting the importance of improving safety in hemodialysis and doing so highlighting both the angle of instilling confidence in patients and as such empowering self-care, as well as underlying structural questions as reporting incidents, awareness and education, and reimbursement.” says Sebastien Bollue, COO of Redsense Medical leading Congress activities and Clamp evaluation. The abstract of the presentation:Venous needle dislodgment (or central venous catheter port disconnection) during hemodialysis sessions may lead to significant or even catastrophic blood loss, particularly during unsupervised therapies.  Our symposium aims to illustrate the scope of this important safety concern and to provide a systematic review of the present mitigation strategies.  Through iterative and usability design, the Redsense vascular access clamp device is developed with the aim to provide additional safety to dialysis without excessive intrusion. Through our presentations and interactive demonstration, we hope to address the aforementioned learning objectives. Our symposium is intended for all dialysis providers and stakeholders. For more details about the presentation: https://era-apps.m-anage.com/era24/en-GB/pag/session/85558 For further information about the Congress: https://www.era-online.org/events/stockholm-2024/ “We look forward to participating in this premier event in the field of nephrology with visitors from all of the world. This Congress is an excellent opportunity for us to engage with stakeholders in the dialysis community and promote patient safety with the Redsense Alarm system and showcase our latest innovation, the Redsense Clamp, providing an extra layer of security for hemodialyis patients.” says Pontus Nobréus, CEO of Redsense Medical.

Relesys A/S announces request for removal from trading and expected commencement of compulsory redemption of minority shareholde

Request for removal from trading on Nasdaq First North Growth Market Denmark In continuation of company announcements no 4-2024 and no. 8-2024 with respect to the sale of approximately 93.5% of the shares in Relesys A/S ("Relesys") to Copilot Capital Limited (“Copilot”), Relesys hereby announces that it has submitted a request to Nasdaq Copenhagen A/S ("Nasdaq") for the removal of trading of its shares on Nasdaq First North Growth Market Denmark, upon request from Copilot. The request is based on the simplified procedure pursuant to rule 2.6(c)(i) of supplement D to the Nasdaq First North Growth Market Rulebook for Issuers of Shares dated 19 April 2024 as Copilot now holds more than 90% of the shares and the voting rights in Relesys. Subject to approval from Nasdaq, the last day of trading of Relesys' shares on Nasdaq First North Growth Market Denmark is expected to be on 14 May 2024. Expected commencement of compulsory redemption Furthermore, Relesys has been informed that Copilot intends to exercise its rights under sections 70 and 72 of the Danish Companies Act, meaning that all remaining minority shareholders of Relesys are expected to be requested to transfer their remaining shares in Relesys to Copilot. The compulsory redemption will be requested in a separate notice which will be published in Euronext Securities and the Danish Business Authority, expectedly on or around 15 May 2024. Pursuant to the compulsory redemption, shareholders will have a four-week period to sell their shares to Copilot. After the four-week period, all remaining shares will be compulsory redeemed.   Certified Adviser for RelesysGrant ThorntonStockholmsgade 452100 Copenhagen ØDenmark

Tietoevry appoints Cosimo De Carlo as Managing Director, Tietoevry Create

Tietoevry Corporation  STOCK EXCHANGE RELEASE13 May 20241:00 p.m. EEST Tietoevry Create, the digital engineering arm of Tietoevry, provides business advisory and design, data engineering and specialized software R&D services globally across a range of industry sectors. The business employs nearly 10 000 professionals worldwide. Cosimo De Carlo is appointed as Managing Director of Tietoevry Create effective 1 September 2024. Cosimo has over 20 years of experience in the engineering services industry, most recently starting from year 2018 as the CEO of EDAG Group, the largest independent engineering services provider to the automotive sector operating globally. Prior to EDAG Cosimo had a leadership position with Altran (today Capgemini Engineering) as Group Vice President Automotive with responsibility for leading the Automotive vertical globally alongside regional responsibility for Germany, Austria and the Czech Republic. Cosimo has further led several key acquisitions and worked with clients worldwide across many industries like Automotive and Aerospace. Cosimo holds master’s degrees in computer science engineering and business engineering. “I am very excited to embark on this new chapter in Tietoevry Create. Already today the business operates globally and comprises a strong customer base combined with a unique combination of skills and capabilities. The business has the ambition of becoming a global leader in digital engineering, which I find highly motivating. I truly look forward to working towards this ambition together with the global Create team and its customers and partners,” comments Cosimo De Carlo. “I warmly welcome Cosimo De Carlo to Tietoevry, to steer our Create business towards its ambition of global leadership in digital engineering. Cosimo brings with him over two decades of relevant international business experience, visible in tangible strategic and commercial achievements. During his career, Cosimo has also demonstrated the ability in leading and building successful businesses and organisations worldwide. I wish Cosimo and everyone in Create the best of success,” comments Kimmo Alkio, Tietoevry CEO. As Managing Director, Tietoevry Create, Cosimo De Carlo will report to Tietoevry’s CEO Kimmo Alkio and be a member of the Group Executive Management team. Cosimo is based in Munich, Germany. Harri Salomaa will continue as the acting Managing Director of Tietoevry Create until Cosimo enters his position. For further information, please contactTommi Järvenpää, Head of Investor Relations, tel. +358 40576 0288, tommi.jarvenpaa (at) tietoevry.comTietoevry Communications, tel. +358 40 5704072, news (at) tietoevry.com Tietoevry Corporation DISTRIBUTION NASDAQ Helsinki NASDAQ Stockholm Oslo Børs Principal Media Tietoevry creates purposeful technology that reinvents the world for good. We are a leading technology company with a strong Nordic heritage and global capabilities. Based on our core values of openness, trust and diversity, we work with our customers to develop digital futures where businesses, societies, and humanity thrive. Our 24 000 experts globally specialize in cloud, data, and software, serving thousands of enterprise and public-sector customers in more than 90 countries. Tietoevry’s annual turnover is approximately EUR 3 billion and the company’s shares are listed on the NASDAQ exchange in Helsinki and Stockholm, as well as on Oslo Børs. www.tietoevry.com

Approval from Nasdaq Copenhagen of request to remove shares from trading on Nasdaq First North Growth Market Denmark

Relesys A/S ("Relesys") announced in company announcement no. 9-2024 earlier today that a request to Nasdaq Copenhagen ("Nasdaq") had been submitted regarding the removal of trading of Relesys' shares from Nasdaq First North Growth Market Denmark. Relesys hereby announces that Nasdaq today has approved the request to remove Relesys' shares from trading based on the simplified procedure pursuant to rule 2.6(c)(i) of supplement D to the Nasdaq First North Growth Market Rulebook for Issuers of Shares dated 19 April 2024, as Copilot now holds more than 90% of the shares and the voting rights in Relesys. Nasdaq Copenhagen has confirmed that the last day of trading of Relesys' shares on Nasdaq First North Growth Market Denmark will be on 14 May 2024. Compulsory redemptionAll remaining minority shareholders in Relesys are expected to be requested by Copilot, by separate notice on 15 May 2024, to transfer all their remaining shares in Relesys to Copilot within a four-week period expected to end on 12 June 2024, in accordance with sections 70 and 72 of the Danish Companies Act. Certified Adviser for RelesysGrant ThorntonStockholmsgade 452100 Copenhagen ØDenmark

Kongsberg Automotive’s Capital Markets Day 2024

Kongsberg, May 13, 2024: Kongsberg Automotive (KA) is hosting its Capital Market’s Day today at 13:00 (CET). Key highlights: · Long-term financial ambitions 2028 of revenues above EUR 1.0 bn and EBIT margin at or above 8.5% · Reestablishment of Kongsberg, Norway as the headquarters · Continued focus to achieve 100% renewable energy in all sites by 2030 and carbon neutral products by 2039 · High focus on innovation and improvement · Strategic aim to become a technology and market leader within our core business areas KA’s Capital Market’s Day 2024 presentation is enclosed and available on KA’s website. Media and communications contact:Therese Sjöborg Skurdal – Director Corporate Communicationstherese.skurdal@ka-group.com+47 982 14 059 Investor Relations contact:Mads Langaard – Head of Investor Relationsmads.langaard@ka-group.com+47 905 81 264 About Kongsberg Automotive ASAKongsberg Automotive provides cutting-edge technology to the global vehicle industry. We drive the global transition to sustainable mobility by putting engineering, sustainability, and innovation into practice. Our product portfolio includes driver and motion control systems, fluid assemblies, and industrial driver interface products. Find more information at: kongsbergautomotive.com 

Stena Line reinforces the Irish Sea management to drive growth in the region

Over recent years, Stena Line's Irish Sea operation has experienced significant expansion solidifying its status as a cornerstone of the company's network. With 13 ships operating across 7 routes and providing an impressive 240 sailings each week, the Irish Sea has become an increasingly vital component of Stena Line's business. The recent launch of the Dublin – Liverpool freight route further underscored the company's commitment to providing efficient and reliable transport solutions across the Irish Sea. As part of its ongoing development, Stena Line will be reinforcing regional management to effectively address the new opportunities and demands that lie ahead. Since 2020, Paul Grant and his dedicated regional management team have demonstrated remarkable resilience and leadership, successfully navigating through both Brexit and the challenges presented by the COVID-19 pandemic. Under their guidance, Stena Line has achieved significant growth, with car volumes increasing by almost 20% and freight volumes by 4%, setting new records for business levels in the region. Effective June 1, 2024, Stena Line will revert to a two-region structure to reflect its growing business needs. Paul Grant, who has played a pivotal role in the success of the Irish Sea operations, will assume responsibility for the newly established Irish Sea North region, overseeing operations from Belfast. In addition, Paul will join the main board of Stena Line (UK) Ltd. and serve as Stena Line’s representative on the UK Chamber of Shipping Ferry & Cruise. "The Irish Sea has long been a key market for Stena Line, and I am pleased to continue leading our efforts and growth in our Belfast hub," says Paul Grant, incoming Trade Director for Irish Sea North. "I am excited about the opportunities that lie ahead and confident that, with our reinforced management team, we will strengthen Stena Line's position as the foremost ferry operator in the Irish Sea." Johan Edelman will take up the role of Trade Director for the Irish Sea South region, overseeing operations from Dublin and Rosslare. With a focus on development and growth, Johan will work to further enhance Stena Line's presence in the region, building upon the strong foundation laid by his predecessors. Johan is currently the Trade Director for Baltic Sea North, covering the routes between Nynäshamn and Ventspils as well as between Liepāja and Travemünde. Johan Edelman, incoming Trade Director for Irish Sea South, states, "I am thrilled to join the team in the Irish Sea and look forward to driving growth and innovation in the Irish Sea South region. Together with Paul and the entire Stena Line team, I am committed to delivering exceptional service and value to our customers while further expanding our market presence." The Irish Sea North and Irish Sea South regions are closely connected, and both Paul and Johan will be dedicated to ensuring seamless collaboration and a unified brand experience across the entire Irish Sea network. As a result of these strategic changes, Stena Line will be well positioned to embark on a new chapter of growth and success in the Irish Sea, reaffirming its position as the preferred choice for passengers and freight operators alike. Further information Stena Line Group Press office +46 (0) 31 85 85 32, press@stenaline.com Stena Line is one of Europe's leading ferry companies with approximately 40 vessels and 20 routes in Northern Europe and the Mediterranean operating 33,300 sailings each year. Stena Line is an important part of the European logistics network and develops new intermodal freight solutions by combining transport by rail, road and sea. Stena Line also plays an important role in tourism in Europe with its extensive passenger operations. The company is family-owned, was founded in 1962 and is headquartered in Gothenburg. Stena Line has 6,100 employees and an annual turnover of 19 billion SEK.   www.stenaline.com

SciBase announces outcome in the directed issue of units

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT. Allotment of unitsAll units in the Directed Issue have been subscribed and the board of directors has therefore today, on 13 May 2024, resolved on allotment of units to Ribbskottet AB, Per Olof Ejendal AB, Kåre Gilstring, Robert Molander, MLJK Konsult AB, Klintemar Konsult AB, Jesper Hoiland, Fredrik Mattsson, Stefan Hansson, Ulti AB, Van Herk Investments B.V., Matt Leavitt, Viktor Drvota, Theodor Invest AB, and Eric Terhaerdt. Ribbskottet AB has chosen to subscribe for additional units in the Directed Issue by taking over Morningside Group AB's undertaking to subscribe for units in the Directed Issue. Thus, Morningside Group AB did not subscribe for and was not allotted any units in the Directed Issue. Each unit consists of one (1) share and five (5) warrants of series TO 2. Through the Directed Issue, SciBase will receive initial proceeds of approximately SEK 33 million before deduction of transaction costs. Number of shares and share capital Through the Directed Issue, the number of shares in SciBase will increase by 77,891,769 shares, from a total of 141,588,705 shares (calculated on the total number of shares in the Company after completion of the announced rights issue) to a total of 219,480,474 shares. Through the Directed Issue, the share capital in the Company will increase by SEK 3,894,588.45, from SEK 7,079,435.25 (calculated on the Company's share capital after completion of the announced rights issue) to SEK 10,974,023.70. The Directed Issue entails a dilution for existing shareholders of approximately 35.5 percent of the number of shares in the Company. Upon full exercise of the warrants of series TO 2 issued in the Directed Issue, the Company's share capital will increase by an additional SEK 19,472,942.25 through the issuance of 389,458,845 new shares entailing an additional dilution effect of approximately 64.0 percent. Advisors Vator Securities is the financial advisor and Advokatfirman Schjødt is the legal advisor to SciBase in connection with the Directed Issue. For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: pia.renaudin@scibase.com The information was submitted for publication, through the agency of the contact persons set out above, at 15.00 CEST on 13 May 2024. Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: ca@vatorsec.se About SciBase: SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The Company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases Important information Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus has been or will be prepared in connection with the Directed Issue. This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act") and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation. Forward-looking statements This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.

The patient study on Zeqmelit® is fully recruited

The phase IV study ZEQ001 on the oral film Zeqmelit®, an innovative oral film for the treatment of severe and acute allergies, commenced at the end of January. Now, 50 patients have been allocated the oral film for use when needed for acute allergic reactions. "The patient recruitment has exceeded our already high expectations, indicating the significant patient need for our pharmaceutical product," says Jonas Jönmark, CEO of AcuCort. "Furthermore, the study results can be used in an application to be included in the benefit system of TLV, the Dental and Pharmaceutical Benefits Agency." The study results will be published in scientific journals and strengthen the product's marketing efforts. The study is ongoing concurrently with the market launch in the Nordic region, where allergy patients are allocated Zeqmelit® for use when needed for acute allergic reactions. The purpose of the study, an open-label non-randomized low-intervention study, is to gather valuable scientific data on the use of Zeqmelit® from patients previously prescribed oral corticosteroids for self-treatment of acute allergic reactions. Dr. Bahram Javizian, the lead investigator for the study and an allergist, elaborates on the study's purpose: "We want to understand patients' experiences with this biofilm, such as: do they feel confident using it? How do they perceive using it? Perhaps most importantly, do patients carry the medication with them?"

Dolphin Drilling AS - UK Legacy tax case – permission to appeal to Supreme Court granted

Oslo, 13 May 2024 Dolphin Drilling AS (the "Company") (ticker code: DDRIL), further to the Company’s market update of 11 January 2024, in which the Company reported on a judgment of the English Court of Appeal in respect of a legacy tax case, the Company is pleased to report that it has today been informed that the UK Supreme Court has granted permission to the Company to proceed with an appeal against the said judgement. The hearing of the appeal by the UK Supreme Court has yet to be scheduled and would be anticipated during 2025. The Company shall continue to update the market in connection with the progress of the appeal. For further information, please contact: Ingolf Gillesdal, email: ingolf.gillesdal@dolphindrilling.com, tel: +47 920 45 320

AegirBio AB calls for payment of Tranche 1 of SEK 7.50 million and intends to carry out a directed set-off issue of 5,175,374 shares to Atlas Special Opportunities, LLC

The Loan Facility The loan facility consists of seven (7) tranches with a total nominal amount of SEK 45.00 million. AegirBio has today called for payment of Tranche 1 corresponding to SEK 7.50 million before deduction of a set-up fee of SEK 0.75 million and transaction costs. Tranches drawn under the Loan Facility are interest-free and mature on April 9, 2027. Atlas has the right to call for conversion of debt in directed issues of all or part of the nominal amount of the called Tranches and the transaction fee up to and including the maturity date. The minimum amount to convert is SEK 0.50 million. To facilitate the administration of the conversions, the parties have agreed that a new issue under the Loan Facility shall be made when Atlas has called for conversion in an aggregate amount of at least MSEK 2.50 or if the market value of the transaction fee shares is less than MSEK 1.00. The Company will only announce conversions to the market when Atlas has called for conversions that lead to a new share issue. For more information on the Loan Facility, readers are referred to the press release dated April 9, 2024 (“AegirBio enters into a conditional agreement on a MSEK 45 loan facility with Atlas Special Opportunities and an agreement to amend the outstanding convertible bonds, subject to EGM approval"). Set-off Issue for Transaction Fee In accordance with the press release on April 9, 2024, a transaction fee of SEK 7,00 million was to be paid to Atlas for the issuance of the Loan Facility, the extension of outstanding Convertible Bonds and the cancellation of outstanding warrants of series TO4, to be paid by set-off against newly issued shares in AegirBio (the "Transaction Fee Shares"). As soon as payment of Tranche 1 has been made, the Board of Directors of AegirBio intends, based on the authorization received from the Annual General Meeting, to resolve to carry out a directed issue of 5,175,374 Transaction Fee Shares shares to Atlas, to be paid in full by Atlas through set-off. The subscription price shall correspond to 100.00 percent of the lowest daily volume-weighted average price according to the Nasdaq First North Growth Markets price list for the share in the Company during the fifteen (15) trading days preceding the date of the resolution of the new share issue, however, not less than the share’s quota value (currently SEK 0.08). Due to the set-off issue, the share capital in AegirBio increases by SEK 414,029.92 to a total of SEK 2,884,179.68 and the number of shares increases by 5,175,374 to a total of 36,052,246, which entails a dilution of approximately 14.36 percent of the total number of shares and votes in the Company after registration of the new shares at the Swedish Companies Registration Office. Prior to the decision to enter into the Loan Facility and amendment of the terms of the existing Convertible Bonds, the Company’s Board of Directors has, together with a financial advisor, carefully investigated the conditions for a rights issue to raise the necessary capital. The board’s assessment is that the Company currently, especially considering that the Company has SEK 40.00 million in outstanding Convertible Bonds that are held by Atlas, cannot meet its’ capital needs in any other way than through the Loan Facility with Atlas. The Board of Directors has together with a financial advisor assessed that a rights issue would require significant guarantee commitments from a guarantee syndicate, which has not been deemed possible for the Company to obtain. In addition, a rights issue would probably have been carried out at a significantly lower subscription price than that which Atlas will be able to convert at in accordance with the terms and conditions of the Loan Facility. The Board of Directors’ overall assessment is thus that the reasons for entering into the Loan Facility and subsequently carrying out directed share issues to Atlas in this way outweigh the reasons that justify the main rule of issuing shares with preferential rights for existing shareholders, and that share issues with deviation from the shareholders’ preferential rights in accordance with the Loan Facility are thus in the interest of the Company and all shareholders. The method for calculating the subscription price in the future share issues has, in consultation with a financial advisor and through analysis of the Company’s debt ratio and several market factors, been determined through arm’s length negotiations with Atlas. It is the Board of Directors’ assessment that the subscription price through this procedure will reflect current market conditions and demand and that it thereby is market-based.

Repurchases of shares by EQT AB during week 19, 2024

The repurchases form part of the repurchase program of a maximum of 2,154,000 own ordinary shares for a total maximum amount of SEK 1,000,000,000 that EQT announced on 22 April 2024. The repurchase program, which runs between 23 April 2024 and 24 May 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/1052. EQT ordinary shares have been repurchased as follows: Date: Aggregated daily Weighted average Total daily volume (number of share price per day transaction value shares): (SEK): (SEK):6 May 2024 94,658 306.0825 28,973,157.297 May 2024 105,000 314.1288 32,983,524.008 May 2024 50,000 312.3432 15,617,160.0010 May 2024 98,370 324.6684 31,937,630.51Total 348,028 314.6628 109,511,471.79accumulatedoverweek19/2024Total 1,084,806 302.8600 328,544,347.36accumulatedduring therepurchaseprogram All acquisitions have been carried out on Nasdaq Stockholm by Skandinaviska Enskilda Banken AB on behalf of EQT. Following the above acquisitions and as of 10 May 2024, the number of shares in EQT, including EQT’s holding of own shares is set out in the table below. [][] Ordinary shares Class C shares[1] TotalNumber of issued 1,245,048,412 881,555 1,245,929,967sharesNumber of shares 61,559,635 - 61,559,635owned by EQTAB[2]Number of 1,183,488,777 881,555 1,184,370,332outstandingshares 1) Carry one tenth (1/10) of a vote.2) EQT AB shares owned by EQT AB are not entitled to dividends or carry votes at shareholders’ meetings. A full breakdown of the transactions is attached to this announcement. ContactOlof Svensson, Head of Shareholder Relations, +46 72 989 09 15 EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

Hoist Finance has successfully issued bonds at a spread of 2.80%

Hoist Finance AB, ("Hoist Finance"), has successfully issued subsequent bonds in a nominal amount of SEK 100 million under its senior unsecured bond due 12 April 2027, bringing the total size of the bond to SEK 550 million. The bonds were issued at a price corresponding to a spread of STIBOR 3m +280 bps, marking a further improvement on the terms of the original issue. “We are very pleased to have completed the tap issue at strong terms, emphasizing our market access and commitment to investors. We are thankful for our investors’ support in Hoist Finance’s journey to becoming the leading investor in and manager of non-performing loans in Europe”, says Harry Vranjes, CEO of Hoist Finance The proceeds from the subsequent bond issue will be used for general corporate purposes. The instruments will be merged with the senior unsecured bond due 12 April 2027 (ISIN: XS2746114136), which is listed on the regulated market of Irish Stock Exchange plc, known as Euronext Dublin. The listed bonds are rated Baa3 by Moody’s. For further information please contact: Christian Wallentin, CFO och deputy CEOir@hoistfinance.com+46 8 55 51 77 90 About Hoist Finance Hoist Finance is an asset manager specialised in non-performing loans. For more than 25 years, we have focused on investing in and managing debt portfolios. We are a partner to international banks and financial institutions across Europe, acquiring non-performing loan portfolios. We are also a partner to consumers and SMEs in a debt situation, creating long-term sustainable repayment plans enabling them to convert non-performing debt to performing debt. We are present in 13 markets across Europe and our shares are listed on Nasdaq Stockholm. For more information, please visit hoistfinance.com.

Starbreeze AB (publ) interim report January-March 2024

First quarter 2024 · Net sales amounted to SEK 56.6 million (26.7). · PAYDAY 2 accounted for SEK 10.9 million (26.4). · PAYDAY 3 accounted for SEK 23.3 million (0). · Third-party publishing accounted for SEK 17.4 million (0). · EBITDA* amounted to SEK 48.5 million (4.1), including items affecting comparability of 19.9 million. · Cash flow from operating activities amounted to SEK 78.4 million (20.7). · Depreciation, amortization and impairment amounted to SEK 71.8 million (15.6). · Profit/loss before taxes amounted to SEK -21.0 million (-24.7). · Basic and diluted earnings per share amounted toSEK -0.01 (-0.03). · Cash and cash equivalents amounted to SEK 387.2 million (78.0). Significant events during and after the quarter · January 9, Starbreeze announced changes in Group management. · January 10, the Starbreeze Nomination Committee announced the proposal to appoint Jürgen Goeldner as the new Chairperson of the Board of Directors at the 2024 Annual General Meeting. · February 15, “Operation Medic Bag” was launched – a focused project to meet the expectations of the player community and improve PAYDAY 3. The game has seen three major updates since February 15. · February 22, The Tribe Must Survive was released in Early Access on Steam. · March 12, Board member Jürgen Goeldner was appointed interim CEO of Starbreeze. A process to recruit a permanent CEO is ongoing. · April 15, a content update was released for Roboquest with new content, new functionality, and improvements. CEO’s message PAYDAY™ 3 evolves with 'Operation Medic Bag' Starbreeze has been a force in the global games industry for more than 25 years and will continue to be so by developing and publishing games globally and leverage the strength of both the organization and the IP portfolio.During my months as interim CEO my focus has been on PAYDAY 3 as well as business development aspects, for example our presence at the Game Developers Conference (GDC) in March, where we among other things met industry peers and new potential partners. We also showed a playable tech demo of Project Baxter and received high interest. RESULTS AND FINANCIAL POSITION Our cash position at the end of the quarter was SEK 387m, with a balance sheet light on debt. The underlying result for the quarter, adjusted for items affecting comparability, was strong thanks to revenues from multiple titles as well as cost control measures. The revenue streams show that we are no longer a one product company. Together with our co-publisher we are running a concerted effort to improve on PAYDAY 3 by reprioritizing and focusing the development based on players’ feedback with only a minor impact on planned investments. PAYDAY 3 PAYDAY 3’s ‘Operation Medic Bag’ is a comprehensive initiative that covers both smaller initiatives as well as improvements to the games’ progression system. On top also matchmaking and server infrastructure and a solo/offline mode. We are going to increase both the cadence and scope of the patches, with several larger milestone releases planned, the first of which will launch in June. The team is working from feedback from our players and community, identifying the changes that we believe are the most impactful ones from a player perspective. We can already see the sentiment shift confirming that we are on the right track. “Operation Medic Bag” has meant that we’ve pushed some content DLCs in favor of adding new features. So, our pipeline for the summer months is very strong. Consequently, we expect to see an impact on sales from the third quarter onwards. The PAYDAY IP is strong, and the potential for the IP remains high, evident not only from our conversations in the industry. PROJECT BAXTER As previously mentioned, Starbreeze’ presence at GDC was in large part to talk to future partners about Baxter. While we will be the publisher of the game, we will enter partnerships where it makes sense. This will be for marketing, distribution in both the digital and physical sense or other support that increases the quality and potential of the project while at the same time lowering the project risk. THIRD PARTY PUBLISHING Roboquest continues to perform strongly, and we continue to work with the developer to expand the game. Roboquest follows a Games as a Service-model with four targeted updates slated for 2024, the first of which was published here in April. The game continues to enjoy a very high rating from both players and media.During the quarter, The Tribe Must Survive launched in Early Access on Steam. The purpose of Early Access is to foster a collaborative relationship with the player community, gathering valuable feedback on all aspects of the game. The 1.0 version of the full game will launch on May 23rd, 2024. ORGANIZATION During the quarter, the number of employees decreased slightly. We continue to hire specific competency for positions on Project Baxter while keeping the organization efficient for all our projects. CLOSING WORDS The search for a permanent CEO is coming to an end. For that position many candidates were identified, interviewed and assessed.With a “vertical slice” of Project Baxter as the next step of the project, interested parties will be invited to submit their offers and we will select the best partner and deal for the product, the brand and ultimately for the company. JÜRGEN GOELDNER, interim CEO Webcast Time: 10.00 CESTParticipation: To connect to the webcast– click here . For more information, please contact: Jürgen Goeldner, interim CEOMats Juhl, CFOTel: +46 0(8) - 209 229Email: ir@starbreeze.com This information is information that Starbreeze AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, via the contact persons set out above, at 6:45 am CEST on May 14, 2024. About StarbreezeStarbreeze is an independent developer, publisher, and distributor of PC and consoles targeting the global market, with studios in Stockholm, Barcelona, Paris and London. Housing the smash hit IP PAYDAY™, Starbreeze develops games based on proprietary and third-party rights, both in- house and in partnership with external game developers. Starbreeze shares are listed on Nasdaq Stockholm under the tickers STAR A and STAR B. Read more at www.starbreeze.com and corporate.starbreeze.com.

OssDsign AB (publ) publishes Q1 2024 interim report

OssDsign AB (publ) announces that the interim report for Q1 2024 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.The Q1 2024 results will also be presented at an investor webcast today May 14th at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q1-2024/  or via the OssDsign website. The first quarter in figures · Net sales amounted to TSEK 27,029 (21,466), now with all sales coming from orthobiologics in the U.S., which corresponds to a sales growth of 207% vs comparable numbers in Q1 2023. · The U.S. business continued its strong underlying growth, quarter on quarter, and has now demonstrated eight consecutive quarters of triple-digit growth. · Gross margin of 93.7% vs a blended margin of 70.4% in the same quarter in the previous year. · Operating loss of TSEK 12,034 (23,696). Sales variable costs increased whereas non-sales variable costs decreased compared to the previous year. Total operating expenses decreased vs the previous year. Continued trend of improved operating leverage in the business, albeit somewhat exaggerated in Q1, as a result of positive gross margin development and lower start of year operating expenses, as the company is transitioning more functions to the U.S. · Loss after taxes amounted to TSEK 11,148 (23,252). · Earnings per share were SEK -0.1 (-0.3). · Cash flow from current operations was TSEK -28,203 (-26,701), showing solid underlying improvement but, as previously stated, was expected to be adversely impacted by the outflow from high 2023 year-end bonus and non-recurring accruals. Important events during the first quarter · OssDsign reports compelling data from the clinical study TOP FUSION. · 12-month data from the clinical study of OssDsign Catalyst published in Biomedical Journal of Scientific & Technical Research. · OssDsign appoints Tom Buckland as Chief Technical Officer. Important events after the end of the first quarter · OssDsign awarded long-term agreement with Premier, Inc. · OssDsign expands military access with new contract covering 100 additional VA orthopedic hospitals.

YIT has sold its stake in joint venture Tieyhtiö Vaalimaa

YIT has sold its stake in joint venture Tieyhtiö Vaalimaa YIT has sold its stake in the joint venture Tieyhtiö Vaalimaa Oy to the company’s other owner Meridiam Infrastructure Finance II S.á.rl. YIT and Meridiam established a joint venture in 2015 to manage the E18 Hamina-Vaalimaa highway project, which was completed in 2018. In the project, YIT oversaw the construction of the road and continues its work as a project partner in road maintenance. Before the transaction, Meridiam owned 80% of Tieyhtiö Vaalimaa and YIT's ownership was 20%. The parties have agreed not to disclose the transaction price. The Hamina-Vaalimaa project comprised approximately 32 kilometres of new motorway construction and other related road alterations. The project significantly improved the safety and operability of the road; and high-quality environmental construction and stringent environmental consciousness played a significant role in project planning. "The cooperation with Meridiam and the Finnish Transport Infrastructure Agency in the implementation of the project was excellent and we will continue as a partner in road maintenance. The transaction is part of our previously communicated target to improve capital efficiency. We are pleased with the result of the transaction and its positive impact on our financial position", said Tuomas Mäkipeska, CFO, YIT Corporation. The sale is part of YIT's transformation program, one of the objectives of which is to improve YIT’s capital efficiency. In 2023, the company initiated a strategic review regarding certain assets and operations to secure the best possible value creation. Further information:YIT Group Communications: tel. +358 44 743 7536, press@yit.fi Distribution: Nasdaq Helsinki, major media, www.yitgroup.com YIT is a leading construction and development company. Building on over 110 years of experience, we develop and build sustainable living environments: functional homes, future-proof public and commercial buildings, and infrastructure to support the green transition. We employ approximately 4,300 professionals in eight countries. Our revenue in 2023 was EUR 2.2 billion. YIT Corporation's shares are listed on Nasdaq Helsinki. Read more: www.yitgroup.com  and follow us on Linkedin  I X  I Instagram  I Facebook 

Norse Atlantic ASA: Q1 2024 demonstrating substantial year-on-year improvements while preparing for growth into busy summer season

• Revenue increased by 97% to USD 78.2 million in Q1 2024 compared to Q1 2023 • 201,462 passengers carried in Q1 2024, up 83% compared to Q1 2023 • ASK up by 72% in Q1 2024 compared to Q1 2023 • Load factor increased by 19 percentage points to 73% in Q1 2024 compared to Q1 2023 • Strong operational performance as 100% of planned flights were completed during the quarter • Record high number of ACMI and charter operations, totalling 107 flights during the quarter • CASK numbers improving, CASK ex fuel being down by 28% in Q1 2024 compared to Q1 2023 • Total cash held at end of quarter at USD 33.2 million • Subsequent to the quarter end, a USD 20 million revolving credit facility was secured from Norse’s two largest shareholders for the purpose of providing a liquidity buffer prior to moving into the more cash generative summer season • Strategic options continue to be developed and explored in collaboration with advisors Seabury Securities “The first quarter has shown major improvement on all metrics compared to the first quarter of the previous year. ASK was up about 72% year-on-year, and load factors increased by 19 percentage points with improved revenues per passenger. Norse Atlantic continued to demonstrate robust operational excellence as 100 % of the quarter’s scheduled planned flights were completed as planned. This winter we have developed seasonal strategies, with more emphasis on holiday destinations and charters. Norse Atlantic managed a record high of 107 charter flights during the quarter. We will refine this strategy further for next winter, with several longer-term contracts secured or under negotiation. We are looking forward to the busiest summer season so far in Norse Atlantic´s short history. During the summer the fleet of aircraft operated in Norse’s own network increases from 10 to 12 aircraft, representing a capacity growth of 20%. Norse will continue to focus on careful and profitable growth. We are happy to see that our footprint in the market has increased as the network expands to include Athens this summer, Las Vegas from the fall, and a new continent as Cape Town joins the network in the winter. Our goal is to see CASK continuously decreasing year-on- year for each quarter. Norse remains steadfast in its commitment to achieve the lowest CASK in the Transatlantic market. Norse is on a path towards year-round profitability, and a successful summer 2024 is the next important stepping-stone on that journey,” said Bjorn Tore Larsen, CEO and Founder Norse Atlantic Airways. For further information please see attached Q1 2024 report and Q1 2024 presentation. A video presentation of the Q1 2024 results can be found here:  https://norse.videosync.fi/2024-q1-results Contacts: Investor contacts: Anders Hall Jomaas, CFO, Anders.Jomaas@flynorse.com Media contacts: Philip Allport, Senior Vice President Communications, media@flynorse.com This information is subject to the disclosure requirements pursuant to Section 5 -12 the Norwegian Securities Trading Act and the Euronext Growth Rule Book part II. Norse Atlantic Airways is an airline that offers affordable fares on long-haul flights, primarily between Europe and the United States. The company was founded by CEO and major shareholder Bjørn Tore Larsen in March 2021. Norse has a fleet of 15 modern, fuel-efficient and more environmentally friendly Boeing 787 Dreamliners that serve destinations including New York, Los Angeles, Orlando, Las Vegas, Cape Town, Bangkok, Miami, Oslo, Athens, London, Berlin, Rome and Paris. The company's first flight took off from Oslo to New York on June 14, 2022.

Saga Pure: First quarter 2024 financial results

For the first quarter 2024, Saga Pure reported a net profit of NOK 18 million. Saga had in the first quarter a gain on short term investments of NOK 14.2 million, and a loss from associate of NOK 2.3 million. At end of first quarter, Saga had short term investments valued at NOK 167.5 million, and investment in associates with a book value of NOK 32.9 million. Saga Pure had a gain net financial items of NOK 8.3 million, as a result of interest income from loans, bonds and bank deposits. First quarter of 2024 ended with a return on equity of plus 2.1 percent year to date for Saga Pure. Saga Pure had NOK 636 million in cash and no debt end of first quarter. The Board of Directors’ report is enclosed. ENDS For additional information, please contact: Espen Lundaas, CEO, +47 924 31 417 Tore Jakob Berg, CFO, +47 934 80 202 About Saga Pure | www.sagapure.com Saga Pure ASA is an investment company with a broad investment mandate. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Espen Lundaas, CEO, Saga Pure ASA, on 14 May 2024 at 07:30 CET.

ASSA ABLOY hosts its Capital Markets Day

Today, Tuesday 14 May, starting at 13:30 CEST, ASSA ABLOY hosts its Capital Markets Day in Prague, Czech Republic, where Nico Delvaux, President & CEO and Erik Pieder, CFO, will provide an update on ASSA ABLOY’s strategy and direction. This will include an overview of strategic activities that ASSA ABLOY is working on to continue to grow the business profitably. The financial targets of an EBIT-margin of 16-17% and an annual sales growth of 10% over a business cycle are re-confirmed. No detailed outlook statement will be made. The CMD will also include an overview of Global Technologies’ business unit Global Solutions, the recently acquired Hardware and Home Improvement (HHI) as well as an overview of the Entrance Systems division.   Speakers during the day are Stephanie Ordan, Head of Global Solutions, Tim Goff, Head of Americas Residential (HHI) and Massimo Grassi, Head of Entrance Systems. The CMD will continue tomorrow with a site visit at our cylinder factory in Rychnov, Czech Republic. Some of the material from the CMD will be made available on our website www.assaabloy.com/group/en/investors a couple of days after the event.

Corporate cost-cutting at a four-year high despite growing economic optimism

Two in five (41%) businesses across Europe plan to cut costs in 2024, the highest level since 2021 according to the annual European Payment Report  from Intrum , the credit management services provider which operates across 20 European markets.The 27th edition of Intrum’s annual study assesses the fortunes of 9,255 companies across 25 European countries. It sheds light on the myriad of challenges they face after an unrelenting 18 months of economic headwinds.After a recent period dominated by economic instability and the cost-of living crisis, economic conditions are improving in Europe, with inflation in March 2024 falling to 3.2% in the UK and 2.4% in the Eurozone. The brighter outlook is starting to feed through to business confidence. Intrum’s research shows 31% of executives say their business has strengthened over the past 12 months, up from 24% in 2022. More than half (55%) even say their business has the opportunity to expand over the coming years.Still, macroeconomic conditions continue to cast a long shadow. Three in five (61%) respondents do not expect interest rate reductions for at least another year, despite suggestions that the ECB may be ready to cut rates sooner.To navigate this testing outlook, the percentage of firms planning cost-cutting measures has increased for a third successive year, from a low of 28% in 2021 to 41% now. More than one in three (34%) businesses are more likely to request longer payment terms from suppliers, or pay later than agreed. A further 15% of businesses say they will begin extending payment terms in 2024 to navigate the economic disruption and downturns.At the same time, almost one in ten (8%) are looking to reduce the payment terms they offer their own clients or customers to help manage cashflow.Table 1: New corporate actions planned for 2024 to manage economic disruption and downturns 2020 2021 2022 2023 2024We plan to cut costs 38% 28% 33% 37% 41%We plan to be more cautious about taking on 34% 22% 23% 22% 20%financial debtWe plan to cut down on recruitment 29% 16% 16% 14% 15%We plan to sell-off part of the company 18% 9% 9% 7% 8%We plan to grow by conducting Mergers & 15% 9% 8% 7% 8%AcquisitionsWe plan to increase our investment in product - 7% 10% 11% 10%innovation and development to become morecompetitiveWe will ask suppliers for longer payment terms - - - 13% 15%than in the pastWe will reduce the payment terms we offer - - - 8% 8%clients/customersWe will offer employees voluntary redundancy - - - 7% 8%We will make compulsory redundancies in our - - - 6% 6%workforce Across Europe, businesses in Spain (20%) are the most likely to ask suppliers for longer payment terms, closely followed by Italy (19%), Portugal (18%), France (17%) and Denmark (17%).However, Intrum’s research highlights the negative impact of longer payment terms, or debtors simply not paying, as businesses spend significant time chasing down late payments.Across Europe, the average business is losing more than a quarter of the working year– 73 working days – a year chasing late payments, channelling valuable time away from focusing on their core business, including growth and innovation.Table 2: Countries where businesses are most likely to request longer payment terms from suppliers Country PercentageSpain 20%Italy 19%Denmark 17%France 17%Norway 16%Hungary 16%United Kingdom 15%Slovenia 15%Bulgaria 14%The Netherlands 13%Belgium 13%Finland 12%Ireland 8% European businesses are currently owed €10.5 trillion – 30% of total GDP and equivalent to the combined GDP of France, Germany and the UK– in outstanding payments from customers and creditors. Large businesses are owed €5.1m on average, while SMEs are each waiting on €448,000.Looking at amounts owed by sector, organisations in government and the public sector have the biggest outstanding amounts (€5,135 million), followed by banking and financial services (€3,782 million) and insurance (€2,813 million ).Andrés Rubio, President & CEO of Intrum, comments:“It’s troubling to see that cost-saving challenges are piling up for thousands of businesses in 2024, to a greater extent than at any time in the last five years. Businesses having to cut costs and ask for longer payment terms from suppliers while insolvencies are increasing is a concerning trend.It is understandable that executives are nervous in the aftermath of recent years’ challenging economic environment. We must help businesses to manage and recoup the money they are owed and encourage suppliers and customers to pay on time, to avoid putting growth on hold and necessitating cost cutting measures to survive the current headwinds.Governments and industry alike must take steps to make sure that businesses are being supported and on time payments encouraged in order to avoid disrupting businesses’ cash flow and their ability to pay their debts. Without doing so, the problem only escalates and creates a cycle of unresolved credit commitments.” ENDS Notes to Editors*10.15 (hours a week) x 52 weeks = 527.8 hours a year. This divided by the average number of working hours in a day (7.28) = 72.5 days, rounded to 73 days.The full report is available as of 14 May 2024 on intrum.com About The European Payment Report 2024The European Payment Report 2024 is an instrument for gaining insight into the payment behaviours of European businesses and examines trends related to late payments, invoice payment practices and overall financial risk. The report is based on an external survey conducted by FT Longitude in 25 countries in Europe. In total, 9,255 small, medium and large companies across 15 industry sectors participated in the research. Respondents were CFOs or other persons with financial knowledge of the company they work for and the companies have been selected randomly from a B2B database. The fieldwork for the study was conducted between 5 December 2023 and 12 March 2024.For more information, please contact:Kristin Andersson, Global Media Relations Director+46 70 585 78 18kristin.andersson@intrum.com

Essity invests in new R&D center in France

Essity is continuously developing new methods to provide the market with sustainable and user-friendly products. The company’s current R&D center in Kunheim, France, has filed 25 patents in recent years for ground-breaking innovations such as Lotus Aqua Tube (flushable toilet roll core), Lotus and Okay Sans Tube (coreless toilet paper), Tork SmartOne (dispenses one sheet at a time) and paper hygiene products based on alternative fibers.  “Essity's research and development is re-shaping paper making to contribute to a more sustainable and circular society, while improving people’s hygiene and health. The new global R&D center in France, will enable us to continue to develop innovative new paper hygiene products and solutions that meet the needs and high expectations of customers and consumers,” says Magnus Groth, President and CEO of Essity. The new R&D center, strategically located near the current facility, ensures the retention of Essity’s more than 80 experts and engineers working there today. Essity aims to create a larger, more efficient center equipped to address future challenges. In addition to France, Essity has R&D centers in Mexico, Sweden, Germany and in the USA, led by the company’s global unit focusing on brands, innovation and sustainability. In 2023, Essity invested SEK 1.7bn (approximately 1.2% of net sales) in research and development. Essity is the world’s largest supplier of hygiene solutions in Professional Hygiene with the globally leading Tork brand. Essity is also the world’s third largest supplier of consumer tissue, with a presence primarily in Europe and Latin America. Essity’s brands such as Lotus, Tempo, Zewa, Cushelle, Plenty and retailer brands lead the European market, while Regio and Familia are key players in Latin America.  

Greenbridge Announces Investment in EpinovaTech

Greenbridge Sàrl (Greenbridge), is pleased to announce an agreement to acquire over 50% of the share capital of EpinovaTech AB (EpinovaTech) through a direct investment in the company and the acquisition of shares from existing shareholders. The completion of the transaction is subject to regulatory approvals and is expected to be finalized during Q2 2024. EpinovaTech was founded in 2019 and is headquartered in Lund, Sweden. A producer of epiwafers, the company has patented a technology called NovaGaN®, which allows the widespread adoption of Gallium Nitride (GaN) into industries such as automotive, 5G and renewable energy, where there is need for high efficiency and power-handling capabilities. The NovaGaN® technology enables faster and smaller electronics with reduced energy consumption, while also offering compatibility with existing chip factories, thus providing economies of scale, industrial scalability, and short time-to-market. This investment underscores Greenbridge's commitment to fostering innovation and growth of companies that are disrupting their industries and have the potential to become the market leader. Greenbridge will take an active ownership role and work closely with the board and management team of EpinovaTech to refine and develop the long-term strategy. “I firmly believe EpinovaTech holds the potential to completely revolutionise the EV industry and the larger electronic and renewable energy industries. Greenbridge will work relentlessly to ensure that happens.” -  Ola Rollén, Greenbridge founder and Chairman. “I am very pleased with this investment and for the interest from Greenbridge in the company's pioneering NovaGaN® technology. I am convinced that this is the beginning of something big.” - Martin Olsson, EpinovaTech AB founder and Inventor. “EpinovaTech has set out to revolutionise the semiconductor industry at its core. We see a perfect match with Greenbridge - a visionary investor with an industrial heart - that shares our belief that strong partnerships are key for success. We are very much looking forward to a close relationship with Greenbridge as an active and long-term owner. “- Victoria Woyland, CEO of EpinovaTech AB For further information, please contact: Alan Hennebery, Chief Financial Officer, Greenbridgealan.hennebery@greenbridge.luJozephine Saers, Investor Relations Manager, Greenbridgejozephine.saers@greenbridge.lu Cecilia Rollén, Market Analyst and Communications, Greenbridgececilia.rollen@greenbridge.lu Martin Olsson, Founder and Inventor, EpinovaTechmartin.olsson@epinovatech.com Victoria Woyland, CEO, EpinovaTechvictoria.woyland@epinovatech.com About Greenbridge Greenbridge is a future-focused, long-term investment company with a mission to identify the trends, technologies and companies that will drive the next industrial revolution. Since 2016, Greenbridge has discovered and supported visionary founders and helped them to redefine their industries and disrupt the present for a greater future. About EpinovaTech AB EpinovaTech is a nano-technology company founded in 2019 looking to make the next generation power-chips based on Gallium Nitride (GaN) offering the highest power density at lowest weight and cost. EpinovaTech’s patented technology, NovaGaN® allows for the adoption of GaN in automotive, currently dominated by Silicon Carbide (SiC), as well as other high-demanding sectors such as 5G and renewable energy, while not only reducing energy waste but also making applications faster and smaller. NovaGaN® is compatible with existing chip manufacturing infrastructure providing economies of scale, industrial scalability, and short time-to-market.

Interim Report January - March 2024

CEO comment On May 1st I started my tenure as President and CEO of Nobia. We are still operating under difficult market conditions, but I am excited, humbled and very energized to take on the responsibility to this great company. The market remains difficult for both our consumer and project businesses. We anticipate that the combination of high interest rates and a decline in housing starts will continue to weigh on our project market throughout the remainder of the year. In the consumer market, we see modest improvements in consumer confidence and an increase in design appointments across all countries, albeit starting from a low base. The challenging market is reflected in our organic net sales that declined 20% in the quarter. Despite improved gross margin and cost out activities the operating income was slightly negative. Together with the Nobia team, I am committed to take all actions necessary to take us through the current headwinds. As we press forward with the execution of our strategy, including transformation of our operations in the UK and unlocking the full potential in the Nordics, in part from the full commissioning of the Jönköping factory, we also need to further reduce our fixed cost base. In the first quarter, we successfully undertook  significant actions to improve our balance sheet. This included divesting non-core assets ewe and Bribus, entering a sale and leaseback agreement for our Jönköping site, conducting a share rights issue, and securing extended credit facilities with our banks. I want to put on record my appreciation to all our shareholders for their support and participation. The transformation of the UK business is progressing  at pace. George Dymond has now assumed my former responsibilities as the Head of our UK operations. Since the beginning of the year, we have taken significant steps towards adopting a more asset-light operational model by closing nine underperforming stores and consolidating our UK manufacturing operations. Magnet has also successfully improved average order values in the consumer channel and entered new partnerships to distribute kitchens, including the signing of Magnet’s first franchisee agreement. Completion of the Nordic factory in Jönköping is also progressing well. I recently visited the factory together with one of our largest customers and it is impressive to witness the progress the team has made and how it will step-change our competitiveness in multiple ways. We produced over 30,000 cabinets from Jönköping in the quarter, this is modest volume but ahead of our plan and an important step toward the full commissioning of the factory. The work is, however, far from complete and the next step is to deliver full kitchen manufacturing and then ramp up volume. The cost program executed in 2023 has rendered savings well ahead of plan. However, as the market continues to be challenging we plan to reduce our fixed cost base further. This includes the transitioning to a more asset light model in the UK, harmonization of processes in the Nordics and supply chain consolidation. I will provide an update on the further actions we are taking in the second quarter. Having encountered numerous challenges in recent years including a material downturn in new house building activity, as a result there is pent-up demand in our markets. While we anticipate facing further challenging conditions for the remainder of 2024 we are making progress across all aspects of our business and these changes will position us well for growth and market share gains. I recognize the significant work ahead but I want to thank our teams for the hard work they do everyday across all our markets and especially so in these challenging times.  Kristoffer LjungfeltPresident & CEO

Swedbank Robur Corporate Governance & Engagement Report 2023

The 2023 report states, among other things, that Swedbank Robur:•    Voted at 968 meetings, in more than 40 different markets•    Evaluated more than 500 shareholder proposals•    Voted for 91% of the equity holdings •    Participated in 100 nomination committees, which is more than any other investor in Sweden•    Contacted 1418 companies in sustainability issues, with focus on, among other things, climate, biodiversity, and children’s rights ”We can both handle sustainability risks effectively and find good investment opportunities through our work with sustainability and corporate governance. We continue to work systematically to create long term and sustainable return to our savers”, says Pia Gisgård, Head of Sustainability and Corporate Governance at Swedbank Robur. All decisions regarding voting are made internally by Swedbank Robur. To not outsource the voting is a conscious strategic choice. Proposals to general meetings are evaluated internally according to Swedbank Robur’s Principles for Shareholder Engagement.”As active owners we believe that it is important to take the opportunity to vote on general meetings. Our senior corporate governance specialists evaluate the proposals. Then we decide how to vote. Our decision is based on what we determine is best for our savers”, says Pia Gisgård.  Swedbank Robur has four themes for its sustainability dialogues, climate, nature, human rights and corporate governance. Swedbank Robur have dialogues directly with companies, but also use engagement service from ISS Ethix and Sustainalytics 360 and is a member of several international investor collaborations.  ”Collaboration through investor initiatives are important since they increase our possibility to impact companies and give us access to exchange of experience. In addition, it is also resource effective, both for us as an investor and for the companies”, says Pia Gisgård. During 2023, Swedbank Robur became a member of the network Farm Animal Investment Risk & Return (FAIRR), which works for a sustainable food industry. They were also founding participants of Nature Action 100, which has the ambition to address nature loss and biodiversity decline and participated in the engagement initiative ”Human Rights in Big Tech”, which was administered by the Council on Ethics of the Swedish National Pension Funds. More information:Swedbank Robur Corporate Governance & Engagement Report 2024 (eng, pdf ) Contact:Carina Sesser Nylund, Head of information, Swedbank Robur, +46 72 230 52 64

Audientes A/S: The board of directors resolves on a rights issue of shares of approx. DKK 4.9 million in total

Background Audientes is positioned to capitalize on a significant growth opportunity in the hearing health sector, particularly within expanding middle-income markets such as India and China, where the demand for affordable hearing solutions remains largely unmet. As projected by the WHO , the number of individuals with disabling hearing loss is expected to reach 630 million by 2030 and 900 million by 2050, driven by demographic shifts and environmental factors. Unlike traditional vendors that target high-income markets with premium products, Audientes has broadened its market reach by offering competitively priced, high-quality hearing aids since mid-2022. Additionally, the Company has during the last year introduced the Companion by Audientes product aiming at addressing the needs of aging populations in developed nations, including Japan, the USA, and the EU. This strategic expansion into the consumer electronics segment positions Audientes uniquely in the market, enhancing its portfolio and reinforcing its commitment to accessible hearing health solutions available across a broad variety of sales channels. Audientes recently diversified its business model in early 2024 by launching a software platform for licensing to OEMs and other brands. This initiative allows third parties to develop and sell innovative products, further extending Audientes' market influence and leveraging its software assets developed since its IPO. Use of proceeds The Rights Issue can initially provide Audientes with approx. DKK 4.9 million (if fully subscribed) before transaction related costs of approx. DKK 0.8 million. The maximum net proceeds of approx. DKK 4.1 million from the initial part of the Rights Issue (after amortization of interest and loan) are intended to finance the following activities (arranged by priority): · Sales, marketing, and operations of the Companion by Audientes product in Japan, China and Europe – approx. 30 percent of the issue proceeds. · Sales, marketing, and operations of Ven and in India, Nepal, and surrounding countries – approx. 20 percent of the issue proceeds. · New product development and certifications for RIC-style (Receiver in Canal) hearing aid product for China, India, and other regulated markets with medical device rules – approx. 20 percent of issue proceeds. · Products already made or to be manufactured at OSM Group – approx. 10 percent of the issue proceeds. · General and administrative costs (incl. financial compliance) – approx. 20 percent of the issue proceeds. Terms for the Rights Issue The Board of Directors of Audientes has today, with the support of existing authorizations, resolved on the Rights Issue of a maximum of 138,768,644 new shares. The Rights Issue can initially provide the Company with a maximum amount of approx. DKK 4.9 million before deduction of transaction related costs. Audientes existing shareholders will receive pre-emptive rights to subscribe for New shares in relation to existing shareholdings. Those who are registered as shareholders in Audientes on the record date of 21 May 2024 will be allocated pre-emptive rights to subscribe for New shares in the Rights Issue. The subscription price in the Rights Issue is DKK 0.035 per share. For each existing share, two (2) pre-emptive subscription rights are allocated (so-called share right). One (1) pre-emptive right entitles the holder to subscribe for one (1) New share. Shares must be subscribed during the subscription period starting from 22 May 2024 up to and including 4 June 2024. The public also has the possibility to subscribe for shares in the Rights Issue. Last day of trading in Audientes’ shares including the right to receive share rights in the Rights Issue is May 16 2024. First day for trading in Audientes’ shares excluding the right to receive share rights is May 17 2024. Trading in subscription rights takes place from 17 May 2024 and including 31 May 2024. The the Rights Issue will result in a share capital increase of a maximum of nominal DKK 1,387,686, from 693,843.22 to a maximum of DKK 2,081,530, through the issue of a maximum of 138,768,644 new shares. The number of shares in Audientes after the Rights Issue will, upon full subscription, amount to 208,152,967 shares. Existing shareholders who choose not to participate in the Rights Issue will be subject to a dilution effect corresponding to approx. 67 percent of the total number of shares and votes in the Company after the Rights Issue, calculated on the number of shares in the Company after the Rights Issue, upon full subscription. Shareholders who choose not to participate in the Rights Issue have the opportunity to compensate for the financial dilution effect by selling their subscription rights no later than 31 May 2024. Complete terms and conditions for the Rights Issue as well as more information about Audientes will be presented in the issuer memorandum which is expected to be published on the Company’s and Spotlight Stock Markets websites around 16 May 2024. Commitments in relation to the Rights Issue In total, approx. 26 percent of the initial part of the Rights Issue, corresponding to approx. DKK 1.3 million, is agreed upon in writing by pre-subscription commitments including Audientes CEO Steen Thygesen, Audientes founder and CTO Hossein Jelveh and other existing shareholders including Michael Ole Fehrn, Johan Jacob Trap Friis, Per Lindström, and Shenzhen Hengtong Partner Company Ltd. Existing providers of the Company’s convertible loans have also undertaken pre-subscription commitments (Gerhard Dal, Selandia Alpha Invest A/S and Renewable Ventures Nordic AB). Audientes will continue to evaluate and take advantage of potential investment interest from professional investors in connection with the Rights Issue during the course of the capital raising. Indicative timetable for the Rights Issue · Board decision and company announcement of the planned rights issue: 14 May 2024 · Issuer memorandum published via Cision (as a company announcement) on Audientes and Spotlights website: 16 May 2024. · Record date for participation in the Rights Issue: 21 May 2024. · Last day of trading in shares including the right to receive subscription rights: 16 May 2024. · First day of trading in shares excluding the right to receive subscription rights: 17 May 2024. · Trading in subscription rights: 17 May 2024 – 31 May 2024 (the last day of trading in subscription rights will be announced through a separate press release). · Subscription period: 22 May 2024 – 4 June 2024 · Publication of the final outcome of the Rights Issue: around 10 June 2024 For more information about the Rights Issue, please contact: Bjørn Wennerlund, Villand Capital Phone: +45 60 13 77 86 or +46730 - 93 96 30 Email: info@villandcapital.com Steen Thygesen,CEO, Audientes A/S Phone: +45 53 17 26 10 Email:st@audientes.com    About Audientes A/S Audientes A/S is a Danish hearing health company specializing in smart, self-fitting and affordable hearing aids and advanced hearables. Audientes’ unique hearing aid solution, Ven™ by Audientes, is available for purchase in the Indian and Nepalese markets and will be introduced in other markets in the coming years. Companion by Audientes is an advanced hearable, a consumer electronics product, that is commercially available in Europe and later in 2024 in Japan, China, and other markets. Audientes’ mission is to make high-quality hearing aids and hearables for hearing improvement or hearing enhancement accessible to everyone who needs them globally. Audientes is listed on Spotlight Stock Market Denmark (AUDNTS) and headquartered in Copenhagen, Denmark with subsidiaries in Hyderabad, India and in Tokyo, Japan. For additional information please refer to the company’s websites, www.audientes.com, www.audientes.eu, or www.audientes.in.

Tranter and Hexxcell forge strategic partnership to revolutionize industrial heat exchanger maintenance.

Combining Tranter's extensive global expertise in the heat exchanger and maintenance services market with Hexxcell's cutting-edge digital solutions, the partnership is positioned to elevate service standards by providing unparalleled insights into effective maintenance strategies. Leveraging Hexxcell’s groundbreaking hybrid-AI digital twin models, plant operators will gain comprehensive insights into heat exchanger performance and identify operational improvements, optimal maintenance actions, and redesign options. Through advanced monitoring, predictive analytics, and prescriptive maintenance, the innovative solution provides actionable recommendations to improve efficiency, reduce downtime, and ensure sustainable operations. “At Tranter, we are dedicated to driving innovation and sustainability in the heat exchanger industry. Our partnership with Hexxcell demonstrates our commitment to delivering cutting-edge solutions that promote sustainable outcomes for both our customers and the environment.” Jan Debruyn, President and CEO, Tranter, Inc. “Hexxcell is at the forefront of digital innovation in heat transfer systems. We are excited about the possibilities our partnership with Tranter brings to customers. By integrating our technologies and services, we enable operators to reduce costs, emissions, and downtime, while ensuring their heat exchangers receive best-in-class service” Francesco Coletti, CEO of Hexxcell Ltd. Tranter is a leading global provider of heat exchanger solutions and maintenance services, and offers a wide range of products and services, through their innovative FullServ® service concept. Regardless of the heat exchanger brand, Tranter provides comprehensive support, ensuring a seamless customer experience. Hexxcell is an industry leader of advanced monitoring and predictive maintenance software for the process industry. Hexxcell Studio™’s Hybrid-AI Digital Twins combine Artificial Intelligence (AI) with rigorous physics-based models and deep domain knowledge to monitoring, design and maintenance of industrial thermal systems. The collaboration between Tranter and Hexxcell unlocks new growth opportunities and paves the way for a new era of predictive maintenance and design optimization in the heat exchanger industry.  For more information, contact: Jamey MarlingGlobal director- Service segmentJamey.Marling@tranter.com Niccolo Le BrunHead of Digital InnovationN.Le-Brun@hexxcell.com 

Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China

China, which is estimated to have up to 5 million patients suffering from the progressive autoimmune disease, IgA nephropathy (IgAN), has the highest prevalence of primary glomerular diseases in the world, with IgAN accounting for about 35% to 50% of cases with a biopsy proven incidence of over 100,000 patients per year. There is a very significant unmet medical need for novel therapies among IgAN patients in China and other Asian countries. “This is a fantastic result from many years of dedication and hard work by teams from both companies and I am delighted that patients in China now can benefit from Nefecon, which has been specifically designed to address the origin of IgAN,” said Renee Aguiar-Lucander, CEO. Results from the Chinese subpopulation analysis of the Phase 3 NefIgArd trial, presented at the American Society of Nephrology (ASN) Kidney Week in 2023, provided evidence that the treatment effect of Nefecon in the Chinese cohort was greater than in the global data set with regards to kidney function, proteinuria and microhaematuria. In the Chinese cohort, the mean absolute change from baseline in estimated glomerular filtration rate (eGFR) at 24 months showed an approximately 66% reduction in loss of kidney function with Nefecon over the period, compared with a 50% reduction in loss of eGFR in the global data set. Nefecon® was awarded conditional approval in IgAN by China’s National Medical Products Administration (NMPA) in November 2023. In addition to being approved and commercially launched in Mainland China, Nefecon® has also received approval in Macau, Hong Kong and Singapore, and was successfully commercially launched and first prescribed in Macau at the end of last year.  New Drug Applications (NDA) for Nefecon® were also successfully accepted for review in Taiwan and South Korea at the end of 2023.

BlueNord: Minutes from Annual General Meeting

Oslo, 14 May 2024: BlueNord ASA (“BlueNord” or the "Company") has today held its annual general meeting (the "AGM") as a digital meeting through the solution Lumi AGM. All items on the agenda were resolved in accordance with the proposals. “I would like to use this opportunity to recognise the job that Mr Rustad has done for almost a decade developing and monetising what was originally largely a company with tax losses into what is today a significant European E&P company.  As a shareholder from the early days, and member of the board for the past three years, I’m confident that BlueNord is now in a solid position to further create, and return, value to its shareholders,” said Jan Lernout in Kite Lake Capital Management (UK) LLP.   “After a fantastic journey that has lasted nearly ten years, I’m now leaving the board of BlueNord with great confidence that management and the new board will continue to take care of the business and further build value for us shareholders,” said Riulf Rustad. Minutes from the AGM are attached to this notice and will be made available on the Company's website: www.bluenord.com. *** Contact:Cathrine Torgersen, Chief Corporate Affairs OfficerPhone: +47 915 28 501Email: cathrine.torgersen@bluenord.com This information is subject to disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. 

Finnair considers issuance of new notes and announces a voluntary tender offer of its outstanding notes maturing in 2025

Finnair Plc               Stock Exchange Release                14 May 2024 at 3:20 p.m. EEST NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES") OR IN OR INTO OR TO ANY PERSON RESIDENT OR LOCATED IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. Finnair Plc (the “Company”) is considering the issuance of new inaugural rated euro-denominated notes (the “New Notes”). The potential issue is expected to take place in the near future subject to market conditions. At the same time, the Company announces that it invites the holders of its 4.250 per cent, unrated notes due 19 May 2025 with an initial nominal amount of EUR 400 million (ISIN: FI4000507132) (the “Notes”) (the "Noteholders") to tender the Notes for cash on the terms and conditions set out in the Tender Offer Memorandum dated 14 May 2024 (the "Tender Offer Memorandum") (the “Tender Offer”). Noteholders are advised to read carefully the Tender Offer Memorandum for full details of, and information on the procedures for participating in, the Tender Offer. Details of the Tender Offer The Company proposes to initially accept for purchase any and all of the Notes validly tendered, although the Company reserves the right, in its sole discretion, to decide on acceptance of the Notes for purchase, including not to accept any Notes for purchase.  Whether the Company will accept for purchase any Notes validly tendered is subject to, without limitation, the pricing of the issue of the New Notes (the “New Issue Condition”). The purchase price of the Notes is EUR 1,005 per EUR 1,000 in principal amount of the Notes. Accrued and unpaid interest will be paid in respect of all Notes accepted for purchase. When considering the allocation of the New Notes, the Company will take into consideration the Notes tendered and may give priority to those Noteholders who, prior to such allocation, have validly tendered or have given a firm intention to the Company or any Dealer Manager that they intend to tender their Notes for purchase pursuant to the Tender Offer. Therefore, a Noteholder that wishes to subscribe for New Notes in addition to tendering its existing Notes for purchase pursuant to the Tender Offer will be eligible to receive, at the sole and absolute discretion of the Company, potential priority in the allocation of the New Notes, subject to satisfaction of the New Issue Condition, the selling restrictions contained in the prospectus for the New Notes and such Noteholder making a separate application for the subscription of such New Notes to a Dealer Manager (in its capacity as a bookrunner of the issue of the New Notes) in accordance with the standard new issue procedures of such Dealer Manager. However, the Company is not obliged to allocate the New Notes to a Noteholder who has validly tendered or indicated a firm intention to tender its Notes for purchase pursuant to the Tender Offer. Any such allocation will also, among other factors, take into account the minimum denomination of the New Notes (being EUR 100,000) and the minimum subscription amount, (being EUR 100,000). Expected Transaction Timeline Unless extended, re-opened or terminated as provided in the Tender Offer Memorandum, the offer period closes at 4:00 p.m. Finnish time (EEST) on 22 May 2024. The final outcome of the Tender Offer will be announced as soon as practicable after the expiry of the offer period. Subject to satisfaction of the New Issue Condition, the settlement date for the Tender Offer and the New Notes is expected to be 24 May 2024. Rationale for the Tender Offer The Company intends to use the proceeds of the New Notes, less costs and expenses incurred by the Company in connection with the issue of the New Notes, to fund the purchase of Notes accepted for purchase in the Tender Offer and refinancing and other general corporate purposes of the group. The rationale of the Tender Offer is, thus, to proactively manage the debt portfolio of the Company. Danske Bank A/S and Nordea Bank Abp act as the Dealer Managers (the "Dealer Managers") and Nordea Bank Abp acts as the Tender Agent (the "Tender Agent") for the Tender Offer. Information in respect of the Tender Offer and the Tender Offer Memorandum may be obtained from the Dealer Managers. Danske Bank A/S, Deutsche Bank Aktiengesellschaft, Nordea Bank Abp, OP Corporate Bank plc and Skandinaviska Enskilda Banken AB (publ) act as Bookrunners for the issue of the New Notes (the "Bookrunners"). Dealer Managers: Danske Bank A/S Telephone: +45 33 64 88 51 Attention: Debt Capital Markets Email: liabilitymanagement@danskebank.dk Nordea Bank Abp Telephone: +45 6136 0379 Attention: Nordea Liability Management Email: NordeaLiabilityManagement@nordea.com For further information: Mikko Hepokari, Group Treasurer, tel. +358 40 745 4292, mikko.hepokari@finnair.com Kristian Pullola, CFO, tel. +358 9 818 4960, kristian.pullola@finnair.com FINNAIR PLC Distribution: NASDAQ OMX Helsinki Principal media Finnair is a network airline, specialising in connecting passenger and cargo traffic between Asia, the Middle East, North America and Europe. Finnair is the only airline with year-round direct flights to Lapland. Sustainability is at the heart of everything we do – Finnair intends to reach carbon neutrality latest by the end of 2045. Customers have chosen Finnair as the Best Airline in Northern Europe in the Skytrax Awards for 13 times in a row. Finnair is a member of the oneworld alliance. Finnair Plc’s shares are quoted on the Nasdaq Helsinki stock exchange. IMPORTANT NOTICE Neither this release nor the Tender Offer Memorandum constitutes a recommendation by Finnair, the Dealer Managers, the Tender Agent, the Bookrunners, or any of their respective directors, officers, employees, agents or affiliates regarding the Tender Offer or a recommendation as to whether the Noteholders should tender any Notes in the Tender Offer or a recommendation to subscribe for any notes potentially issued by the Company. The Noteholders should consult their own tax, accounting, financial and legal advisers and make an independent decision as to whether to tender any Notes held by them for purchase pursuant to the Tender Offer or to invest in any notes potentially issued by the Company. Distribution restrictions The distribution of this release and the invitation to tender the outstanding Notes is prohibited by law in certain countries. The Tender Offer is not made to the public either inside or outside of Finland. Persons resident outside of Finland may receive this release, the Tender Offer Memorandum and any other information and materials relating to the Tender Offer only in compliance with applicable exemptions or restrictions. Persons into whose possession this release, the Tender Offer Memorandum and any other such information and materials may come are required to inform themselves about and comply with such restrictions. This release, the Tender Offer Memorandum and any other such information or materials may not be distributed or published in any country or jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction or would require actions under the laws of a state or jurisdiction other than Finland, including the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore and South Africa. The information contained in this release shall not constitute an offer to sell or tender, or a solicitation of an offer to buy or sell the Notes to any persons in any jurisdiction in which such offer, solicitation or sale or tender would be unlawful. None of Finnair, the Dealer Managers or the Tender Agent or any of their respective affiliates and representatives assume any legal responsibility for such violations, regardless of whether the parties contemplating investing in or divesting the Notes are aware of these restrictions or not. United States The Tender Offer is not being made, and will not be made, directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of or of any facilities of a national securities exchange of, the United States or to any U.S. Person (as defined in Regulation S of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) (each, a “U.S. Person”)). This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Notes may not be tendered in the Tender Offer by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States or by, or by any person acting for the account or benefit of, a U.S. Person. Accordingly, copies of this release, the Tender Offer Memorandum and any other documents or materials relating to the Tender Offer are not being, and must not be, directly or indirectly mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States or to any persons located or resident in the United States or to any U.S. Person. Any purported tender of the Notes in the Tender Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported tender of Notes made by, or by any person acting for the account or benefit of, a U.S. Person or by a person located in the United States or any agent, fiduciary or other intermediary acting on a nondiscretionary basis for a principal giving instructions from within the United States will be invalid and will not be accepted. Each Noteholder participating in the Tender Offer will represent that it is not a U.S. Person, it is not located in the United States and it is not participating in the Tender Offer from the United States, or it is acting on a non-discretionary basis for a principal located outside the United States that is not giving an order to participate in the Tender Offer from the United States and is not a U.S. Person. For the purposes of this paragraph, United States means the United States of America, its territories and possessions, any state of the United States of America and the District of Columbia. United Kingdom The communication of this release, the Tender Offer Memorandum and any other documents or materials relating to the Tender Offer is not being made and such documents and/or materials have not been, and will not be, approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. This release, the Tender Offer Memorandum and any such other offer material relating to the Tender Offer may only be distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, (iv) persons who are within Article 43 of the Order and (v) other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i) to (v) above together being referred to as “relevant persons”). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this release, the Tender Offer Memorandum or any of its contents. France The communication of this release and the Tender Offer is not being made, directly or indirectly, to the public in France. Neither the Tender Offer Memorandum nor any other documents or offering materials relating to the Tender Offer have been or shall be distributed to the public in France and only qualified investors (investisseurs qualifiés) within the meaning of Article 2(e) of Regulation (EU) 2017/1129 are eligible to participate in the Tender Offer. The Tender Offer Memorandum has not been and will not be submitted to the clearance procedures (visa) of the Autorité des marchés financiers. Republic of Italy None of the Tender Offer Memorandum nor any other documents or materials relating to the Tender Offer have been or will be submitted to the clearance procedure of the Commissione Nazionale per le Società e la Borsa (“CONSOB”) pursuant to Italian laws and regulations. In the Republic of Italy, the Tender Offer is being carried out as an exempted offer pursuant to Article 101 bis, paragraph 3 bis of Legislative Decree no. 58 of February 24, 1998, as amended (the “Financial Services Act”) and article 35 bis, paragraphs 3 and 4 of CONSOB Regulation No. 11971 of May 14, 1999, as amended (the “CONSOB Regulation”). Noteholders or beneficial owners of the Notes that are located in Italy can tender Notes for purchase through authorized persons (such as investment firms, banks or financial intermediaries permitted to conduct such activities in the Republic of Italy in accordance with the Financial Services Act, CONSOB Regulation No. 16190 of 29 October 2007, as amended from time to time, and Legislative Decree No. 385 of 1 September 1993, as amended from time to time) and in compliance with applicable laws and regulations or with requirements imposed by CONSOB or any other Italian authority. General This release or the Tender Offer Memorandum do not constitute an offer to buy or the solicitation of an offer to sell any Notes (and tenders of the Notes in the Tender Offer will not be accepted from any Noteholders thereof) in any circumstances in which such offer or solicitation would be considered unlawful. In those jurisdictions where the securities, investor protection or other laws require the Tender Offer to be made by a licensed broker or dealer and the Dealer Managers or any of the Dealer Managers' affiliates is such a licensed broker or dealer in any such jurisdiction, the Tender Offer shall be deemed to be made by the Dealer Managers or such affiliate, as the case may be, on behalf of Finnair in such jurisdiction. In addition to the representations referred to above in respect of the United States, each Noteholder participating in the Tender Offer will also be deemed to give certain representations in respect of the other jurisdictions referred to above and generally as set out in the Tender Offer Memorandum. Any tender of the Notes for purchase pursuant to the Tender Offer from any Noteholder that is unable to make these representations will not be accepted. Each of Finnair, the Dealer Managers and the Tender Agent reserves the right, in its absolute discretion, to investigate, in relation to any tender of the Notes for purchase pursuant to the Tender Offer, whether any such representation given by any Noteholder thereof is correct and, if such investigation is undertaken and as a result Finnair determines (for any reason) that such representation is not correct, such tender shall not be accepted. Disclaimer This release is for information purposes only and is not to be construed as an offer to sell any securities of Finnair. No actions have been taken to register or qualify the New Notes, or otherwise to permit a public offering of the New Notes, in any jurisdiction. If Finnair decides to proceed with the issue of the New Notes, any offering material or documentation related to the New Notes may be received only in compliance with applicable exemptions or restrictions. None of Finnair, the Dealer Managers, the Tender Agent nor the Bookrunners or their representatives accept any legal responsibility for any violation by any person, whether or not the persons contemplating investing in or divesting Finnair’s securities, including the New Notes, are aware of such restrictions. The New Notes have not been and will not be registered under the U.S. Securities Act, or under the securities laws of any state or other jurisdiction of the United States. The New Notes may not be offered, sold, pledged or otherwise transferred directly or indirectly within the United States or to, or for the account or benefit of, U.S. Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act.

Water in Communications Workshops

Water has never been a more pressing and relevant issue. Which is why it’s never been more important to communicate about water. Since the Water in Communications programme launched in 2021, more than 1,000 journalists and communicators have participated in the series of training workshops that serve as a prelude to, and integral part of, World Water Week .  The free online workshops seek to improve the accuracy, intensity, and quality of reporting and storytelling on water, thereby broadening awareness about water issues and climate change. They provide inspirational keynote presentations and discussions to give participants the knowledge and skills needed to broaden their reach and empower people to make better decisions about water.  This year’s programme highlights include: • A deep dive into the theme of World Water Week 2024: Bridging Borders: Water for a Peaceful and Sustainable Future including sessions on human security and water diplomacy. • Interactive masterclass session with Anders Sahlman, Science Communicator, and Presentation Coach. • Several sessions on representation, how to decolonize visual communications, and strengthen the voice of women.  For the first time, all sessions will be simultaneously translated into Spanish.  All workshop sessions are recorded to ensure everyone can watch (or re-watch) the training programme when convenient.   The 2024 Water in Communications programme will run on selected dates from 4 to 27 June 2024, starting at CEST 2pm, with sessions held on Zoom.  More information as well registration under this link .

Neste enables Signature Aviation transition to offering only blended sustainable aviation fuel for all business aviation customers at its Los Angeles International Airport terminal

Neste Corporation, News, 14 May 2024 Photo: Signature Aviation Enabled by its partnership with Neste, Signature Aviation, who operates the world’s largest network of business aviation terminals, is now providing only blended Neste MY Sustainable Aviation Fuel™  to all aircraft refueling at its terminal at Los Angeles International Airport (LAX).  Since April 1, Signature’s LAX terminal has become the second business aviation terminal worldwide, joining Signature’s terminal at San Francisco International Airport, to offer only blended SAF to business aviation customers. The blended fuel provided by Signature to their customers at LAX consists of 30% SAF and 70% conventional jet fuel. This enables customers using the blended fuel to achieve up to a 24%* reduction in greenhouse gas (GHG) emissions from their air travel compared to flights powered by conventional fossil jet fuel.  "We are proud to continue to expand our collaboration with committed partners like Signature Aviation, who recognize the key role sustainable aviation fuel can play in reducing GHG emissions from air travel. Offering blended Neste MY Sustainable Aviation Fuel to all of its customers at LAX is a shining example of how the business aviation community can work together with fuel producers to accelerate SAF adoption and emission reductions," says Carrie Song, Senior Vice President Commercial, Renewable Products at Neste.  "This is a transformative time for Signature, and our partnership with Neste is helping us take another significant step towards net zero by providing a 100% supply of blended SAF at our Los Angeles location," said Derek DeCross, Chief Commercial Officer at Signature Aviation. "This collaboration exemplifies how we're working together with both our guests and our partners to accelerate the adoption of environmentally friendly practices and paving the way for a more sustainable future in aviation." Today’s announcement builds on the partnership between Signature and Neste to accelerate SAF adoption that dates back to 2020. In October 2022, Signature expanded the availability of Neste MY SAF to all of its locations in California enabled by Neste’s growing SAF production and supply capabilities. Neste will increase its global SAF production capability to 515 million gallons of SAF (1.5 million metric tons) per annum in 2024 and has been working with industry partners to expand the availability of its renewable products. In 2023, Neste commissioned terminal capacity at Vopak’s Los Angeles terminal in California for storing SAF and renewable diesel, enabling GHG emission reductions in the transportation sector and supporting the energy transition in the region.  Sustainable Aviation FuelSustainable aviation fuel is a renewable aviation fuel providing a more sustainable alternative to conventional, fossil-based jet fuel. Neste’s SAF is made from sustainably sourced, 100% renewable waste and residue raw materials, such as used cooking oil and animal fat waste. Using Neste MY Sustainable Aviation Fuel reduces greenhouse gas emissions by up to 80%* over the fuel’s life cycle, compared to using conventional jet fuel. SAF is currently approved for use blended up to 50% with conventional jet fuel. It is blended with conventional jet fuel before use and works seamlessly with existing aircraft engines and fueling infrastructure.  *) Estimated based on an up to 80% emission reduction for the SAF when used in neat form (i.e. unblended). It is calculated with established life cycle assessment (LCA) methodologies, such as CORSIA methodology. 

Bulletin from Sobi’s Annual General Meeting (AGM)

Adoption of the profit and loss statements and balance sheet and discharge of liability The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits. The Board members and the chief executive officer were discharged from liability for the financial year 2023. Election of Board of Directors, remuneration to the Directors, election of Auditor and remuneration to the Auditor The ordinary Board members Christophe Bourdon, Annette Clancy, Helena Saxon, StaffanSchüberg, Filippa Stenberg and Anders Ullman were re-elected as Board members and Zlatko Rihter was elected as new Board member for the period until the end of the next AGM. Annette Clancy was re‑elected as chair of the Board of Directors. Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM. The AGM approved the remuneration to the Board of Directors and the Auditor in accordance with the Nomination Committee’s proposal. Remuneration report, guidelines for executive remuneration, long-term incentive programmes, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares The AGM resolved to approve the Board of Directors’ remuneration report. The AGM resolved to approve the Board of Directors’ proposal for guidelines for executive remuneration. The AGM resolved to approve the Board of Directors’ proposal to implement long-term incentive programmes, consisting of hedging arrangements in respect of the programmes by way of directed issues of no more than 1,641,103 series C shares in the aggregate, authorisation for the Board of Directors to resolve on a repurchase of all issued series C shares and transfer of no more than 3,156,277 own common shares in the aggregate to participants of the programmes. The AGM approved the Board of Directors’ proposal regarding the authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 39,370,000 shares in total. The Board of Directors’ proposal regarding transfer of no more than 1,006,742 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the incentive programmes 2020 and 2021, was also approved by the AGM. For full details on each proposal adopted by the AGM, please refer to sobi.com. Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn . Contacts For details on how to contact the Sobi Investor Relations Team, please click here . For Sobi Media contacts, click here . Gerard Tobin Head of Investor Relations

Report from Epiroc’s Annual General Meeting 2024

The income statements and the balance sheets of the parent company and the Group were approved. The Directors of the Board and the President and CEO were discharged from liability for the financial year 2023.  The proposed dividend of SEK 3.80 per share, to be paid in two equal instalments of SEK 1.90, was approved. The record date for the first instalment is May 16, 2024, and for the second instalment October 22, 2024. The first instalment is expected to be distributed by Euroclear on May 21, 2024, and the second instalment on October 25, 2024. The Annual General Meeting approved the remuneration report. The following nine Board members were re-elected: Anthea Bath, Lennart Evrell, Johan Forssell, Helena Hedblom, Jeane Hull, Ronnie Leten, Ulla Litzén, Sigurd Mareels and Astrid Skarheim Onsum. Ronnie Leten was re-elected Chair of the Board.  The Annual General Meeting approved the fees to the Board members elected by the meeting and not employed by the company as follows: Remuneration of SEK 2,710,000 to the Chair of the Board and SEK 850,000 each to the other Board members. To the Chair of the Audit Committee SEK 360,000 and SEK 235,000 each to the other members. To the Chair of the Remuneration Committee SEK 165,000 and SEK 120,000 each to the other members, and remuneration of SEK 80,000 to each Board member who, in addition to the above, participates in a committee in accordance with a decision of the Board of Directors. The Annual General Meeting approved the proposal allowing Board members to choose between receiving 50% of the Board remuneration in the form of synthetic shares and the rest in cash or to receive the whole remuneration in cash. The Annual General Meeting also approved that the obligation of Epiroc AB to pay an amount corresponding to the synthetic shares shall be hedged through the purchase of own series A shares.  The Annual General Meeting re-elected Ernst & Young as Epiroc AB’s auditor. The remuneration to the auditor shall be as per approved invoice. The Annual General Meeting approved the proposal of the Board of Directors regarding a performance-based personnel option plan for 2024. The Annual General Meeting authorized the Board to decide on the purchase and transfer of own series A shares, in order to fulfill obligations related to the performance stock option plan for 2024, and to the part of the Board fee that consists of synthetic shares. The Board was authorized to sell shares in order to fulfill obligations related to the performance stock option plans for 2018, 2019, 2020 and 2021, and to cover costs related to synthetic shares to the Board of Directors.  The Annual General Meeting approved the proposed instruction for the Nomination Committee. A speech by President and CEO Helena Hedblom will be available on Epiroc’s webpage www.epirocgroup.com/agm, where the minutes from the Annual General Meeting will also be published. For more information please contact:Karin Larsson, VP Investor Relations and Media+46 10 755 0106ir@epiroc.comOla Kinnander, Media Relations Manager+46 70 347 2455media@epiroc.com Epiroc is a global productivity partner for mining and construction customers, and accelerates the transformation toward a sustainable society. With ground-breaking technology, Epiroc develops and provides innovative and safe equipment, such as drill rigs, rock excavation and construction equipment and tools for surface and underground applications. The company also offers world-class service and other aftermarket support as well as solutions for automation, digitalization and electrification. Epiroc is based in Stockholm, Sweden, had revenues of more than SEK 60 billion in 2023, and has around 18 200 passionate employees supporting and collaborating with customers in around 150 countries. Learn more at www.epirocgroup.com.

Getinge's financial target 2024-2028: Adjusted EPS growth of above 12% on average

In the letter from the U.S. FDA, there are no new field actions referred to, but healthcare providers are advised to transition from Getinge’s Cardiosave Intra-Aortic Balloon Pump (IABP), Cardiohelp System, and HLS Sets Advanced to alternative products, and to continue using Getinge’s products only if no other alternatives are available. Getinge is estimated to have a market share in the U.S. of over 60% for the mentioned products, which includes both hardware and consumables.  “We take this very seriously and as a result of the U.S. FDA’s letter, we have decided to immediately pause promotional activities of the Cardiohelp System and Cardiosave IABP in the U.S. until outstanding actions related to quality improvements have been addressed and approved. The sale of these hardware products will be limited to customers who have no available alternatives. We will also inform all customers about the regulatory requirements for the use of the Cardiohelp System. Regarding Intra-Aortic Balloon catheters and HLS sets, we will continue to supply and service the installed base”, says Mattias Perjos, President & CEO of Getinge. For markets outside the U.S., Getinge has implemented product improvements, and will continue to sell Cardiosave IABP and the Cardiohelp System as well as continue to provide intra-aortic balloon catheters and HLS sets in markets where they are permitted and approved for use. In recent years, Getinge has taken important steps to correct quality-related deficiencies, focusing on product upgrades. For example, Getinge has developed a new packaging for HLS sets, which was recently submitted for approval in CE markets. At the same time, Getinge has accelerated the development of the next generation of the Cardiohelp System and Cardiosave IABP hardware, where the company expects to submit applications for clearance in the U.S. end of H1 to end of H2 2025 followed by an update and submission for clearance of the HLS set. The mentioned decisions are likely to have a negative financial impact until the new products are approved and launched. However, it is too early to have a firm opinion on the exact extent, which is why Getinge does not have stated targets for organic net sales growth and adjusted EBITA margin for the period. Structurally, however, Getinge assesses the justified organic net sales CAGR during the period to be in the area of 3-6% and the EBITA margin in the area of 16-19% at the end of the period, after taking today's decision into account. All in all, this contributes to the following financial target for 2024-2028: Adjusted EPS growth above 12% on average. Getinge’s dividend policy remains unchanged and amounts to 30-50% of the company’s net profit. For 2024, Getinge repeats its guidance of 2-5% organic growth in net sales and 3-5% growth from acquired units. Getinge does not provide any annual guidance for adjusted EBITA margin. Getinge also updates its sustainability targets as follows. These are not tied to the period 2024-2028. Socially • Employee engagement: >70% • Compliance in quality, audit results/inspection: <1.5 deviation Environment • Reduce Scope 1 and 2 emissions by 90% by 2030[2)] • Reduce Scope 3 emissions by 25% by 2030 and by 90% by 2050[2)] Governance • Percentage of employees who have completed training in business ethics: >90% 1) Base year: 2023. 2) Base year: 2021. Contact informationLars Mattsson, SVP Corporate DevelopmentCorporate Strategy | M&A | Investor RelationsPhone:  +46(0)10 335 0043E-mail:  lars.mattsson@getinge.com  This information is information that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20.15 pm CEST on May 14, 2024. About GetingeWith a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in 135 countries.

Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing

Leqembi is approved for biweekly intravenous (IV) treatment, which is normally done at medical facilities. Subcutaneous administration with an autoinjector simplifies home treatment and the injection process requires less time than the IV formulation. This makes the treatment easier for patients and their care partners and may reduce the need for hospital visits and nursing care compared to IV administration, in addition to being more convenient for patients to continue the treatment. Alzheimer’s disease is an ongoing neurotoxic process that begins before and continues after amyloid-beta (Aβ) plaque deposition, which is a hallmark of the disease. Data suggests that early and continued treatment may prolong the benefit even after Aβ plaque is cleared from the brain. If approved by the FDA, patients who have completed the biweekly IV initiation phase could transfer to the subcutaneous autoinjector 360 mg weekly maintenance regimen, currently under review. This would maintain effective drug concentrations to sustain the clearance of highly toxic protofibrils[i] which can continue to cause neuronal injury even after the Aβ plaque has been cleared from the brain. The BLA is based on data from the Phase 3 Clarity AD open-label extension (OLE) study, and modeling of observed data. Leqembi is now approved in the U.S., Japan and China, and applications have been submitted for review in the European Union, Australia, Brazil, Canada, Hong Kong, Great Britain, India, Israel, Russia, Saudi Arabia, South Korea, Taiwan, Singapore and Switzerland. In March 2024, Eisai submitted to the FDA a Supplemental Biologics License Application (sBLA) for less frequent monthly IV maintenance dosing of Leqembi. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region. --- This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on May 15, 2024, at 01.30 a.m. CET. For further information, please contact: Oskar Bosson, VP Communications and IRE-mail:  oskar.bosson@bioarctic.sePhone: +46 70 410 71 80 Jiang Millington, Director Corporate Communication and Social MediaE-mail: jiang.millington@bioarctic.sePhone: +46 79 33 99 166About lecanemab (generic name, U.S., Japan and China brand name: Leqembi®)Lecanemab (Leqembi) is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, and China with the following indications:  · U.S.: For the treatment of Alzheimer’s disease (AD). It should be initiated in patients with mild cognitive impairment or mild dementia stage of disease. See full US prescribing information  including boxed waring. · Japan: For slowing progression of mild cognitive impairment (MCI) and mild dementia due to AD. · China: For the treatment of MCI due to AD and mild AD dementia. Lecanemab approvals were based on the large global Phase 3 Clarity AD study. In the Clarity AD study, lecanemab met its primary endpoint and all key secondary endpoints with statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference , and simultaneously published in the New England Journal of Medicine , a peer-reviewed medical journal. Eisai has also submitted applications for approval of lecanemab in 14 countries and regions, including the European Union (EU). Eisai has completed a lecanemab subcutaneous bioavailability study, and subcutaneous dosing is currently being evaluated in the Clarity AD (Study 301) open-label extension (OLE) study. A maintenance dosing regimen has been evaluated as part of the Phase 2b study (Study 201). Since July 2020 Eisai’s Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health and Eisai. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the collaboration between BioArctic and EisaiSince 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales. About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se. [i] Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.[ii] Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.[iii] [ii] Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z [iii] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)

Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and Eisai and BioArctic are currently preparing for a joint commercialization in the region. BioArctic's report for the first quarter 2024 will be published on May 17 at 08.00 a.m. CET. --- This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on May 15, 2024, at 05.45 a.m. CET.              For further information, please contact: Oskar Bosson, VP Communications and IRE-mail:  oskar.bosson@bioarctic.sePhone: +46 70 410 71 80 Jiang Millington, Director Corporate Communication and Social MediaE-mail: jiang.millington@bioarctic.sePhone: +46 79 33 99 166About lecanemab (generic name, U.S., Japan and China brand name: Leqembi®)Lecanemab (Leqembi) is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, and China with the following indications:  · U.S.: For the treatment of Alzheimer’s disease (AD). It should be initiated in patients with mild cognitive impairment or mild dementia stage of disease. See full US prescribing information . · Japan: For slowing progression of mild cognitive impairment (MCI) and mild dementia due to AD. · China: For the treatment of MCI due to AD and mild AD dementia. Lecanemab approvals were based on the large global Phase 3 Clarity AD study. In the Clarity AD study, lecanemab met its primary endpoint and all key secondary endpoints with statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference , and simultaneously published in the New England Journal of Medicine , a peer-reviewed medical journal. Eisai has also submitted applications for approval of lecanemab in 14 countries and regions, including the European Union (EU). Eisai has completed a lecanemab subcutaneous bioavailability study, and subcutaneous dosing is currently being evaluated in the Clarity AD (Study 301) open-label extension (OLE) study. A maintenance dosing regimen has been evaluated as part of the Phase 2b study (Study 201). Since July 2020 Eisai’s Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health and Eisai. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the collaboration between BioArctic and EisaiSince 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales. About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se.

Everfuel – Q1 2024: Focus on HySynergy 1 completion and execution of realigned strategy

Herning, Denmark, 15 May 2024 – Everfuel A/S today published its first quarter 2024 financial results. Key events Q1 2024: · HySynergy 1 start-up moved to second half 2024 due to failed commissioning tests of certain sub-systems provided by the supplier postponing internal Everfuel and supplier software validation  · LOI with undisclosed industrial offtaker of green hydrogen in Germany · Political agreement in Denmark for financing of the hydrogen pipeline infrastructure · Five trailers in operation, serving the Heinenoord bus station and upcoming bus depots in Germany · Q1 EBITDA of EUR -2.6. million (EUR -5 million Q1 2023) · Cash position of EUR 25.4 million at end of March 2024  · Significant cost reduction in downstream business activities · Current liquidity position expected to fund investment and operation plans well into 2025 · Updated long-term ambition of >2 GW installed capacity, EUR >1 billion revenue by end-2035 with an EBITDA margin of 30-35% Everfuel’s ambition is to make green hydrogen for zero emission industrial activity and mobility commercially available across Europe. Everfuel primarily focus on the development of large-scale green hydrogen production capacities starting in Denmark and providing green hydrogen for industrial and mobility users in Europe. The Company is engaging with partners, customers and authorities across the entire value chain, from production to distribution and fuelling, when executing its long-term strategy for value creation as a leading European green hydrogen company.   On May 8, Everfuel announced a Letter of Intent (LoI) with a large industrial offtaker in Germany for the supply of up to 10,000 tons of green hydrogen per year from 2028. Industrial-scale green hydrogen production, distribution and fuelling networks are required for Europe to meet stated climate targets. Everfuel’s activities support these targets and maintains the ambition of being one of the first green hydrogen companies to reach over EUR 1 billion in revenue from hydrogen sales to industry and mobility customers. “Everfuel continues the implementation of our realigned strategy, prioritising the development of large-scale electrolysers supplying industry and heavy-duty mobility, while at the same time reducing cash burn and adding financial flexibility. Today, we present our updated long-term ambitions as a leading European independent hydrogen producer, enabling hard-to-abate industries to decarbonise, as reflected in the recent LOI signed with a new partner in Germany. Execution of our strategy is supported by the Hy24 JV, which positions us to accelerate the deployment of green hydrogen production to meet strong European demand growth driven by the urgent need for zero-emission energy and transport systems,” said Jacob Krogsgaard, the founder and CEO of Everfuel. Following the strategy realignment, Everfuel has updated the company’s financial model and set new long-term ambitions based on the development of the hydrogen backbone infrastructure in line with agreements announced Danish and German Governments. Everfuel targets to have more than 2 GW of green hydrogen production capacity installed by end-of 2035 based on the execution of three electrolyser projects in Denmark, supporting the above-mentioned revenue target and an expected EBITDA margin of 30-35%. Total investments are forecast to around EUR 2 billion, of which EUR  300 million is expected externally raised equity financing and the remainder being expected cashflow from operations, debt at group and SPV level and various grants. Of the EUR 300 million equity requirement, approximately one-third has already been raised. Everfuel recognises, that as an early mover in a new industry, the Company is breaking new ground and continuously contribute to constructive maturation of technology together with suppliers and stakeholders, exposing the Company to protracted political progress, immature technology, supply chain challenges, cost inflation and scarce resources including access to competence. Key financials Total revenue, representing the sale of hydrogen, projects and other operating income, was EUR 1.2 million in the first quarter of 2024, up from EUR 0.6 million in the same period of 2023. Total revenue included EUR 0.4 million in proceeds from sales of legacy assets related to the downstream business. EBITDA was negative EUR 2.5 million (negative EUR 5.0 million in first quarter 2023). The improvement is driven by high-grading of the downstream project portfolio and optimised downstream operations as well as savings in group cost. Total Group assets at 31 March 2024 were EUR 107.6 million, compared with EUR 111.2 million at year-end 2023. The increase in non-current assets reflects that the construction phase of HySynergy 1 is close to completion. The decrease in current assets reflects that accrued grants have been received and a reduction in in cash and cash equivalents. At period end, the cash position was EUR 25.4 million, compared to EUR 28.6 million at year-end 2023. The decrease reflects investments made during the period. Total equity amounted to EUR 67.5 million (EUR 70.3 million). Changes from year-end reflects the net loss in the period. HySynergy 1 update On 24 April 2024, Everfuel provided an update on the commissioning of the 20 MW HySynergy 1 electrolyser with focus on sub-systems required to start production and delivery of green hydrogen. The main electrolyser facility is ready for start-up, while some sub-systems experience delays following commissioning tests. This is impacting the planned start-up of the HySynergy 1 facility with production now expected to commence in the second half of 2024. Testing, verification and certification is being executed in close cooperation with the electrolyser supplier, Nel, and other sub-suppliers with focus on the following areas; Gas holder rebuild, high-pressure systems, compressors and finalisation of software and automation, documentation and certifications. Everfuel and sub-suppliers have committed highest attention and priority for completing the remaining commissioning steps which are strongly interdependent with certain steps subject to specific time windows for external expertise to undertake testing and verification. As a consequence of the mentioned activities, commissioning of the main compressor, final validation of the high -pressure system and completion of the automation and software system are affected. Outlook Everfuel maintains a high level of activity related to multiple business development projects. For 2024, the completion of the HySynergy 1 commissioning and start of hydrogen deliveries will be the first major milestone. Everfuel continues to progress HySynergy 2 towards FID and are maturing the other large-scale electrolyser projects to be executed as SPVs under the strategic collaboration with Hy24. The JV with Hy24 and the cooperation with ITOCHU and Osaka Gas are part of Everfuel’s strategy to systematically build a strong foundation for capitalisation of large-scale electrolyser projects under development. In 2024, the Company will continue to strengthen this foundation as part the ongoing engagement with existing and potential new strategic partners which support execution of Everfuel’s green hydrogen growth ambitions. The financial results for the first quarter of 2024 reflect that the company is still in the initial stages of commercialising the green hydrogen value chain. HySynergy 1 is expected to have material positive impact on revenue generation when it is in operation. The delayed start-up will impact cash flow from hydrogen sales, however, Everfuel expects to have liquidity to finance the current approved investments well into 2025 before requiring additional equity. Longer-term, the combination of increased green hydrogen production, distribution and end-user deliveries are expected to drive revenue growth and cash generation. For 2024, Everfuel maintains the expectation to report a negative financial result, in the range of EUR 15 to EUR 11 million, with a significant improvement in cash flow compared to 2023. Webcast CEO Jacob Krogsgaard and CFO Jesper Ejlersen will present the company's results today at 09:00 CEST and invite investors, analysts, and media to join the live webcast presentation. The presentation is expected to last up to one hour, including Q&A, and can be followed via live webcast. Join the results webcast on Teams via the following link: Q1 2024 results presentation     Questions can be submitted through the online webcast during the presentation. A recorded version of the presentation will be made available at www.everfuel.com after the presentation has concluded. For further information, please contact: Jesper Ejlersen, CFO, Everfuel, jej@everfuel.comMads Tirsgaard Mortensen, Investor Relations Director, Everfuel, mm@everfuel.com, +45 7730 4727 About Everfuel | www.everfuel.com Everfuel own and operate green hydrogen infrastructure and partner with industry and vehicle OEMs to connect the entire hydrogen value chain and seamlessly provide hydrogen fuel to enterprise customers under long-term contracts. Green hydrogen is a 100% clean energy carrier made from renewable solar and wind power and key to decarbonising industry and transportation in Europe. We are an ambitious, rapidly growing company, headquartered in Herning, Denmark, and with activities in Denmark, Germany and The Netherlands, and a plan to grow across Europe. Everfuel is listed on Euronext Growth in Oslo under EFUEL. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024

Key highlights Lundbeck’s revenue increased by 7% CER[1] (+5% DKK) to DKK 5,288 million in the first quarter of 2024, mainly driven by growth in the U.S. and Europe · United States: DKK 2,498 million (+9% CER; +7% DKK) · Europe: DKK 1,248 million (+9% CER; +6% DKK) · International Markets: DKK 1,481 million (+4% CER; -1% DKK) The revenue of Lundbeck’s strategic brands increased by 17% CER (+15% DKK), reaching DKK 3,759 million, representing 71% of total revenue · Brintellix[®]/Trintellix[®]: DKK 1,168 million (+11% CER; +8% DKK) · Rexulti[®]: DKK 1,115 million (+7% CER; +5% DKK) · Abilify Maintena[®]/Asimtufii: DKK 859 million (+10% CER; +9% DKK) · Vyepti[®]: DKK 617 million (+79% CER; +76% DKK) Adjusted EBITDA[2] decreased to DKK 1,746 million (-2% CER; -5% DKK) as a result of a lower adjusted gross margin, following quarterly fluctuations in stock valuation. In addition, the first quarter of 2024 reflects higher R&D costs to support the pipeline in progress and targeted investments in sales and promotion mainly for Rexulti[®] and Vyepti[® ]in the U.S. Adjusted EBITDA margin reached 33.0% equivalent to a decrease of 3.6 percentage points. Adjusted earnings per share (EPS) reached DKK 1.38 (+1%). Excluding the effect from quarterly fluctuations in stock valuation, the underlying growth in the adjusted EBITDA was 6% CER, constituting an adjusted EBITDA margin decrease of 0.6 percentage points. In connection with the corporate release, Lundbeck’s President and CEO, Charl van Zyl said: “I am pleased to present another solid quarter for Lundbeck with a robust operational performance and a 7% revenue growth driven by the continued strong performance of our strategic brands. In line with our Focused Innovator strategy, we are driving forward promising scientific innovations such as our potential first-in-class therapy for migraine prevention, anti-PACAP, and a possible first treatment option targeting the rare neurological condition, Multiple System Atrophy.”  Key figures []DKK million Q1 2024 Q1 2023 Change Change(DKK) (CER)[1]Revenue 5,288 5,044 7% 5%EBITDA 1,746 1,744 4% 0%Adjusted EBITDA 1,746 1,845 (2%) (5%)EPS (DKK) 1.01 0.89 13%Adjusted EPS (DKK) 1.38 1.36 1% Recent events On 30 April 2024, U.S. Food and Drug Administration (FDA) communicated to Lundbeck that Lu AF82422 orphan drug designation request has been granted for treatment of Multiple System Atrophy (MSA). On 9 April 2024, Lundbeck and Otsuka Pharmaceutical Co., Ltd. submitted a supplemental New Drug Application (sNDA) for U.S. FDA review of brexpiprazole as combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD) in adults. The sNDA submission is based on previously disclosed results, including data from the two clinical phase III trials and the clinical phase II trial. All three trials investigated the treatment of PTSD in adults treated with brexpiprazole in combination with sertraline versus sertraline plus placebo. On 27 March 2024, Lundbeck and Otsuka Pharmaceutical Europe Ltd. announced that the European Commission (EC) has approved Abilify Maintena[®] 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole. The EC decision applies to all European Union (EU) member states, as well as Iceland, Norway and Liechtenstein. On 15 March 2024, Lundbeck announced the advancement of the clinical development of Lu AG09222 for migraine prevention with the initiation of PROCEED, a randomized, double-blind, phase IIb, dose-finding trial to assess efficacy and safety of multiple subcutaneously administered doses. The PROCEED trial builds on the positive results of the HOPE phase IIa Proof-of-Concept trial demonstrating efficacy of intravenously administered Lu AG09222 in migraine prevention. On 5 March 2024, Lundbeck announced clinical data from the AMULET phase II, double-blind, randomized trial of Lu AF82422 in MSA at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024). Based on the encouraging AMULET trial outcomes, Lundbeck plans to initiate a phase III study, following further dialogue with health authorities. Lundbeck announced key leadership changes on 23 February 2024. Michala Fischer-Hansen joined as Executive Vice President and Head of Europe & International Markets. Additionally, Tine Østergaard Hansen and Dianne Hol were appointed Senior Vice President of Corporate Communication & Public Affairs and Executive Vice President of People & Organization, respectively. Furthermore, on 13 May 2024, Lundbeck announced the appointment of Maria Alfaiate as Executive Vice President Commercial and Corporate Strategy. Financial guidance 2024 maintained On 7 February 2024, Lundbeck communicated the financial guidance for 2024 focusing on revenue performance and adjusted EBITDA at CER. The revenue growth is expected to be 7% to 10% at CER when compared to revenue of the prior year excluding the effect from hedging. The adjusted EBITDA growth is expected to be 10% to 16% at CER when compared to adjusted EBITDA of the prior year excluding effects from hedging. Further details are available in section 2.7 Outlook. [1] Change at CER (Constant Exchange Rates) does not include effects from hedging. [2] EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortization. Adjusted EBITDA is defined as EBITDA adjusted by certain items, for details see section 4 Notes, note 3 Adjusted EBITDA.

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On May 13, 2024, BlackRock's holding in Metso’s shares fell below the 5 percent threshold and amounted to 40,869,435 shares or 4.93 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 904,576 shares, which corresponds to 0.10 percent of the total amount of Metso’s shares. On May 13, 2024, BlackRock's total position amounted to 41,774,011 or 5.03 percent of Metso’s shares and votes. Metso’s total number of shares and voting rights is 828,972,440.BlackRock, Inc.’s holdings according to the notification: % of % of shares and voting rights Total of both shares through financial instruments in % (7.A + and (total of 7.B) 7.B) voting rights (total of 7.A)Resulting 4.93% 0.10% 5.03%situation on thedate onwhich thresholdwas crossed orreachedPosition of 5.02% 0.07% 5.10%previousnotification A: Shares and votingrightsClass/type of Number of % ofshares shares and shares and voting voting rights rightsISIN code Direct(SMA Indirect(SMA Direct(SMA Indirect(SMA 9:5) 9:6 and 9:7) 9:5) 9:6 and 9:7)FI0009014575 40,869,435 4.93%SUBTOTAL A 40,869,435 4.93%B: FinancialInstruments accordingto SMA 9:6aType of financial Expiration Exercise/ Physical or Number % of sharesinstrument date Conversion cash of and voting Period settlement shares rights and voting rightsAmerican Depositary N/A N/A Physical 9,005 0.00%Receipt(US5926721094)Securities Lent N/A N/A Physical 895,571 0.10% SUBTOTAL B 904,576 0.10% Metso Corporation  Distribution:  Nasdaq Helsinki Ltd Main media www.metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com, x.com/metsoofficial

Stora Enso raises its guidance for the full year 2024 adjusted EBIT (Inside information)

Stora Enso estimates that the previous full year 2024 adjusted EBIT guidance will be exceeded, thanks to successful implementation of profit improvement actions and more favourable market conditions. The Company has therefore revised its full year 2024 adjusted EBIT guidance to be significantly higher (+50% and above) than the full year 2023 of EUR 342 million. The previous guidance for the full year 2024 was the adjusted EBIT to be higher (more than +15%, but less than +50%) than full year 2023.In the outlook comment in its Q1 2024 report, published on 25 April, Stora Enso stated that it anticipates a gradual recovery in market conditions in 2024, with increased demand for consumer board, higher pulp demand and prices. These market trends are continuing with improved volume and pricing. The Group’s profit improvement actions are becoming visible in the result development. Consequently, Stora Enso has revised its internal forecasts for the full year 2024 to a higher level than previously estimated.The outlook has improved due to increasing orderbooks and volumes for consumer board, as well as improved pricing outlook for the containerboard and consumer board businesses. Pulp prices continue to increase, and the outlook for the rest of this year is stronger than previously estimated. Challenging market conditions still continue in the Wood Products and Packaging Solutions divisions.Market uncertainties such as a continued high inflationary environment, strikes, demand and price development, and other external disruptions which may impact the Group’s profits, are still expected to persist towards the end of 2024. Stora Enso Oyj will publish its Half-year Report for January–June 2024 on Wednesday 24 July 2024 at approximately 8:30 EEST (7:30 CEST).Part of the global bioeconomy, Stora Enso is a leading provider of renewable products in packaging, biomaterials and wooden construction, and one of the largest private forest owners in the world. Stora Enso has approximately 20,000 employees and our sales in 2023 were EUR 9.4 billion. Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded in OTC Markets (OTCQX) in the USA as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors    STORA ENSO OYJ

Interim Report Q1, January-March 2024

January – March 2024 · Net sales decreased to SEK 508 million (575) · Operating profit before depreciation amounted to SEK 39 million (39) · Operating profit decreased to SEK 19 million (22) · Earnings after tax amounted to SEK 1 million (8) · Earnings per share amounted to SEK 0.01 (0.04) · Cash flow after investing activities amounted to SEK 49 million (22) Bong is one of the leading providers of envelope products in Europe that also offers solutions for distribution and packaging of information, advertising materials and lightweight goods. Important growth areas in the Group are packaging within retail and e-commerce and the envelope market within Eastern Europe. The Group has annual sales of approximately SEK 2.1 billion and about 1,000 employees in 13 countries. Bong has strong market positions in most of the important markets in Europe and the Group sees interesting possibilities for continued development. Bong is a public limited company and its shares are listed on Nasdaq Stockholm (Small Cap). For further information, please contact Carsten Grimmer, CFO of Bong AB (publ). Tel (switchboard) +46 44-20 70 00. This is information that Bong AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.10 CET on 15 May 2024.

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Right to participate in the annual general meeting and notice of participation Participation in the annual general meeting at the venue A shareholder who wishes to participate in the annual general meeting at the venue in person or represented by a proxy must (i) be recorded as a shareholder in the share register maintained by Euroclear Sweden AB relating to the circumstances on 7 June 2024, and (ii) no later than 11 June 2024 give notice by post to Calliditas Therapeutics AB (publ), Annual General Meeting 2024, c/o Euroclear Sweden, Box 191, SE-101 23 Stockholm, Sweden or via e-mail to GeneralMeetingService@euroclear.com. When providing such notice, the shareholder shall state name, personal or corporate registration number, address, telephone number and the number of any accompanying assistant(s) (maximum two assistants) as well as information about any proxy. If a shareholder is represented by proxy, a written, dated proxy for the representative must be issued. A proxy form is available on the company’s website, www.calliditas.se. If the proxy is issued by a legal entity, a certificate of registration or equivalent certificate of authority should be enclosed. To facilitate the registration at the general meeting, the proxy and the certificate of registration or equivalent certificate of authority should be sent to the company as set out above so that it is received no later than 16 June 2024.  Participation by advance voting A shareholder who wishes to participate in the annual general meeting by advance voting must (i) be recorded as a shareholder in the share register maintained by Euroclear Sweden AB relating to the circumstances on 7 June 2024, and (ii) give notice no later than 11 June 2024, by casting its advance vote in accordance with the instructions below so that the advance vote is received by Euroclear Sweden AB no later than on that day.  A shareholder who wishes to participate in the annual general meeting at the venue in person or represented by a proxy must give notice thereof in accordance with what is set out under Participation in the annual general meeting at the venue above. This means that a notification by advance vote is not sufficient for a person who wishes to participate at the venue. A special form shall be used when advance voting. The advance voting form is available on the company’s website www.calliditas.se. A completed and signed form may be submitted by post to Calliditas Therapeutics AB (publ), Annual General Meeting 2024, c/o Euroclear Sweden, Box 191, SE-101 23 Stockholm, Sweden or via e-mail to GeneralMeetingService@euroclear.com. The completed form shall be received by Euroclear Sweden AB not later than 11 June 2024. Shareholders who are natural persons may also cast their votes electronically through BankID verification via https://anmalan.vpc.se/EuroclearProxy/. The shareholder may not provide special instructions or conditions in the voting form. If so, the advance vote in its entirety is invalid. Further instructions and conditions are included in the form for advance voting. If a shareholder votes by proxy, a written and dated proxy shall be enclosed to the advance voting form. A proxy form is available on the company’s website www.calliditas.se. If the shareholder is a legal entity, a certificate of registration or equivalent certificate of authority should be enclosed. If a shareholder has voted in advance and then attends the annual general meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder participates in a voting procedure at the general meeting or otherwise withdraws its casted advance vote. If the shareholder chooses to participate in a voting at the general meeting, the vote cast will replace the advance vote with regard to the relevant item on the agenda.  For questions regarding the annual general meeting or to have the advance voting form sent by post, please contact Euroclear Sweden AB, by telephone +46 8 402 91 33 (Monday-Friday 09:00-16:00 CEST). Nominee-registered shares To be entitled to participate in the annual general meeting, a shareholder whose shares are held in the name of a nominee must, in addition to providing notification of participation, register its shares in its own name so that the shareholder is recorded in the share register relating to the circumstances on 7 June 2024. Such registration may be temporary (so-called voting right registration) and is requested from the nominee in accordance with the nominee’s procedures and in such time in advance as the nominee determines. Voting right registrations completed by the nominee not later than 11 June 2024 are taken into account when preparing the share register. Number of shares and votes As per the date of this notice there are a total of 53,672,069 ordinary shares outstanding in the company that entitle to one vote per share at the annual general meeting. Furthermore, as of the date of this notice, the company holds 5,908,018 own ordinary shares which cannot be represented at the annual general meeting. Thus, there are a total of 59,580,087 ordinary shares and votes in the company, of which 53,672,069 shares and votes can be represented at the annual general meeting. Proposed agenda 1. Opening of the meeting 2. Election of a chairman of the meeting 3. Preparation and approval of the voting register 4. Approval of the agenda 5. Election of one or two persons to approve the minutes 6. Determination of whether the meeting was duly convened 7. Presentation by the CEO 8. Presentation of the annual report and auditor’s report and the consolidated financial statements and auditor’s report for the group 9. Resolutions regarding: a. Adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet, b. Allocation of the company’s profit or loss according to the adopted balance sheet, and c. Discharge from liability for board members and the CEO 10. Determination of the number of members of the Board of Directors and the number of auditors11. Determination of remuneration for the Board of Directors and the auditors12. Election of the Board of Directors13. Election of chairman of the Board of Directors14. Election of accounting firm or auditors15. Resolution on principles for appointing the nomination committee16. Resolution on approval of the Board of Directors’ remuneration report17. Resolution to authorize the Board of Directors to resolve on issue of new shares, warrants and/or convertibles18. Resolution to authorize the Board of Directors to resolve on transfer of own ordinary shares19. Resolution, in order to adopt a long-term performance-based incentive program for members of the Board of Directors, on: a. Adoption of a long-term performance-based incentive program for members of the Board of Directors b. Issue of warrants c. Equity swap agreement with a third party 20. Resolution, in order to adopt a long-term incentive program for the company’s management and key personnel, on: a. Adoption of a long-term incentive program for the company’s management and key personnel b. Issue of warrants c. Equity swap agreement with a third party 21. Resolution on amendment of previously outstanding long-term incentive programs adopted in 2020, 2021, 2022 and 202322. Resolution on guidelines on remuneration to group management and board members23. Closing of the meeting Item 2, 10-14 – The nomination committee’s proposal to the annual general meeting 2024 The nomination committee of Calliditas Therapeutics, which consists of Karl Tobieson (Linc AB) (chairman of the nomination committee), Patrik Sobocki (Stiftelsen Industrifonden) and Spike Loy (BVF Partners L.P.) proposes the following: · that Dain Hård Nevonen, member of the Swedish Bar Association, shall be appointed chairman at the annual general meeting. · that the number of members of the Board of Directors shall be six (6) without deputies. · that the number of auditors shall be one (1) without deputies. · that the directors’ fee shall be paid with SEK 940,000 (940,000) to the chairman of the Board of Directors and SEK 365,000 (365,000) to each one of the other members who are not employed in the group, SEK 200,000 (200,000) to the chairman of the audit committee and SEK 100,000 (100,000) to the other members of the audit committee who are not employed in the group as well as SEK 50,000 (50,000) to the chairman of the remuneration committee and SEK 25,000 (25,000) to the other members of the remuneration committee who are not employed in the group. In addition to the above-proposed remuneration for ordinary board work, it is proposed that board members residing in the United States shall receive an additional amount of SEK 140,000 (140,000) and board members residing in Europe, but outside the Nordics, shall receive an additional amount of SEK 50,000 (50,000). · that the fee to the auditor shall be paid in accordance with approved statement of costs. · that the board members Elmar Schnee, Hilde Furberg, Diane Parks, Henrik Stenqvist, Fred Driscoll and Elisabeth Björk are re-elected as board members for the period up until the end of the next annual general meeting. · that Elmar Schnee is re-elected chairman of the Board of Directors. · that Ernst & Young AB is re-elected, in accordance with the audit committee’s recommendation. Should Ernst & Young AB be re-elected, the nomination committee notes that Ernst & Young AB has communicated that Jakob Grunditz will be appointed as the auditor in charge. A presentation of the individuals proposed for re­election is available at www.calliditas.se/en/. Item 9b – Allocation of the company’s profit or loss according to the adopted balance sheet The Board of Directors proposes that no dividends shall be paid for the financial year 2023 and that that SEK 904,299 thousand is carried forward. Item 15 – Resolution on principles for appointing the nomination committee The nomination committee proposes that the annual general meeting resolves that the principles for appointing the nomination committee shall be left unchanged from the previous year, in accordance with the below. The nomination committee shall be composed of the chairman of the Board of Directors together with one representative of each of the three largest shareholders, based on ownership in the company as of the expiry of the third quarter of the financial year. Should any of the three largest shareholders renounce its right to appoint one representative to the nomination committee, such right shall transfer to the shareholder who then in turn, after these three, is the largest shareholder in the company. The Board of Directors shall convene the nomination committee. The member representing the largest shareholder shall be appointed chairman of the nomination committee, unless the nomination committee unanimously appoints someone else. Should a shareholder having appointed a representative to the nomination committee no longer be among the three largest shareholders at a point in time falling three months before the annual general meeting at the latest, the representative appointed by such shareholder shall resign and the shareholder who is then among the three largest shareholders shall have the right to appoint one representative to the nomination committee. Unless there are specific reasons otherwise, the already established composition of the nomination committee shall, however, remain unchanged in case such change in the ownership is only marginal or occurs during the three month period prior to the annual general meeting. Where a shareholder has become one of the three largest shareholders due to a material change in the ownership at a point in time falling later than three months before the annual general meeting, such shareholder shall however in any event have the right to take part of the work of the nomination committee and participate in its meetings. Should a member resign from the nomination committee before his or her work is completed, the shareholder who has appointed such member shall appoint a new member, unless that shareholder is no longer one of the three largest shareholders, in which case the largest shareholder in turn shall appoint the substitute member. A shareholder who has appointed a representative to the nomination committee shall have the right to discharge such representative and appoint a new representative. Changes to the composition of the nomination committee shall be announced immediately. The term of office for the nomination committee ends when the next nomination committee has been appointed. The nomination committee shall carry out its duties as set out in the Swedish Code of Corporate Governance. Item 17 – Resolution to authorize the Board of Directors to resolve on issue of new shares, warrants and/or convertibles The Board of Directors proposes that the annual general meeting resolves to authorize the Board of Directors to, at one or several occasions and for the period up until the next annual general meeting, increase the company’s share capital by issuing new shares, warrants and/or convertibles. Such share issue resolution may be carried out with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions. The authorization may only be utilized to such extent that the number of shares issued by virtue of the authorization, or the number of shares created in connection with exercise of warrants or conversion of convertibles, together with any ordinary shares transferred by virtue of the authorization under item 18 below (provided that the annual general meeting resolves in accordance with the proposal), in aggregate does not exceed 20 percent of the total number of ordinary shares issued at the time of the general meeting’s resolution on the proposed authorization, calculated after full exercise of the hereby proposed authorization. The purpose of the authorization is to increase the financial flexibility of the company and the general flexibility of the Board of Directors. Should the Board of Directors resolve on an issue with deviation from the shareholders’ preferential rights, the reason for this shall be to finance an acquisition of operations, to procure capital to finance the development of projects, repayments of loans or to commercialize the company’ s products. Upon such deviation from the shareholders’ preferential rights, the new issue shall be made at market terms and conditions. The CEO shall be authorized to make such minor adjustments to this resolution that may be necessary in connection with the registration thereof. Item 18 – Resolution to authorize the Board of Directors to resolve on transfer of own ordinary shares In 2022, Calliditas Therapeutics had a so called At-The-Market program (“ATM Program”) in place, directed towards the US market. In order to facilitate for the implementation of the ATM program, the annual general meeting 2022 adopted resolutions whereby, among other things, a new class of shares (C-shares) was introduced in the articles of association and the Board of Directors was authorized to resolve on the issue, repurchase and transfer of 5,908,019 C-shares after conversion to ordinary shares. On 20 June 2022, the board of directors resolved by virtue of the authorizations to issue and repurchase 5,908,019 C-shares as well as to convert the C-shares to ordinary shares, which the company has held in treasury since. The company did not carry forward with the ATM program after the initial year, meaning that the program have been terminated without any of the 5,908,019 ordinary shares being exercized, and as a complement to the proposal to authorize the Board of Directors to resolve on issue of new shares, warrants and/or convertibles in accordance with item 17 above, the Board of Directors therefore proposes that the annual general meeting resolves to authorize the Board of Directors to resolve on transfer of own ordinary shares in accordance with this item 18. The Board of Directors proposes that the annual general meeting resolves to authorize the Board of Directors, for the period up until the next annual general meeting, on one or several occasions, to resolve on transfer (sell) of own ordinary shares. Transfers may be carried outside Nasdaq Stockholm at a price with or without deviation from the shareholders’ preferential rights, against cash payment or against payment through set-off or in kind, or on other conditions. Upon such transfers, the price shall be established so that it is not below market price. Transfers of own ordinary shares pursuant to this item may be made by a maximum of 5,908,018 ordinary shares held by the company at the time of this notice (or the lower number of own ordinary shares held by the company at any given time), provided that the total number of shares transferred, together with shares issued or shares that may be created in connection with the exercise of warrants or conversion of convertibles issued by virtue of the authorization under item 17 above (provided that the annual general meeting resolves in accordance with the proposal), in aggregate does not exceed 20 percent of the total number of ordinary shares issued at the time of the general meeting’s resolution on the proposed authorization, calculated after full exercise of the proposed authorization under item 17. The purpose of the authorization is to finance an acquisition of operations, to procure capital to finance the development of projects, repayment of loans or to commercialize the company’ s products. Item 19 – Resolution, in order to adopt a long-term performance-based incentive program for members of the Board of Directors, on: The nomination committee proposes that the annual general meeting resolves to implement a long-term performance-based incentive program for members of the Board of Directors of Calliditas Therapeutics (“Board LTIP 2024”) in accordance with items 19a – 19b below. The resolutions under items 19a – 19b below are proposed to be conditional upon each other. Should the majority requirement for item 19b below not be met, the nomination committee proposes that Calliditas Therapeutics shall be able to enter into an equity swap agreement with a third party in accordance with item 19c below and resolutions under items 19a and 19c shall then be conditional upon each other. Board LTIP 2024 is a program under which the participants will be granted, free of charge, share awards subject to performance vesting (“Share Awards”) that entitle to ordinary shares in Calliditas Therapeutics to be calculated in accordance with the principles stipulated below, however not more than 50,000 ordinary shares. In order to ensure the delivery of ordinary shares under Board LTIP 2024 not more than 50,000 warrants can be issued in accordance with item 19b below. 19a – Adoption of a long-term performance-based incentive program for members of the Board of Directors The rationale for the proposal Board LTIP 2024 is intended for members of the Board of Directors in Calliditas Therapeutics. The nomination committee believes that an equity-based incentive program is a central part of an attractive and competitive remuneration package in order to attract, retain and motivate internationally competent members of the Board of Directors, and to incentivise the participants on delivering exceptional performance which contributes to value creation for all shareholders. Board LTIP 2024 is adapted to the current position and needs of Calliditas Therapeutics. The nomination committee is of the opinion that Board LTIP 2024 will increase and strengthen the participants’ dedication to Calliditas Therapeutics’ operations, improve company loyalty and be beneficial to both the shareholders and Calliditas Therapeutics. Conditions for Share Awards The following conditions shall apply for the Share Awards. 1. The Share Awards shall be granted free of charge to the participants as soon as practicable after the annual general meeting. 2. The Share Awards shall vest gradually over approximately three years, corresponding to three terms up to the date of, whichever is earliest, (i) the annual general meeting 2027 or (ii) 1 July 2027 (the “Vesting Date”), where each term equals the period from one annual general meeting up until the day falling immediately prior to the next annual general meeting or the Vesting Date, as applicable (each such period a “Term”). The Share Awards shall vest with 1/3 at the end of each Term, provided that the participant is still a Board member of Calliditas Therapeutics on the said date. In addition to the vesting conditions just stated, the Share Awards are subject to performance vesting based on the development of the Calliditas Therapeutics share price, in accordance with the vesting conditions below. 3. The Share Awards are subject to performance vesting based on the development of the Calliditas Therapeutics share price over the period from the date the Share Awards are allocated (“Grant Date”) up to and including the day before the Vesting Date. The development of the share price will be measured based on the volume-weighted average price of the company’s share on Nasdaq Stockholm for the 10 trading days immediately preceding the Grant Date and the 10 trading days immediately preceding the Vesting Date, respectively. In the event Calliditas Therapeutics’ share price has increased by more than 60 percent, 100 percent of the Share Awards shall vest, and should the share price have increased by 20 percent, 33 percent of such Share Awards shall vest. In the event of an increase of the share price of between 20 and 60 percent, vesting of the Share Awards will occur linearly. Should the increase of the share price be less than 20 percent, vesting will not occur at all. 4. The earliest point in time at which ordinary shares may be obtained from vested Share Awards shall be as soon as possible after the Vesting Date and once an assessment of the performance criteria has been made. 5. Each vested Share Award entitles the holder to receive one ordinary share in Calliditas Therapeutics without any compensation being payable provided that the holder is still a Board member of Calliditas Therapeutics at the relevant time of vesting with the exception of certain customary “good leaver”-situations (death and permanent incapacity to complete the assignment due to illness or accident) and this shall also apply during the first year up until the day of the annual general meeting 2025. 6. The number of Share Awards will be re-calculated in the event that changes occur in Calliditas Therapeutics’ equity capital structure, such as a bonus issue, merger, rights issue, share split or reverse share split, reduction of the share capital or similar measures. 7. The Share Awards cannot be transferred and may not be pledged. 8. The Share Awards can be granted by the parent company as well as any other company within the Calliditas Therapeutics group. 9. In the event of a public take-over offer, asset sale, liquidation, merger or any other such transaction affecting Calliditas Therapeutics, the Share Awards will vest in their entirety upon completion of such transaction.10. The Share Awards shall otherwise be subject to the terms set forth in the separate agreements with the participants and the detailed terms for Board LTIP 2024. Allocation The number of Share Awards that shall be granted to each participant shall equal the below amount for the respective participant divided by the volume-weighted average price of the Calliditas Therapeutics share on Nasdaq Stockholm for the 10 trading days preceding the Grant Date. The Share Awards under Board LTIP 2024 shall be awarded in accordance with the following:              · Share Awards calculated based on SEK 1,300,000 to the chairman of the Board of Directors; and · Share Awards calculated based on SEK 500,000 to each of Hilde Furberg, Diane Parks, Henrik Stenqvist, Elisabeth Björk and Fred Driscoll. In any event, Board LTIP 2024 will comprise a total number of Share Awards which, if all Share Awards are vested in accordance with the vesting conditions above, can entitle to not more than 50,000 ordinary shares in Calliditas Therapeutics. Preparation of the proposal Board LTIP 2024 has been prepared by the nomination committee and has been structured based on an evaluation of prior incentive programs and market practice for comparable European (including Swedish) and American listed companies. Dilution Assuming a volume-weighted average price of the Calliditas Therapeutics share on Nasdaq Stockholm for the 10 trading days preceding the Grant Date of SEK 110, Board LTIP 2024 will comprise not more than 34,545 ordinary shares in total, which corresponds to a dilution of approximately 0.1 percent on a fully diluted basis. Taking into account also the ordinary shares which may be issued pursuant to previously implemented incentive programs in the company, the maximum dilution amounts to 10.0 percent on a fully diluted basis. Taking into account also the ordinary shares which may be issued pursuant to previously implemented incentive programs in the company as well as the incentive program for the company’s management and key personnel proposed to the annual general meeting 2024, the maximum dilution amounts to 12.5 percent on a fully diluted basis. Information about Calliditas Therapeutics’ existing incentive programs can be found in Calliditas Therapeutics’ annual report for 2023, note 10, which is available on the company’s website, www.calliditas.se/en/. Scope and costs of the program Board LTIP 2024 will be accounted for in accordance with “IFRS 2 – Share‐based payments”. IFRS 2 stipulates that the Share Awards shall be expensed as personnel costs over the vesting period and will be accounted for directly against equity. Personnel costs in accordance with IFRS 2 do not affect the company’s cash flow. Social security costs will be expensed in the income statement during the vesting period. Assuming a volume-weighted average price of the Calliditas Therapeutics share on Nasdaq Stockholm for the 10 trading days preceding the Grant Date of SEK 110, the annual cost for the Board LTIP 2024, according to IFRS 2, is estimated at approximately SEK 1.1 million before tax. The estimated IFRS 2 cost has been calculated with a Monte Carlo simulation. The annual cost for social security contributions is estimated at SEK 0.2 million, based on an annual increase in the share price of 10 percent, the aforementioned assumptions and a social security tax rate of 17 percent. The total annual cost for Board LTIP 2024 during the term of the program, including costs according to IFRS 2 and social security charges, is therefore estimated to approximately SEK 1.3 million. The total cost of the Board LTIP 2024, including all costs referred to above and social security charges, is estimated to amount to approximately SEK 4.0 million under the above assumptions. Delivery of ordinary shares under Board LTIP 2024 In order to ensure the delivery of ordinary shares under Board LTIP 2024, the nomination committee proposes that the annual general meeting resolves to issue warrants in accordance with item 19b below. 19b – Issue of warrants In order to ensure the delivery of ordinary shares under Board LTIP 2024 the nomination committee proposes that the annual general meeting resolves to issue not more than 50,000 warrants whereby the company’s share capital can increase by not more than SEK 2,000 in accordance with the following: 1. The right to subscribe for the warrants shall, with deviation from the shareholders’ pre-emptive rights, only vest with Nefecon AB, a wholly owned subsidiary of Calliditas Therapeutics. The reason for the deviation from the shareholders’ pre-emptive rights is the implementation of Board LTIP 2024. Nefecon AB shall be entitled to transfer the warrants to participants of Board LTIP 2024 or a financial intermediary in connection with the exercise of Share Awards. 2. The warrants shall be issued free of charge and shall be subscribed for on a subscription list no later than 1 July 2024. The Board of Directors may extend the subscription period. 3. The detailed terms of the warrants are set out in the complete proposal which is kept available to the shareholders. 4. The exercise price for subscription for ordinary shares based on the warrants shall correspond to the share’s quota value. 5. The CEO shall be authorized to make such minor adjustments that may be necessary in connection with the registration of the new issue. 6. Notification of subscription of ordinary shares by the exercise of Warrants can be made from and including the day of registration of the Warrants with the Swedish Companies Registration Office up until and including 31 December 2027. 7. Ordinary shares which are issued following subscription shall entitle to participation in the distribution of profits for the first time on the nearest record date occurring after the subscription has been exercised. 19c – Equity swap agreement with a third party Should the majority requirement for item 19b above not be met, the nomination committee proposes that the annual general meeting resolves that Board LTIP 2024 shall instead be hedged so that Calliditas Therapeutics can enter into an equity swap agreement with a third party on terms in accordance with market practice, whereby the third party in its own name shall be entitled to acquire and transfer ordinary shares of Calliditas Therapeutics to the participants. Item 20 – Resolution, in order to adopt a long-term incentive program for the company’s management and key personnel, on: The Board of Directors of Calliditas Therapeutics proposes the introduction of a long-term incentive program for the company’s management and key personnel (including employees and consultants) in accordance with the following. The Board of Directors proposes that the annual general meeting resolves to implement a long-term incentive program for management and key personnel (including employees and consultants) in Calliditas Therapeutics (“ESOP 2024”) in accordance with items 20a – 20b below. The resolutions under items 20a – 20b below are proposed to be conditional upon each other. Should the majority requirement for item 20b below not be met, the Board of Directors proposes that Calliditas Therapeutics shall be able to enter into an equity swap agreement with a third party in accordance with item 20c below and resolutions under items 20a and 20c shall then be conditional upon each other. ESOP 2024 is a program under which the participants will be granted, free of charge, stock options to acquire ordinary shares in Calliditas Therapeutics (“Options”), subject to vesting over a three-year period in accordance with the below. The Board of Directors proposes that a maximum of 2,000,000 Options are allocated to the participants. 20a – Adoption of a long-term incentive program for the company’s management and key personnel The rationale for the proposal ESOP 2024 is intended for members of management and key personnel (including employees and consultants) in Calliditas Therapeutics. The Board of Directors of Calliditas Therapeutics believes that an equity-based incentive program in the form of stock options is a central part of an attractive and competitive remuneration package in order to attract, retain and motivate competent members of management and key personnel (including employees and consultants) in Calliditas Therapeutics, and to focus the participants on delivering exceptional performance which contributes to value creation for all shareholders. The proposed program is key for the company’s ability to attract, retain and motivate competent key persons in the United States as well as in Europe in the company’s operations and commercial functions scaling up the market launch of TARPEYO in the United States and the development of the company’s pipeline assets. During the fourth quarter of 2021, the company received accelerated approval for TARPEYO in the United States and since January 2022, the company commercializes TARPEYO in the United States. TARPEYO received full approval by the FDA in December 2023 . When recruiting and maintaining experienced commercial personnel in the United States and other key employees in the United States and Europe, it is important for Calliditas Therapeutics to be able to offer attractive compensation terms. A competitive equity-based incentive program is a key component in order to be able to attract and retain highly skilled and experienced individuals across clinical development, supply and regulatory areas, as well as relevant capabilities related to Calliditas Therapeutics’ continuous commercialization of TARPEYO in the United States. The Board of Directors of Calliditas Therapeutics believes that ESOP 2024 will fortify the alignment of the interests of the participants and the interests of the shareholders. ESOP 2024 is adapted to the current position and needs of Calliditas Therapeutics. The Board of Directors is of the opinion that ESOP 2024 will increase and strengthen the participants’ dedication to Calliditas Therapeutics’ operations, improve company loyalty and that ESOP 2024 will be beneficial to both the shareholders and Calliditas Therapeutics. Conditions for Options The following conditions shall apply for the Options. · The Options shall be granted free of charge to the participants. · The Board of Directors shall resolve upon the allocation of Options between the date of the annual general meeting 2024 and the date of the annual general meeting 2025 (with each respective granting falling on a “Grant Date”). · Each Option entitles the holder to acquire one share in Calliditas Therapeutics for a pre-determined exercise price. The exercise price will correspond to 115 percent of the volume weighted average price of the Calliditas Therapeutics share on Nasdaq Stockholm during the ten trading days preceding the Grant Date (the “Exercise Price”). · ESOP 2024 shall be settled by using a net share-settlement method, as further described below. · The Options shall vest over a three-year period, with 20 percent on the first anniversary of the Grant Date, with an annual vesting of 40 percent during the second year after the Grant Date, and with an annual vesting of 40 percent during the third year after the Grant Date, and thereafter be exercisable, provided that the holder, with certain exceptions, still is employed by Calliditas Therapeutics (or, in the case of consultants, still provides services to Calliditas Therapeutics). · Following the expiry of the vesting period, the Options may be exercised during a one-year period. · The number of Options shall be subject to customary re-calculation, for example in the event that changes occur in Calliditas Therapeutics’ equity capital structure, such as a bonus issue, merger, rights issue, share split or reverse share split, reduction of the share capital or similar measures. · The Options are non-transferable and may not be pledged. · The Options may be granted by the parent company as well as any other company within the Calliditas Therapeutics group. · In the event of a public take-over offer, asset sale, liquidation, merger or any other such transaction affecting Calliditas Therapeutics, the Options will vest in their entirety following the completion of a change of control. Allocation The right to receive Options shall accrue to up to 250 employees or consultants of the company. The Board of Directors may grant Options, on one or several occasions, between the date of the annual general meeting 2024 and the date of the annual general meeting 2025. The maximum number of Options that may be allocated to the participants under ESOP 2024 is 2,000,000. The maximum allocation per individual in each category shall be 300,000 Options for Category 1 (CEO), 250,000 Options for Category 2 (Management) and 100,000 Options for Category 3 (Other key personnel and consultants). Net share-settlement for ESOP 2024 ESOP 2024 shall be settled by using a net share-settlement method (“Net share-settlement”). The Net share-settlement entails that Options are settled by delivering a number of ordinary shares corresponding to the Option Value (as defined below) to the participants free of charge without any payment of the Exercise Price. The number of ordinary shares to be delivered is calculated by deducting the Exercise Price of the exercised Options from the prevailing share price of the Calliditas ordinary shares on the stock market at the time of exercise (“Market Price”) (the “Option Value”) and dividing the Option Value with the Market Price. Illustrative example of Net share-settlement A participant in ESOP 2024 holds 100 Options with Market Price of the ordinary shares of SEK 75 and Exercise Price of SEK 50. The difference between the Market Price and the Exercise Price is SEK 25 per option (“Option Value”). Instead of the participant paying the Exercise Price (number of options (100) multiplied by the Exercise Price (SEK 50)) and the company delivering 100 ordinary shares worth 75 SEK each (Market Price), the company would use Net-settlement by delivering ordinary shares in an amount corresponding to the Option Value divided with the Market Price ((25*100)/75) – i.e. the company would deliver 33.33 ordinary shares meaning 33 ordinary shares and SEK 25 in cash. In this example, dilution is therefore reduced by 67 percent. To enable Net share-settlement, the company intends to issue warrants in accordance with item 20b below. Preparation, administration and the right to amend the terms of the Options The Board of Directors is responsible for preparing the detailed terms and conditions of ESOP 2024, in accordance with the above-mentioned terms and guidelines. To this end, the Board of Directors shall be entitled to make adjustments to meet foreign regulations or market conditions, including resolving on cash or other settlement if deemed favorable for Calliditas Therapeutics based on foreign tax regulations. The Board of Directors may also make other adjustments if significant changes in Calliditas Therapeutics or its environment would result in a situation where the adopted terms and conditions of ESOP 2024 no longer serve their purpose. Preparation of the proposal ESOP 2024 has been initiated by the Board of Directors of Calliditas Therapeutics and has been structured based on an evaluation of prior incentive programs and market practice for comparable European (including Swedish) and American listed companies. ESOP 2024 has been prepared by the Remuneration Committee and reviewed by the Board of Directors. Dilution Subject to certain recalculation conditions, the maximum number of ordinary shares that may be issued under ESOP 2024 is 2,000,000 which corresponds to a dilution of approximately 3.25 percent on a fully diluted basis. Taking into account also the ordinary shares which may be issued pursuant to already allocated warrants under the company’s outstanding incentive programs, the maximum dilution amounts to approximately 12.57 percent on a fully diluted basis. Accounting for the use of the Net share-settlement method, the dilution for ESOP 2024 is expected to be no more than 65 percent of the total program size, representing a dilution of approximately 2.14 percent. Taking into account also the ordinary shares which may be issued pursuant to already allocated warrants under the company’s outstanding incentive programs, including the use of estimated effect of 65 percent of the total program size using the Net share-settlement method for ESOP 2020, 2021, 2022 and 2023, the maximum dilution is expected to approximately 8.59 percent on a fully diluted basis. Information about Calliditas Therapeutics’ existing incentive programs can be found on Calliditas Therapeutics’ website, www.calliditas.se/en/, under “Remuneration” as well as in the company’s annual report. Scope and costs of the program ESOP 2024 will be accounted for in accordance with “IFRS 2 – Share‐based payments”. IFRS 2 stipulates that the Options shall be expensed as personnel costs over the vesting period. Personnel costs in accordance with IFRS 2 do not affect the company’s cash flow. Social security costs will be expensed in the income statement according to UFR 7 during the vesting period. Assuming a share price at the time of allocation of Options of SEK 110, an annual increase in the share price of 10 percent and that all Options are allocated up-front under the assumptions set out under “Dilution” above, the average annual cost for Calliditas Therapeutics according to IFRS 2 is estimated to approximately SEK 31.4 million per year before tax. The average annual social security costs over the vesting period are estimated to approximately a total of SEK 2.3 million, based on the above assumptions, that all Options are fully vested, a vesting period for all Options of three years and social security costs of 17 percent. If necessary, social security costs will be covered by hedging measures through the issue of warrants (see item 20b below) which would be exercised by a financial intermediary in connection with the exercise of the Options. The social security costs associated with ESOP 2024 will be fully covered and will hence not affect the company’s cash flow. The total cost of ESOP 2024, including all social security costs, is estimated to amount to approximately SEK 101.3 million under the above assumptions. Delivery of ordinary shares under ESOP 2024 In order to ensure the delivery of ordinary shares under ESOP 2024 and if necessary for hedging of social security costs, the Board of Directors proposes that the annual general meeting resolves to issue and use warrants in accordance with item 20b below. 20b – Issue of warrants In order to ensure the delivery of ordinary shares under ESOP 2024, and, if necessary, for hedging of social security costs, the Board of Directors proposes that the annual general meeting resolves to issue not more than 1,300,000 warrants (which includes warrants to potentially hedge social security costs), whereby the company’s share capital could be increased by not more than SEK 52,000. The right to subscribe for the warrants shall, with deviation from the shareholders’ pre-emptive rights, only be granted Nefecon AB, a wholly owned subsidiary of Calliditas Therapeutics. The reason for the deviation from the shareholders’ pre-emptive rights is the implementation of ESOP 2024. Nefecon AB shall be entitled to transfer the warrants to participants or a financial intermediary in connection with exercise. The warrants shall be issued free of charge. The exercise price for subscription for ordinary shares based on the warrants shall correspond to the share’s quota value. The full terms and conditions for the warrants are presented in the complete proposal which is kept available to the shareholders in accordance with the below. 20c – Equity swap agreement with a third party Should the majority requirement for item 20b above not be met, the Board of Directors proposes that the annual general meeting resolves that ESOP 2024 instead shall be hedged through an equity swap agreement with a third party on terms in accordance with market practice, whereby the third party in its own name shall be entitled to acquire and transfer ordinary shares of Calliditas Therapeutics to the participants. 21 – Resolution on amendment of previously outstanding long-term incentive programs adopted in 2020, 2021, 2022 and 2023 The Board of Directors has considered revised terms and conditions as well as different methods for transfer of ordinary shares to participants under the company’s long-term incentive programs based on employee stock options in order to have relevant terms and manage the programs in a cost-effective and flexible manner and to limit dilution under the ESOP 2024 as well as other outstanding incentive programs. In light of this, the Board of Directors has proposed that ESOP 2024, in accordance with what is stated above, is implemented with adjusted terms and conditions compared to previous incentive programs whereby settlement of ESOP 2024 shall take place through a Net share-settlement method. The Board of Directors therefore proposes that the above amendments be approved and apply also to the previously outstanding long-term incentive programs adopted by the annual general meetings 2020, 2021, 2022 and 2023 (“ESOP 2020-2023”) as set out in the following. The Board of Directors proposes that an amendment of the terms is implemented regarding ESOP 2020-2023. The proposal entails the inclusion of a Net share-settlement method which means that settlement of ESOP 2020-2023 is carried out using a Net share-settlement method (as described in item 20a above under the heading “Net share-settlement for ESOP 2024”). In order to ensure delivery of ordinary shares in accordance with ESOP 2020-2023 and to cover costs related to social contributions, the Extraordinary General Meeting 2020 and the Annual General Meetings 2021-2023, respectively, resolved on the issue and transfer of warrants. Since the Board of Directors through this proposal suggests that certain terms for the ESOP 2020-2023 are amended, the Board of Directors also proposes that the Annual General Meeting approves that the warrants issued for hedging purposes under ESOP 2020-2023 may also be used under ESOP 2020-2023 if revised according to this item 21. In line with the previous approvals from the Extraordinary General Meeting 2020 and the Annual General Meetings 2021-2023, respectively, the warrants shall be used to secure the delivery of ordinary shares and to secure social contribution costs. 22 – Resolution on guidelines on remuneration to group management and board members The Board of Directors proposes that the annual general meeting adopts the following updated guidelines on remuneration to members of group management and board members. Resolution on guidelines on remuneration to group management and board members The Board of Directors proposes that the annual general meeting adopts the following guidelines on remuneration to members of group management and board members. The Board of Directors’ proposal for guidelines for remuneration to group management and board members The executive management for the group falls within the provisions of these guidelines. Executive management refers to the CEO and other members of the executive management, as well as board members. The guidelines are forward-looking, i.e. they are applicable to remuneration agreed, and amendments to remuneration already agreed, after adoption of the guidelines by the annual general meeting 2024. The guidelines shall be in force until new guidelines are adopted by the annual general meeting and for a maximum of four years. These guidelines do not apply to any remuneration decided or approved by the general meeting. The guidelines’ promotion of Calliditas Therapeutics’ business strategy, long-term interests and sustainability Calliditas Therapeutics’ business strategy is to commercialize its lead candidate Nefecon and accelerate the development of the product pipeline. Calliditas Therapeutics commercialize Nefecon for IgA nephropathy on a standalone basis in the United States market and through partnerships in other regions. Calliditas Therapeutics may also selectively consider leveraging the group’s capabilities through accessing additional product candidates with a strong strategic and commercial fit development and commercialization. Calliditas Therapeutics’ business strategy and safeguarding of its long-term interests, including its sustainability, presumes that Calliditas Therapeutics is able to recruit and retain qualified personnel. To this end, it is necessary that Calliditas Therapeutics offers competitive remuneration. These guidelines enable Calliditas Therapeutics to offer the executive management a competitive total remuneration. Types of remuneration Calliditas Therapeutics shall offer remuneration in accordance with market practice which enables the recruitment and retention of qualified executives. Remunerations within the group shall be based on principles of performance, competitiveness and fairness. The remuneration to the executive management may consist of fixed remuneration, variable remuneration, share and share-price related incentive programs, pension and other benefits. If local conditions justify variations in the remuneration principles, such variations may occur. The fixed remuneration shall reflect the individual’s responsibility and experience level. The fixed remuneration shall be reviewed annually. The variable cash remuneration covered by these guidelines shall aim at promoting Calliditas Therapeutics’ business strategy and long-term interests, including its sustainability, by for example being clearly linked to the business strategy or promote the executive’s long-term development. The satisfaction of criteria for awarding variable cash remuneration shall be measured over a period of one year. Variable remuneration paid in cash may not exceed 80 percent of the annual fixed cash salary. Variable remunerations shall be connected to predetermined and measurable criteria, designed with the aim of promoting the group’s long-term value creation. To which extent the criteria for awarding variable cash remuneration has been satisfied shall be evaluated/determined when the measurement period has ended. The Remuneration Committee is responsible for the evaluation so far as it concerns variable remuneration to the CEO and to other executives. For financial objectives, the evaluation shall be based on the latest financial information made public by the group. Pension shall be premium-based. Variable cash remuneration shall not qualify for pension benefits. For the CEO and other executives, the premium may, in situations where premium-based pension is applicable, amount to a maximum of 30 percent of the annual fixed cash salary. Notwithstanding the above, the Board of Directors is entitled to offer other solutions which, in terms of cost, are equivalent to the above. Executives may be awarded customary other benefits, such as company car, occupational health service, etc. Such other benefits may amount to not more than 15 percent of the fixed annual cash salary. Long-term share-related incentive plans for employees, consultants and certain board members have been implemented in Calliditas Therapeutics. Such plans have been resolved by the general meeting and are therefore excluded from these guidelines. For more information regarding these incentive plans, including the criteria on which the outcome depends on, please see https://www.calliditas.se/en/remuneration/. Between Calliditas Therapeutics and the CEO, the notice period shall be twelve months upon notice by the company. Upon notice by the CEO, the notice period is six months. For other members of the executive management, notice periods of three to six months apply. During the notice period, normal cash salaries shall be paid. In addition, remuneration may be paid for non-compete undertakings. Such remuneration shall compensate for loss of income and shall only be paid in so far as the previously employed executive is not entitled to severance pay. The remuneration shall amount to not more than 60 percent of the fixed cash salary at the time of termination of employment and be paid during the time the non-compete undertaking applies, however not for more than twelve months following termination of employment. To the extent a board member conducts work for Calliditas Therapeutics, in addition to the board work, consulting fees and other compensation for such work may be payable. For employments governed by rules other than Swedish, pension benefits and other benefits may be duly adjusted for compliance with mandatory rules or established local practice, taking into account, to the extent possible, the overall purpose of these guidelines. Salary and employment conditions for employees In the preparation of the Board of Directors’ proposal for these remuneration guidelines, salary and employment conditions for employees of Calliditas Therapeutics have been taken into account by including information on the employees’ total income, the components of the remuneration and increase and growth rate over time, in the Remuneration Committee’s and the Board of Directors’ basis of decision when evaluating whether the guidelines and the limitations set out herein are reasonable. The decision-making process to determine, review and implement the guidelines The Board of Directors has established a Remuneration Committee. The committee’s tasks include preparing the Board of Directors’ decision to propose guidelines for executive remuneration. The Board of Directors shall prepare a proposal for new guidelines at least every fourth year and submit it to the general meeting. The guidelines shall be in force until new guidelines are adopted by the general meeting. The Remuneration Committee shall also monitor and evaluate programs for variable remuneration for the executive management, the application of the guidelines for executive remuneration as well as the current remuneration structures and compensation levels in the group. The members of the Remuneration Committee are independent to Calliditas Therapeutics and its executive management. The CEO and other members of the executive management do not participate in the Board of Directors’ processing of and resolutions regarding remuneration-related matters in so far as they are affected by such matters. Derogation from the guidelines The Board of Directors may temporarily resolve to derogate from the guidelines, in whole or in part, if in a specific case there is special cause for the derogation and a derogation is necessary to serve Calliditas Therapeutics’ long-term interests, including its sustainability, or to ensure the group’s financial viability. As set out above, the Remuneration Committee’s tasks include preparing the Board of Directors’ resolutions in remuneration-related matters. This includes any resolutions to derogate from the guidelines. Description of material changes to the guidelines and how the views of shareholders’ have been taken into consideration The proposal for guidelines to be presented at the annual general meeting 2024 entails a change regarding that the variable remuneration paid in cash may not exceed 80 percent of the annual fixed cash salary, as opposed to the previous guidelines which stated 60 percent. Otherwise, the proposal does not entail any material changes in relation to the company’s existing guidelines on remuneration. The Board of Directors has not received any comments from the shareholders to consider in the preparation of this proposal. Majority rules The implementation of the Board of Directors’ proposals under items 17 and 18 are subject to the approval at the annual general meeting with at least two thirds (2/3) of both the votes cast and of the shares represented at the meeting. Resolution in accordance with items 19b, 20b and 21 above requires approval of at least nine tenths (9/10) of the shares represented and votes cast at the annual general meeting. Shareholder’s right to obtain information Shareholders are reminded of their right to, at the annual general meeting, obtain information from the Board of Directors and CEO in accordance with Chapter 7 Section 32 of the Companies Act. Shareholders who wish to submit questions in advance may do so by sending post to Calliditas Therapeutics AB (publ), att. Fredrik Johansson, Kungsbron 1 D5, SE-111 22 Stockholm, Sweden, or via e-mail to fredrik.johansson@calliditas.com. Other information The annual report and the auditor’s report for the financial year 2023, proxy form and advance voting form, the remuneration report and other supporting documents for the general meeting, including complete proposals, as well as the statement from the auditor pursuant to Chapter 8, Section 54 of the Companies Act will be available to the shareholders at the company’s office on Kungsbron 1 D5, SE-111 22 Stockholm, Sweden, and on the company’s webpage, www.calliditas.se/en/, no later than 27 May 2024. In connection with the publication of the notice, the nomination committee’s proposal and motivated statement will be available on the address stated above as well as on the website stated above. Copies of the documents will be sent to the shareholders who so request and who states their postal address. Processing of personal data For information on how your personal data is processed, please see the integrity policy that is available at Euroclear’s website, https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. __________________________ Stockholm, May 2024 Calliditas Therapeutics AB (publ) The Board of Directors This is an in-house translation of the Swedish original wording. In case of discrepancies between the English translation and the Swedish original, the Swedish text shall prevail.

Nel ASA: The potential new fueling company will be named Cavendish Hydrogen

The purpose of the spin-off is to create two independent pure-play companies aiming to become market leaders in their respective fields. Furthermore, Nel is pleased to announce that the following have been elected as members of the board of directors of Cavendish Hydrogen  – Jon André Løkke (Chair)  – Mimi K. Berdal (Board Member)  – Vibeke Strømme (Board Member)  – Allan Bødskov Andersen (Board Member)  – Kim Søgård Kristensen (Board Member) Robert Borin will act as CEO, and Marcus Halland will act as CFO of Cavendish Hydrogen. Nel has also completed an internal reorganization whereby Nel’s assets, rights, and liabilities related to the Fueling division and shares in the relevant Fueling subsidiaries have been transferred from Nel to Cavendish Hydrogen. Subject to Nel’s decision to complete the spin-off and pursue the separate listing of Cavendish Hydrogen, the shares in Cavendish Hydrogen are intended to be distributed to the shareholders of Nel as dividend in kind. The decision to spin off and separately list Cavendish Hydrogen has not yet been concluded, and no assurances can be given that it will be completed. However, if such a decision is made, the company plans to conduct the spin-off by the end of the second quarter of 2024. If completed, the shares of Nel (comprising its Electrolyser division) will remain listed on the OSE under the ticker "NEL". Carnegie AS is acting as global coordinator, and Arctic Securities AS and Fearnley Securities AS as joint lead managers (together the “Managers”) to Nel and Cavendish Hydrogen, and Wikborg Rein Advokatfirma AS is acting as Nel and Cavendish Hydrogen's legal counsel. Advokatfirmaet Thommessen AS is acting as legal counsel to the Managers. This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. ENDS For additional information, please contact: Kjell Christian Bjørnsen, CFO, +47 917 02 097 Lars Nermoen, Head of Communications, +47 902 40 153 About Nel ASA | www.nelhydrogen.com Nel has a history tracing back to 1927 and is today a leading pure play hydrogen technology company with a global presence. The company specializes in electrolyser technology for production of renewable hydrogen, and hydrogen fueling equipment for road-going vehicles. Nel's product offerings are key enablers for a green hydrogen economy, making it possible to decarbonize various industries such as transportation, refining, steel, and ammonia. Forward-looking statements: This announcement contains certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Invitation to a webinar about Crunchfish’s interim report for Q1 2024

During the webinar, the chat function will be active, and the participants will be able to ask question regarding the report. In order to participate, registration is done via the following link .   A recording of this webinar will also be available afterward on Crunchfish’s website  as well as Västra Hamnen Corporate Finance’s website .  For more information, please contact: Joachim Samuelsson, CEO of Crunchfish AB +46708 46 47 88 joachim.samuelsson@crunchfish.com This information was provided by the above for publication on 15th May 2024 at 12:00 CET. Västra Hamnen Corporate Finance AB is the Certified Adviser. Email: ca@vhcorp.se. Telephone +46 40 200250. About Crunchfish – crunchfish.com  Crunchfish is a deep tech company developing adevice-agnosticgeneric trusted client application platform foroffline payments, tokenized card payments as well as other mobile client / server systems. Crunchfish has been listed on Nasdaq First North Growth Market since 2016, with headquarters in Malmö, Sweden and with a subsidiary in India.

Dolphin Drilling AS – Update on Blackford Dolphin

(Oslo, 15 May 2024) Dolphin Drilling AS (Dolphin Drilling, OSE:DDRIL) refers to the 10 May 2024 announcement regarding the termination of the drilling contract with General Hydrocarbons Limited (GHL), and the request for arbitration to pursue the recovery of sums remaining due by GHL. The termination of the contract is disputed by GHL, which also made an application to the Nigerian courts for an interim injunction seeking to maintain status quo, pending the appointment of an arbitrator. GHL is portraited in Nigerian media to have been granted a permanent restraining order for the rig, which is inaccurate. This has been brought to the court’s attention, whereupon the court has directed GHL’s counsel to take steps to prevent any such further pre-emptive or prejudicial communications from being instigated by GHL, with counsel also undertaking to do so. The company wishes to clarify that no new decision has been made by the Nigerian court in relation to restraining of the Blackford Dolphin. The situation is that the court has today appointed a mutually acceptable sole arbitrator and will hear arguments on 20 May 2024 on the discharge of the status quo orders earlier granted. The company will continue to update the market on any material developments in the arbitration and court processes as they occur. For further information, please contact: Ingolf Gillesdal, Corporate Finance and Investor Relations, tel: +47 920 45 320 Stephen Cox, CFO, tel: +44 7800 612 130

Calliditas Therapeutics to Present Data at ERA 2024 May 23 – 26 in Stockholm

Data presentations will include an efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) in primary immunoglobulin A nephropathy (IgAN) as well as a real-world analysis of the challenges associated with the use of systemic glucocorticoids (SGC) in IgAN. “We are delighted to participate in ERA and look forward to engaging with the leaders in the renal space,” said Richard Philipson, Chief Medical Officer at Calliditas. “We are especially excited to be in Stockholm, where Calliditas is headquartered and where we developed the first treatment specifically designed for IgA nephropathy, to present analyses that highlight the continued opportunity for our treatment to address the significant unmet need in this rare disease.” The presentation and symposium details are below. Following the meeting, they will be available on the Presentations and Publications page  on Calliditas’ corporate website. Presentation Details: Title: “Matching-adjusted indirect comparison of eGFR in patients with immunoglobulin A nephropathy treated with Nefecon (TRF budesonide) or sparsentan” Oral Poster Presentation: 501129 Date and Time: May 25 3:15-4:30 CET Location: Focused Oral Room 3 Title: “Real-world challenges associated with the use of systemic glucocorticoids in a US IgAN cohort” Poster Number: 2533 Date and Time: May 26 8:54-9:06 CET Location: A5 Symposium Details: Title: Clinical Markers in IgA Nephropathy: Is All Proteinuria the Same? Date and Time: Saturday, May 25: 10:15 - 11:15 am (Room A2+A3) Moderator: Prof. Jonathan Barratt, Renal Medicine at Leicester University. Panel: Shikha Wadhwani, MD, MS, FASN Northwestern University; Richard Lafayette, M.D., F.A.C.P., Stanford Healthcare For more information, visit the ERA 2024 website here . Indication TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Important Safety Information Contraindications: TARPEYO is contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of TARPEYO. Serious hypersensitivity reactions, including anaphylaxis, have occurred with other budesonide formulations. Warnings and Precautions Hypercorticism and adrenal axis suppression: When corticosteroids are used chronically, systemic effects such as hypercorticism and adrenal suppression may occur. Corticosteroids can reduce the response of the hypothalamus-pituitary-adrenal (HPA) axis to stress. In situations where patients are subject to surgery or other stress situations, supplementation with a systemic corticosteroid is recommended. When discontinuing therapy or switching between corticosteroids, monitor for signs of adrenal axis suppression. Patients with moderate to severe hepatic impairment (Child-Pugh Class B and C respectively) could be at an increased risk of hypercorticism and adrenal axis suppression due to an increased systemic exposure to oral budesonide. Avoid use in patients with severe hepatic impairment (Child-Pugh Class C). Monitor for increased signs and/or symptoms of hypercorticism in patients with moderate hepatic impairment (Child-Pugh Class B). Risks of immunosuppression: Patients who are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible patients or patients on immunosuppressive doses of corticosteroids. Avoid corticosteroid therapy in patients with active or quiescent tuberculosis infection; untreated fungal, bacterial, systemic viral, or parasitic infections, or ocular herpes simplex. Avoid exposure to active, easily transmitted infections (e.g., chicken pox, measles). Corticosteroid therapy may decrease the immune response to some vaccines. Other corticosteroid effects: TARPEYO is a systemically available corticosteroid and is expected to cause related adverse reactions. Monitor patients with hypertension, prediabetes, diabetes mellitus, osteoporosis, peptic ulcer, glaucoma or cataracts, or with a family history of diabetes or glaucoma, or with any other condition where corticosteroids may have unwanted effects. Adverse reactions: In clinical studies, the most common adverse reactions with TARPEYO (occurring in ≥5% of TARPEYO treated patients, and ≥2% higher than placebo) were peripheral edema (17%), hypertension (12%), muscle spasms (12%), acne (11%), headache (10%), upper respiratory tract infection (8%), face edema (8%), weight increased (7%), dyspepsia (7%), dermatitis (6%), arthralgia (6%), and white blood cell count increased (6%). Drug interactions: Budesonide is a substrate for CYP3A4. Avoid use with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine. Avoid ingestion of grapefruit juice with TARPEYO. Intake of grapefruit juice, which inhibits CYP3A4 activity, can increase the systemic exposure to budesonide. Use in specific populations Pregnancy: The available data from published case series, epidemiological studies, and reviews with oral budesonide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with IgAN. Infants exposed to in-utero corticosteroids, including budesonide, are at risk for hypoadrenalism. Please see Full Prescribing Information . About TARPEYO TARPEYO is an oral 4mg delayed release formulation of budesonide, designed to remain intact until it reaches the ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum, including the Peyer’s patches, which are responsible for the production of galactose-deficient IgA1 antibodies (Gd-Ag1) causing IgA nephropathy. About Primary Immunoglobulin A Nephropathy Primary immunoglobulin A nephropathy (IgA nephropathy or IgAN or Berger’s Disease) is a rare, progressive, chronic autoimmune disease that attacks the kidneys and occurs when galactose deficient IgA1 is recognized by autoantibodies, creating IgA1 immune complexes that become deposited in the glomerular mesangium of the kidney. This deposition in the kidney can lead to progressive kidney damage and potentially a clinical course resulting in end- stage renal disease. IgAN most often develops between late teens and late 30s.

ExpreS2ion to present in spring investor events

By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website . 16 May 2024 | First quarter 2024 financial results webcast, hosted by HC Andersen Capital10:00 CET | VirtualExpreS2ion CEO Bent Frandsen and CFO Keith Alexander will present the 2024 first quarter results and answer investors’ questions. More information and registration can be found on the H.C. Andersen Capital Events website . 30 May 2024 | The BioStock Global Forum11:00 CET | Lund, SwedenBent Frandsen will present at The Global Forum 2024, an event focusing on international expansion, partnerships, and capital attraction. For those interested in participating, registration is available on the BioStock event website . 4 June 2024 | HC Andersen Capital Life Science SeminarVirtualCEO Bent Frandsen will be participating in the H.C. Andersen Life Science Seminar on June 4[th], which presents a good opportunity for us to engage with the life science community and share our latest developments. Bent will be providing an update on ExpreS2ion, discussing our unique platform and giving insights into our pipeline. More information and registration can be found on the H.C. Andersen Capital Events website . Certified AdviserSvensk Kapitalmarknadsgranskning AB

Does Your House Need Rewiring? - Look Out For These Warning Signs

Electricity is something that most homeowners take for granted, and most don't give much thought to it. However, in some cases, your home may need to be rewired for safety and efficiency. If your home does need to be rewired, you could be putting your home and your family at risk if you don't do something about it. Faulty or old wiring can be dangerous and may lead to shocks or fires. [A person using a drill Description automatically generated] Rewiring your house can be quite a large job, but it’s definitely worth it when you consider the dangers that may come. Homeowners should be aware of the potential warning signs that your home’s wiring needs to be replaced. Below, electrical expert Eric Davis at MyJobQuote.co.uk  has created a list of the four most common signs that your home needs to be rewired. Eric also provides some information on the benefits of rewiring a house, what the job involves, and how long it takes to complete. The Signs That Your House May Need Rewiring Discoloured or Scorched Switches or Sockets If you notice any black or brown marks on your electrical sockets, this may be a result of some tiny fires caused by loose connections within the sockets. These loose connections can create small arcs of electricity and fire. Even if there are no scorch marks present, this doesn't necessarily mean that there are no problems present. The arching may occur within the wiring inside the walls and, therefore, won't be visible from the outside. However, if you notice any discolouration on your sockets or switches, don't ignore them. This may be an issue that becomes a lot more dangerous if it isn't dealt with properly and timely. Fuses blowing Repeatedly If the fuses in your home blow repeatedly, regularly, and randomly, this could signify that your house needs to be rewired. However, it may also be that you have a faulty appliance that is causing these issues. However, if you notice that fuses keep blowing and you can’t identify an appliance that may be causing the issue, it would be worth getting a professional electrician to come out and check out the wiring in your home. If Your House Is Old If you live in a property that is more than 30 years old and you’re not sure if it’s been rewired in the past, you should get a professional electrician to come out and complete an inspection on your home’s wiring to make sure everything is working as it should. Similarly, if you have any old-looking sockets, switches, or fuse boxes, you should get these checked out too. Persistent Smell of Burning If you haven't burned your food recently and there's a burning smell you can't seem to get rid of, this may be a sign that your house needs to be rewired. If there is a burning smell in your home and you can't quite locate the source, turn your home's electrical power off at the circuit and then contact an electrician right away. Electrical burning smells tend to replicate the smell of fish. If you notice anything that doesn't smell quite right, it's not worth taking the risk. Contact a professional electrician who will come and complete an inspection of your home's wiring to ensure there are no issues. What Does a House Rewiring Job Involve? A house rewiring is a process where a single electrician or a team of electricians will remove all of the electrical wiring in every single room of your home. All of the sockets, lights and switches will also be removed so that they can be replaced with new, modern alternatives. The work can be quite disruptive as the walls will need to be cut into so that new wiring can be hidden, and your floorboards will also need to be removed so that cables can be fed between them. With this in mind, it's best to carry out a rewiring job when you're planning on redecorating or remodelling your house anyway. Rewiring your house makes your electrics much safer and more reliable. It also gives you the opportunity to add more sockets, lights, and switches as needed. You can even completely move the location of your sockets and switches, allowing you to customise the room to exactly how you want it. What Are the Benefits of Rewiring a House? Safety The main reason why you should get your home rewired is to improve the safety of your electrics. This ensures that you and your family remain as safe as possible, and it prevents the possibility of any electrical problems. Cheaper Insurance Most home insurers will provide cheaper insurance to those who have a more reliable electrical system. If you get your electrics regularly services too, then you can expect a great deal of savings on your home insurance. Insurers recognise how dangerous old and faulty electrical systems can be. Add Value to the Home Upgrading the electrical system in your home can increase your home’s value by hundreds and even thousands of pounds once it’s been signed off by an inspector. Old electrical systems can instantly put people off wanting to purchase your home whereas new systems are very desirable to potential buyers. Save Money on Bills Old and faulty wirings can often be the cause of high electricity bills. When you have your home rewired, all of the old and faulty wiring will be removed and replaced with modern, efficient wiring. You’ll notice your electricity bills will reduce significantly as soon as your new wiring system is in place. Prevent Malfunctions Faulty wiring around your home can affect your appliances – even some of your bigger appliances. As a homeowner, you will want to ensure that all of your appliances are in good working order. If you leave faulty wiring, it can start to cause disruptions and could end up costing you a lot of money in appliance repairs or replacements. Reduce Chances of Power Cut Power cuts are never fun. Electrical surges are usually the main cause of a power cut, and they can occur for a number of reasons. One of those reasons is faulty electrical wiring. When you have a home rewiring, you eliminate the chances of this occurring because you'll upgrade all of your old and faulty wires for new wiring. How Long Does It Take to Rewire a House? One of the most important things to think about when taking on any kind of house job is the time that the work is going to take. The timescales of your electrical work will have an effect on the cost of labour as the longer the job takes, the longer you will be required to pay for the contractor. There are a number of factors that can affect how long it will take to complete a house rewiring. The main factors include the size of the house, the level of rewiring needed, and whether the electrician runs into any complications during the installation process. On average, you can expect the work to take around 5-9 days to complete. This involves all the steps including removing the old wiring system, replacing the wires, and replacing all of the sockets, light fittings, and switches. Final Thoughts If you're noticing any of the warning signs mentioned above,it's crucial to consult a qualified electrician.They can assess your home's electrical system and recommend the best course of action,whether it's repairs,upgrades,or a full rewire. Remember,ignoring electrical problems can be dangerous and costly.Taking proactive steps now will ensure your home is safe and your electrical system functions efficiently for years to come.So don't hesitate to call in a professional – your peace of mind and safety are worth the investment. MyJobQuote is one of the UK's top trades matching sites that helps individuals find a reputable tradesperson in their local area. MyJobQuote  also has a wide range of experts with extensive knowledge in interior design, cleaning, gardening, property, construction and more. MyJobQuote's experts have been featured in over 700 publications, including Woman and Home, The Times, House Beautiful, BBC News and more. For more information on MyJobQuote's release or comment requests, please email the PR team atContentTeam@ICMEnterprises.co.uk. Copyright © 2024. MyJobQuote.co.uk. All reserved.

A Guide to Using Colour Theory In Your Home For Wellness

Colour is a powerful tool that can influence our mood, energy levels, and even our physical well-being. By understanding colour theory and its psychological effects, you can create a home environment that promotes relaxation, focus, or whatever feeling you desire. [A person and person painting a wall Description automatically generated] Interior design expert Ryan McDonough at MyJobQuote.co.uk  has created this guide on how to use colour theory in your home for wellness. Read on for a deep dive into how to harness the power of colour for a happier, healthier you. Understanding Colour Psychology Colours can be broadly categorised into three categories - warm, cool, and neutral, each with distinct psychological effects that can be leveraged to create specific moods and atmospheres in your home: Warm Colours (Red, Orange, Yellow) These vibrant hues evoke feelings of energy, enthusiasm, and warmth. They can stimulate the appetite, increase heart rate, and encourage conversation. Imagine a kitchen bathed in sunny yellow – it can make you feel more energetic and ready to tackle meal prep. However, too much warmth can be overwhelming. Red, for example, can trigger feelings of urgency or anger if used excessively. Think of a room painted entirely in a bright red shade  – it might feel too intense to relax in after a long day. Cool Colours (Blue, Green, Purple) Associated with calmness, peace, and relaxation. Cool colours have a soothing effect on the nervous system, slowing the heart rate and lowering blood pressure. Blue tones can create a sense of trust and security, perfect for a home office where you need to feel focused and grounded. Greens connect us to nature and promote feelings of growth and renewal. Imagine a serene bathroom painted  in a calming seafoam green – it can feel like a mini escape to a tranquil spa. Darker cool colours like navy blue can feel sophisticated and luxurious, while lighter shades of blue and green inspire tranquillity. Think of a master bedroom painted in a soft lavender – it can lull you into a restful sleep. Neutrals (White, Grey, Beige) These versatile colours provide a sense of balance and can be used effectively anywhere in your home. They act as a canvas for bolder colours or create a minimalist, zen feel. White can make a space feel open and airy, perfect for a small living room. Gray offers a touch of sophistication, ideal for a modern kitchen. Beige creates a warm and inviting atmosphere, well-suited for a cosy family room. Neutrals can also ground bolder accent colours, preventing them from feeling overwhelming. Putting Colour Theory to Work By understanding the psychology of colour, you can create specific moods and atmospheres in different rooms of your home: Living Room This is the heart of your home, a space for socialising, relaxing, or entertaining. Consider calming blues or greens for relaxation or pops of yellow or orange for stimulating conversation and activity. If your living room doesn't get a lot of natural light, opt for lighter and warmer colours like pale yellow or beige to create a sense of spaciousness and energy. You can then add pops of colour with throw pillows or artwork in bolder hues. Bedroom Your bedroom should be a haven of tranquillity, designed to promote restful sleep. Opt for serene blues, lavenders, or light greens to create a calming and peaceful environment. Deeper, cooler tones like a smoky blue or a rich teal can also be effective but avoid overly dark colours like charcoal grey that can feel heavy or gloomy. Experiment with different shades and tints within a cool colour palette to find what works best for you. Bathroom Similar to the bedroom, your bathroom should be a space for relaxation and self-care. Create a spa-like retreat with calming greens, blues, or greys. Lighter colours like pale aqua or sky blue can make a small bathroom feel more spacious, while richer jewel tones like emerald green or sapphire blue can add a touch of luxury. Consider incorporating natural elements like wood or stone accents to complement the calming colour scheme. Home Office Here, the goal is to create a space that promotes focus and productivity. Light blues can boost focus and concentration, while yellows can spark creativity and mental agility. Consider incorporating pops of brighter colours like red or orange for short bursts of energy, but use them sparingly to avoid creating an overwhelming environment. A red accent wall might be too stimulating for long periods of focused work, but a red lampshade or a piece of modern art in red could add a welcome touch of energy. Factors to Consider While colour psychology offers valuable insights, it's important to consider other factors when creating your colour palette: Shades and Tints Don't underestimate the power of variations within a colour family. A soft blue is far more calming than a bright royal blue. Experiment with shades (darker tones) and tints (lighter tones) to achieve the desired mood. For example, a pale lavender can create a feeling of serenity in a bedroom, while a bolder shade of purple can add a touch of drama to a living room. Complimentary Colours Colours opposite each other on the colour wheel, like red and green or blue and orange, can create a vibrant and stimulating energy. Use them in moderation or as accents to add visual interest without overwhelming the space. A throw pillow in a complementary colour can add a pop of personality without being overpowering. Personal Preference While colour psychology offers great insights, your own experiences and associations with colours matter most. Choose colours that make you feel happy and relaxed. Perhaps you have fond childhood memories associated with a particular shade of green, or a certain colour brings back a calming beach vacation. Let your personal connection to colour guide your choices. Consider Lighting The way light interacts with colour can dramatically affect the overall feel of a space. Natural light tends to soften colours, while artificial light can make them appear brighter or cooler. Pay attention to how natural and artificial light affects your chosen colours throughout the day. Trust Your Gut In the end, the most important factor is how the colours make you feel. If a particular colour feels calming and inviting, go for it! Don't be afraid of breaking the rules a little bit and creating a colour scheme that is uniquely you. After all, your home is a reflection of your personality, and your colour choices should reflect that. Ultimately, colour theory is a guide, not a rigid set of rules. The most important aspect is to create a space that feels comfortable and inviting to you. Trust your gut instinct, experiment with different colour combinations, and have fun with the process! After all, there's nothing quite like the feeling of walking into a room that makes you smile, a space that reflects your inner peace and inspires you to live your best life. Final Thoughts By following these tips and embracing the power of colour theory, you can transform your home into a haven of wellness and create a space that promotes relaxation, focus, and overall well-being. Remember, your home is your sanctuary, a place to unwind, recharge, and be yourself. The colours you choose should reflect that. Don't be afraid to experiment, to let your creativity flow, and to create a space that feels uniquely you. RYAN MCDONOUGH:  Ryanis an interior design expert with 15 years worth of experience in the field.Ryanworks closely with clients to make their visions come to life at a price that suits their budget.Ryanalso provides expert interior design commentsfor MyJobQuote and has been featured in a range of top publications. MyJobQuote is one of the UK's top trades matching sites that helps individuals find a reputable tradesperson in their local area. MyJobQuote  also has a wide range of experts with extensive knowledge in interior design, cleaning, gardening, property, construction and more. MyJobQuote's experts have been featured in over 700 publications, including Woman and Home, The Times, House Beautiful, BBC News and more. For more information on MyJobQuote's release or comment requests, please email the PR team atContentTeam@ICMEnterprises.co.uk. Copyright © 2024. MyJobQuote.co.uk. All reserved.

DanCann Pharma A/S: Updated time plan and material terms of the rights issue

As set out in press release published on 30 March 2023, the Company will carry out a rights issue (i.e. an issue of new shares with pre-emptive rights for the Company’s existing shareholders). Below is set out the material terms of the rights issue. Material terms of the rights issue The Offer The Offer is comprised by a maximum of 1,832,907,879 new shares of the Company, each of a nominal value of DKK 0.01, and in the event of full subscription of the rights issue, the share capital of the Company will be increased by nominally DKK 18,329,078.79 (equivalent to a total issue of 1,832,907,879 new shares).The rights issue of new shares is directed at investors in Denmark and Sweden. The new shares are offered to the public with pre-emptive subscription rights for existing shareholders. The New Shares issued in the rights issue will carry the same rights as the existing shares of the Company. Allocation of pre-emptive rightsEach holder of existing shares registered with Euronext Securities on 10 June 2024 (the record date) at 5:59 pm CET as a shareholder in the Company will be allocated eleven (11) pre-emptive rights for each existing share. For each (1) pre-emptive right, the holder is entitled to subscribe for 1 new share at a subscription price of DKK 0.01 per new share. Subscription PriceThe subscription price is DKK 0.01 per new share. Subscription PeriodThe subscription period of the new shares will commence on 11 June 2024 at 9:00 am CET and will close on 24 June 2024 at 5:00 pm CET. Guarantee commitmentsDanCann Pharma has received guarantee commitments (i.e. commitments to subscribe for shares) of approximately DKK 8.959 million, which corresponds to approx. 48.88% of the issue volume, of which (i) approximately DKK 5.5 million consists of bottom-up guarantee commitments, and (ii) approximately DKK 3.459 million consists of top-down guarantee commitments. Any subscription of shares by those having provided bottom-up guarantee commitments will be by way of cash subscription of new shares. Any subscription of shares by those having provided top-down guarantee commitments will be carried out by way of conversion of existing debt in the Company.In addition to the above, an existing lender of the Company (New Growth Opportunities 2) has committed to convert an outstanding loan of an amount of DKK 3,350,000 to shares of the Company at a price of DKK 0.01, provided that the Company receives cash subscriptions of DKK 5.5 million in the rights issue (which the Company has secured) but otherwise regardless of the outcome of the rights issue. Publication of the outcome of the rights issueThe result of the rights issue will be communicated in a company announcement expected to be published through Spotlight no later than three trading days after the expiry of the subscription period, and the result of the rights issue is therefore expected to be announced on 27 June 2024. The proceeds and issue costsIn the event of full subscription of the rights issue, the Company’s gross proceeds will be DKK 18,329,078.79. In the event of full subscription of the rights issue, the Company’s costs in connection with the Offer are estimated at approx. DKK 4.7 million, and hence the net proceeds will in this case be approx. DKK 13.629 million. In the event that the rights issue will not be subscribed for by any other than those having provided guarantee commitments, the costs of the Company in connection with the rights issue are estimated at DKK 3.3 million. Share capital of the CompanyOn the 17 April 2024, an extraordinary general meeting of the Company resolved to complete a reduction of the Company's share capital from 6,248,549.5875 to 1,666,279.89 by transfer of the amount to a special reserve fund (in Danish: henlæggelse til særlig reserve) by way of reduction of the nominal value per share of the Company. The capital reduction will be completed on 16 May 2024 following a 4-week notice period (“proklama”) Therefore, as of the date on which the offer memorandum is published, the nominal value of the Company’s registered share capital is DKK 1,666,279.89 divided into 166,627,989 shares, each having a nominal value of DKK 0.01. The Company’s share capital is not divided into share classes, and all shares carry the same rights. All shares are issued in accordance with the provisions of the Danish Companies Act, fully paid-up and freely transferable. Each Existing Share carries 1 vote.In the event of full subscription of the rights issue, the share capital of the Company will increase from nominally DKK 1,666,279.89 to 19,995,358.68, and the number of outstanding shares will increase from 166,627,989 shares  to 1,999,535,868 shares. Dilution Upon issue of the new shares, existing shareholders’ share of ownership of the Company may be reduced. In the event of full subscription of the rights issue, if an existing shareholder refrains from exercising its pre-emptive rights allocated to the existing shareholder in connection with the rights issue, the existing shareholder's ownership will be diluted by approximately 91.67%. If the existing shareholders elect to partly exercise the pre-emptive rights allocated to them, the rate of dilution will be between 0 to 91.67% depending on the exercise (in the event of full subscription of the rights issue). If the existing shareholders exercise their pre-emptive rights in full, they will not be diluted. Full terms and conditions for the rights issue as well as other information about the Company will be included in the offer memorandum regarding the rights Issue that the Company is expected to publish on 24 May 2024. Updated time plan for the rights issue Date of publication of the memorandum 24 May 2024Last trading day with existing shares 6 June 2024including pre-emptive rightsFirst trading day with existing shares 7 June 2024excluding pre-emptive rightsRecord date for allocation of pre 10 June 2024-emptive rightsPeriod of trading with Pre-Emptive 7 June 2024 at 9:00 am CET -Rights 20 June 2024 at 5:00 pm CETPeriod of trading with temporary Shares 7 June 2024 - 8 July 2024Subscription Period 11 June at 9:00 am CET - 24 June at 5:00 pm CETAnnouncement of the outcome of rights 27 June 2024issueDate of registration of the capital 3 July 2024increase with the Danish BusinessAuthorityFirst day of trading with new shares 9 July 2024 Please note that adjustments may be made to the time plan. Advisors EK Equity AB is acting as a financial advisor to DanCann Pharma.Mazanti-Andersen is acting as the legal adviser of DanCann Pharma. About DanCann Pharma A/S DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm. For more information, visit: www.dancann.com For further information, please contact: Jeppe Krog Rasmussen, CEO E-mail: jkr@dancann.com Forward-looking-statement: Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Bulletin from Sivers Semiconductors AB (publ)’s Annual General Meeting on 15 May 2024

Adoption of the annual report and the auditor’s report  The Annual General Meeting resolved to approve the profit and loss statement and the balance sheet regarding the parent Company and the Group, appropriation of the profit in accordance with the Board of Directors proposal and not to distribute any dividends for the financial year 2023, as well as to discharge the CEO and Board members from liability. Election of Board members As members of the Board of Directors it was resolved to re-elect Tomas Duffy, Erik Fällström, Todd Thomson and Bami Bastani, and to elect Karin Thurberg and Keith Halsey as a new member of the Board of Directors. Beth Topolosky has declined re-election. Bami Bastani was re-elected as the Chairman of the Board of Directors and Tomas Duffy was re-elected as the Vice Chairman of the Board of Directors. It was resolved that the total remuneration for the Board of Directors shall amount to SEK 2,700,000 of which SEK 1,050,000 shall be paid to the Chairman of the Board of Directors, SEK 600,000 to the Vice Chairman of the Board of Directors and SEK 350,000 to each of the other members of the Board of Directors except for Todd Thomson who has waived Board remuneration. In addition, remuneration of SEK 100,000 shall be paid annually to the Chairman of the Audit Committee and SEK 50,000 shall be paid annually to the other members. For work on the Investment Committee, remuneration of SEK 60,000 shall be paid annually to the Chairman and SEK 30,000 shall be paid annually to the other members. For work on the Remuneration Committee, remuneration of SEK 50,000 shall be paid annually to the Chairman and SEK 25,000 shall be paid annually to the other members. Election of auditor The Annual General Meeting resolved to re-elect Deloitte AB as auditor with authorised public accountant Alexandros Kouvatsos as auditor-in-charge. The fees shall be paid in accordance with approved invoices. Resolution on approval of allotment of stock options The Annual General Meeting 2023 resolved on an incentive program (“P08”) comprising stock options for the Group’s employees (the “Stock Options”). The Chairman of the Board of Directors, also being Executive Chairman of Sivers Semiconductors Inc., has been allotted 400,000 Stock Options in accordance with the resolution of the Annual General Meeting 2023 on P08. In addition, the Chairman has been allotted 50,000 Stock Options, conditional upon the Annual General Meetings subsequent approval. As a result thereof, the Annual General Meeting resolved to approve the allotment of 50,000 additional stock options to the Chairman within the framework of P08. The performance conditions shall not apply to the Stock Options. Resolution on authorisation for the Board of Directors to resolve on issues of shares and/or convertible bonds The Annual General Meeting resolved to authorise the Board of Directors to, on one or several occasions during the period until the next Annual General Meeting, with or without deviation from the shareholders’ preferential rights, resolve on share issues and/or issues of convertible bonds that involve the issue of or conversion to a maximum of 26,100,000 ordinary shares, corresponding to a dilution of approximately 10.0 percent of the share capital and the voting rights, based on the current number of shares in the Company. Payment for subscribed shares and/or convertible bonds shall be made in cash, in kind or by way of set-off. The purpose of the authorisation and the reason for the deviation from the shareholders’ preferential rights, is to give the Board of Directors flexibility in the work to secure that the Company in a time-efficient and appropriate way can achieve capital for financing of the operation and to enable continued expansion both organically as well as through acquisitions, alternatively to increase the number of shareholders with one or several owners of strategical importance for the Company. The issuance of shares and/or convertible bonds under this authorisation shall be made at a subscription price according to the prevailing market conditions at the time of the issuance of the shares and/or convertible bonds. For more information, please contact:Anders StormCEO, Sivers Semiconductors AB (publ)Email: anders.storm@sivers-semiconductors.comTel: +46 (0)70 262 63 90 Sivers Semiconductors AB (publ) is a leader in SATCOM, 5G, 6G, Photonics and Silicon Photonics that drivers innovation in global communications and sensor technology. Our business units, Photonics and Wireless, supply cutting-edge, integrated chips and modules critical for high-performance gigabit wireless and optical networks. Catering to a broad spectrum of industries from telecommunication to aerospace, we fulfill the increasing demand for computational speed and AI application performance, replacing electric with optical connections for a more sustainable world.Our wireless solutions are forging paths in advanced SATCOM/5G/6G systems, while our photonics expertise is revolutionizing custom semiconductor photonic devices for optical networks and optical sensing, making us a trusted partner to Fortune 100 companies as well as emerging unicorns. With innovation at our core, Sivers Semiconductors is committed to delivering bespoke, high-performance solutions for a better-connected and safer world. The company is listed on Nasdaq Stockholm under SIVE. The head office is located in Kista, Sweden. Discover our passion for perfection at www.sivers-semiconductors.com.

Interim report January – March 2024 Sweco AB (publ)

January–March 2024 · Net sales increased to SEK 7,720 million (7,140) · EBITA amounted to SEK 793 million (849), margin 10.3 per cent (11.9) · EBITA increased 16 per cent year-on-year after adjustment for the significant negative calendar effect in the quarter · EBIT amounted to SEK 778 million (839), margin 10.1 per cent (11.7) · Net debt amounted to SEK 3,118 million (2,916) · Net debt/EBITDA amounted to 1.1x (1.1) · Profit after tax decreased to SEK 558 million (625), corresponding to SEK 1.55 per share (1.75) Comments from President and CEO Åsa Bergman: "A positive start to the year Sweco delivered a good first quarter. Net sales increased 8 per cent and EBITA improved 16 per cent, adjusted for the significant negative calendar effect from Easter. The improvement was mainly driven by continued positive momentum in pricing as well as strong demand within the green transition in energy, transportation, industry and urban development. We are also seeing increasing demand in growth segments such as pharma, defence and data centres. Sweco’s strong market position is reflected in a growing order backlog.  Overall, the demand for Sweco’s services was favourable in most segments, although demand in residential and commercial buildings, as well as traditional industry, remained weaker. A solid quarter with operational improvements Net sales increased to SEK 7,720 million (7,140), with an organic growth of 4 per cent, adjusted for calendar. Nominally, EBITA decreased to SEK 793 million (849) and the margin to 10.3 per cent (11.9), both driven by the large negative calendar effect. Adjusted for calendar effects, EBITA increased 16 per cent or SEK 139 million.  The EBITA improvement was mainly driven by higher average fees, a growing number of employees and contribution from acquisitions, while higher personnel expenses and a lower billing ratio impacted negatively.  Six out of eight business areas reported positive organic growth and EBITA improvements. Sweco Belgium, Denmark and Sweden all reported good organic growth and EBITA improvements, with double-digit margins. Germany and Central Europe continued to improve operational performance with strong organic growth and an increasing EBITA and margin. Finland improved its margin in the quarter, partly driven by the previously communicated redundancy program, and is also taking further improvement actions. The Netherlands reported higher EBITA levels. The weaker performance in Norway is explained by the calendar effect from the early Easter holiday. The repositioning of Sweco’s UK business is progressing and the performance improved significantly compared to the previous quarter. As part of the turnaround, the UK is making further personnel reductions in the first half of 2024. Projects and acquisitions  The projects won in the first quarter highlight Sweco’s multi-disciplinary role in the green transition. In the Netherlands, Sweco won a SEK 1,100 million contract to support energy operator Gasunie in the development of new energy infrastructure for the transportation of hydrogen, carbon dioxide, renewable gas and heat. In Belgium, Sweco has been commissioned to design an open-access rail terminal in Zeebrugge’s back port and in Germany, Sweco will support the City of Bremen in the expansion of its public transportation. In Norway, we will provide architectural design to support a sustainable uplift of an urban area in Oslo.  In early January we closed the first acquisition this year – Econsultancy. With their team of 200 environmental experts, we are strengthening Sweco’s position and offering, both in the Netherlands and across Europe within ecological and environmental services. Priorities going forward Our focus ahead is clear: to capture growth opportunities in the market and deliver continued profitable growth, with improved margins. This requires investments in attractive segments in combination with firm measures to optimise our offering and efficiency. The actions we are taking in the UK, the adjustments of staffing in Finland, Norway and Sweden, and the ongoing organisational review to streamline our operations in all business areas are designed to drive efficiency. A lean, efficient and client-centric organisation has always been and will continue to be our recipe for success." Information meeting Sweco's President and CEO Åsa Bergman and CFO Olof Stålnacke will present the report in a webcast and teleconference on May 16 at 09:00 CET.  · Webcast registration: Click here  · Conference call registration: Click here 

Bioretec Ltd’s business review January–March 2024: Controlled launch in the U.S. progresses

This announcement summarizes Bioretec Ltd’s business review for January–March 2024. The complete business review is attached to this release as a PDF file and available on the company’s website at https://bioretec.com/investors/investors-in-english/releases. January–March 2024 in brief · Net sales amounted to EUR 682 thousand (1–3/2023: EUR 1,071 thousand). · The sales margin was EUR 478 (718) thousand, or 70.1% (67.0%) of net sales. The sales margin of 2024 includes other income of EUR 60 thousand accrued relating to the Business Finland grant. When excluding the grant effect, the sales margin for the current reporting period is EUR 418 thousand, or 61.3%. The main reason for the lower sales margin percentage has been the planned production shutdown due to the ramp-up of new production capacity. · EBITDA was EUR -1,112 (-491) thousand. EBITDA was EUR -1,112 (- 491) thousand. It was burdened by increased personnel costs due to headcount growth and additional fixed costs relating to U.S. commercialization and R&D projects. · The result for the reporting period amounted to EUR -1,097 (-557) thousand. This business review is unaudited. This is Bioretec’s first business review for the first quarter, and comparison period figures have not been published earlier. Key figures +-------------------------------------------+--------+--------+------+---------+|EUR 1,000 unless otherwise noted |1–3/2024|1–3/2023|Change|1–12/2023|+-------------------------------------------+--------+--------+------+---------+|Net sales |682 |1,071 |-36.4%|3,906 |+-------------------------------------------+--------+--------+------+---------+|Sales margin |478 |718 |-33.4%|2,810 |+-------------------------------------------+--------+--------+------+---------+|Sales margin, % of net sales |70.1% |67.0% | |71.9% |+-------------------------------------------+--------+--------+------+---------+|EBITDA |-1,112 |-491 |126.6%|-2,833 |+-------------------------------------------+--------+--------+------+---------+|EBIT |-1,139 |-543 |109.6%|-3,034 |+-------------------------------------------+--------+--------+------+---------+|Profit/-loss for the period (+/-) |-1,097 |-557 |97.0% |-3,789 |+-------------------------------------------+--------+--------+------+---------+|R&D spend on total costs, % |25.9% |24.8% | |25.6% |+-------------------------------------------+--------+--------+------+---------+|Equity ratio, % |74.3% |44.3% | |77.3% |+-------------------------------------------+--------+--------+------+---------+|Cash and cash equivalents at end of period |5,981 |587 |919.3%|6,910 |+-------------------------------------------+--------+--------+------+---------+|Number of personnel at end of period |39 |28 |39.3% |37 |+-------------------------------------------+--------+--------+------+---------+ Key events during the reporting period · European market authorization application for the RemeOsTM trauma screw proceeded to expert panel evaluation. The approval is estimated to be granted during the second quarter of 2024. · Bioretec was granted an FDA Breakthrough Device Designation status for its RemeOs™ Spinal Interbody Cage. · Bioretec’s RemeOs™ biodegradable magnesium alloy composition was granted a patent by the U.S. Patent Office. Timo Lehtonen, CEO of Bioretec Ltd: ” In the first quarter of 2024, our focus was on the production and distribution of our Activa product line as the U.S. market continued to utilize inventories of the RemeOs™ trauma screw from Q4 2023. Net sales this quarter were distinctly marked by contributions from different regions: Europe accounted for 27% of net sales (19% in the comparison period), the U.S. increased from 16% to 24%, while the rest of the world decreased from 65% to 49%. The controlled launch of RemeOs™ trauma screw continued, with an evolving number of surgeries performed utilizing this innovative product. We are actively collecting and analyzing follow-up data from the surgeries to assess the efficacy of the fracture healing treated with our screws. In preparation for continued US sales growth, the need to enhance our production capabilities resulted in a planned production shutdown In January, which is reflected in our profitability numbers for this period. This operational enhancement included the commissioning, qualification, and ramp-up of the new CNC machine dedicated to our trauma screw line and increasing our resource allocation to operational personnel and projects, setting the stage for increased output in subsequent quarters. Looking ahead, we are waiting to receive market authorization for the RemeOs™ trauma screws in Europe during the second quarter of 2024. Our development efforts are ongoing for the next RemeOs™ pipeline products, supported by the new RemeOs™ magnesium alloy patent and the new FDA Breakthrough Device Designation received for the Spinal Interbody Cage. Additionally, we are advancing our plans for the next U.S. market authorization and initiating the RemeOs™ DrillPin clinical study in Austria, waiting for the ethical committee and other regulatory approvals to start the First-in-Human study. As we have concentrated on enhancing our production capabilities in the first quarter, we project that our net sales will be more heavily concentrated in the second half of the year. This strategic growth platform building has been required to expand production capabilities to serve the future anticipated market demand and product portfolio expansions. We are grateful to our investors, customers, and personnel for their continued confidence and support. Your trust encourages our commitment to innovation and excellence as we navigate these exciting opportunities and challenges.” Financial reporting in 2024 In 2024, Bioretec will publish the following financial reports: · half-year report for January–June 2024 on Thursday 15 August 2024 · business review for January–September 2024 on Thursday 14 November 2024 The releases will be available online at Bioretec Ltd’s website at https://bioretec.com/investors/investors-in-english/reports-and-presentations. Tampere, 16 May 2024 Board of Directors Bioretec Ltd Further inquiries: Timo LehtonenJohanna Salko CEOCFO +358 50 433 8493+358 40 754 8172 timo.lehtonen@bioretec.comjohanna.salko@bioretec.com Certified advisor: Nordic Certified Adviser AB, p. +46 70 551 67 29 Information about Bioretec Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.  Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark is expected to be received during the second quarter of 2024. Bioretec is positioning itself to enter the addressable over USD 7 billion global orthopedic trauma market and to become a game changer in surgical bone fracture treatment. Better healing – Better life. www.bioretec.com Appendix Bioretec Ltd’s business review January–March 2024 (pdf)

Judges and physicians have very different views about appointing a legal guardian for people with dementia

Dementia often leads to the appointment of a legal guardian for the individual affected, as their legal capacity diminishes as the disease progresses. Conducted in Finland, a recent study explored how physicians and legal experts perceive the association of the need for legal guardianship with the neuropsychiatric and cognitive symptoms of dementia. Cognitive symptoms of dementia include, e.g., memory impairment and language deficits, while neuropsychiatric symptoms include, e.g., impulsivity and sensitivity to stimuli. According to the study, the significance attributed to different symptoms varies greatly when assessing the need for legal guardianship. Significant differences of opinion were found both within and between the professional groups, and similar symptoms may even lead to entirely opposing conclusions, the study found. “The significance attributed to various symptoms is largely based on each professional’s personal views rather than on research evidence. In particular, subjective opinions were prominent in the interview responses of legal experts, which can undermine equality before the law of those who may need legal guardianship,” says Doctoral Researcher Kaisa Näkki of the University of Eastern Finland. According to the study, legal experts regarded memory impairment and dyscalculia as the most evident symptoms necessitating legal guardianship. However, opinions were divided regarding other symptoms. In particular, impulsivity as a neuropsychiatric symptom strongly divided the opinions of legal experts, as some of them regarded impulsivity as an expression of free will rather than as a symptom of progressive neurodegeneration. Physicians, on the other hand, regarded neuropsychiatric symptoms, and especially impulsivity, as the most evident symptom necessitating legal guardianship. Often, neuropsychiatric symptoms were found to necessitate legal guardianship already in the early or mild stages of dementia. Physicians were most consistent in their views of memory impairment being a factor that leads to the need for legal guardianship in the moderate stage of dementia. However, physicians’ perceptions of the significance of other symptoms varied greatly. “Our findings, combined with a lack of previous international research on this topic, indicate that there is an urgent need, both here in Finland and internationally, for a consensus definition of how various symptoms affect legal capacity in dementia. Decisions should not be based on the personal experiences of physicians or judges but on research evidence, which requires systematic data collection. Additionally, there is a need for training for both physicians and legal experts,” says Associate Professor of Clinical Research and Director of Brain Research Unit Eino Solje of the University of Eastern Finland. “Our study is the first to combine the perceptions of both physicians and legal experts on the need for legal guardianship. The fact that both medicine and law are represented in our team creates an interdisciplinary approach that opens up new avenues for research in these fields,” Professor of Law and Ageing Anna Mäki-Petäjä-Leinonen of the University of Eastern Finland says. The findings of the study can be used to improve the consistency of medical and legal assessments, and to ensure equal treatment of those who may need legal guardianship. “This study provides deeper insight into the weaknesses of guardianship assessment. The study is also the first step towards the development of relevant medico-legal criteria as well as towards broader collection of data internationally. Based on international data, it is possible to formulate uniform guidelines on the impact of cognitive and neuropsychiatric symptoms on legal capacity, and on the need for legal guardianship,” Näkki concludes. For further information, please contact: Doctoral Researcher Kaisa Näkki, University of Eastern Finland, Law School, Centre for Law and Welfare, kaisa.nakki@uef.fi, https://uefconnect.uef.fi/en/person/kaisa.nakki/ Professor of Law and Ageing Anna Mäki-Petäjä-Leinonen, University of Eastern Finland, Law School, Centre for Law and Welfare, anna.maki-petaja-leinonen@uef.fi,https://uefconnect.uef.fi/en/person/anna.maki-petaja-leinonen/ Associate Professor of Clinical Research, Director of the UEF Brain Research Unit Eino Solje, University of Eastern Finland, Institute of Clinical Medicine, eino.solje@uef.fi, https://uefconnect.uef.fi/en/person/eino.solje/ Research article: Näkki K, Mäki-Petäjä-Leinonen A, Ervasti K, et al. Diverging medical and legal perceptions of the need for legal guardianship in people with dementia: A qualitative study. Eur J Neurol. 2024;00:e16334https://doi.org/10.1111/ene.16334  10.5.2024

Metacon publishes interim report for Q1 2024

We have successfully secured access to world-leading technology and partners for our efforts to become a leading manufacturer of large-scale, industrial electrolysis plants, comments Christer Wikner, President and CEO. For the full CEO-comment, see the Interim report in its entirety. Quarter 1 January–31 March · Revenues amounted to SEK 8.3 (16.3) million. · Earnings before depreciation and amortization (EBITDA) amounted to SEK -14.5 (-12.7) million. · Operating profit (EBIT) amounted to SEK -17.2 (-15.4) million. · Profit/Loss after financial items amounted to SEK -18.2 (-15.5) million. · Earnings per share amounted to SEK -0,04 (-0.05). Events during and after the quarter · On January 25, 2024, Metacon announces an exclusive license agreement with PERIC for rights to build a "Gigafactory" for the manu-facture of its own electrolysis plants. · On January 25, 2024, the Board of Directors of Metacon announces a rights issue of units of approximately SEK 119 million and announces the terms of the rights issue. · On February 20, 2024, Metacon will announce the final outcome of the rights issue. · On April 10, it is announced that Mattias Jansson has been hired as Chief Financial Officer of Metacon AB (publ) with effect from July 1, 2024, replacing Göran Rasberg who plans to retire. · On May 7, a partnership with Siemens is announced for cooperation in the development of Metacon's technology portfolio and planned factory for the manufacture of large alkaline electrolysers. This information is information that Metacon AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 16 May 2024 at 08:00 CEST. For further information, please contact Christer Wikner, by phone 0707-647389 or e-mail info@metacon.com About  MetaconMetacon AB (publ) develops and manufactures energy systems for the production of fossil-free "green" hydrogen. The products in the Reforming business area are based, among other things, on a patented technology that generates hydrogen through so-called catalytic steam reforming of biogas or other hydrocarbons. The development of Metacon's reforming products is done within the wholly owned subsidiary Metacon S.A in Patras, Greece. The business is focused on catalytic process chemistry and advanced reformers for high-efficiency hydrogen production. Metacon also offers complete electrolysis plants and integrated refueling stations for green hydrogen, a large and globally growing area for the production of green hydrogen. Electrolysis is a process of driving a chemical reaction to split water by adding electricity. If the electricity used is non-fossil, the hydrogen will also be fossil-free and climate-neutral. Green hydrogen can be used in sectors such as transport, basic industry and the real estate sector, with a better environment and climate as a result. www.metacon.com For more information see:www.metacon.com | X: @Metaconab | LinkedIn: www.linkedin.com/company/metaconab

Invitation to the presentation of Calliditas´s interim report January – March 2024

A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast:  Calliditas Therapeutics Q1 Report 2024 (financialhearings.com)  To participate via conference call please register via this link: https://conference.financialhearings.com/teleconference/?id=50047214 After registration, you will receive a phone number and a conference ID to log in to the conference call. Via the telephone conference, there is an opportunity to ask oral questions.

Metso launches the first diesel-electric Lokotrack EC range units

Metso’s Lokotrack[®] EC range brings a new diesel-electric power line to the aggregates market. All the process functions of the range are electric, significantly reducing the use of hydraulic oil needed in the crushing operations. All Lokotrack EC range units can be powered with external electricity. In its Lokolaunch event in Tampere, Finland, Metso launched the first two products of the new EC range. Lokotrack LT400J is a 68-ton mobile jaw crusher designed for the primary crushing of hard rock and recycled aggregates. Lokotrack LT350C is a 50-ton mobile cone crusher for secondary and tertiary crushing. To reach high capacity, LT350C is equipped with the new Nordberg[®] HP350e cone crusher, while LT400J counts on the proven Nordberg[®] C120 jaw crusher. Both units can be seamlessly combined with each other as well as with the Lokotrack mobile screens to produce high quality aggregates. “When external electricity is available, the new electric power transmission provides high capacity with minimized operational cost and CO2 emissions. When not available, the onboard diesel gensets allow maximum independent operation time. Also, auxiliary units, such as mobile screens and stackers, can be powered from the same gensets, which will further reduce the needed power to run the complete plant,” says Jarmo Vuorenpää, Director, New Lokotrack Offering at Metso. Lokotrack EC range has been developed using new, modular architecture, which reduces the number of components and provides scalable solutions that can be adapted for different applications and capacities. “The new way to do product development enables a faster and more agile way to meet the changing customer needs. Furthermore, it enables more efficient support for the machines with less parts needed and easier upgrades of new features,” says Renaud Lapointe, Senior Vice President of Metso Products business line in the Aggregates business area. All the components of the new EC range are designed and tested to perform in demanding conditions to reach maximum uptime for the customers. Safety and usability have been given special attention. The design of the LT400J and LT350C fulfills the latest safety standard while being easier to use than ever. With new digital tools, the units can be operated safely from the excavator and be quickly set from transport to operation. About Metso’s Lokotrack[®] range The concept of track-mounted crushers and screens was developed in Finland in 1985 to minimize cost and energy use. Lokotrack units are ideal for processing both natural aggregates and recycled materials. Lokotrack EC is a new diesel-electric range that complements the existing offering. Lokotrack EC range contributes significantly to Metso’s Planet Positive offering with lower CO2 emissions when operated with electric power. It also helps reduce carbon footprint due to the lower need for hydraulic oil. Further information can be found on our website at Lokotrack EC - Metso .  Further information:    Jarmo Vuorenpää, Director, Aggregates, New Lokotrack offering, Metso, tel. +358 20 484 100, email: jarmo.vuorenpaa(at)metso.com     Helena Marjaranta, Vice President, Communications and Brand, Metso Corporation, tel. +358 20 484 3212, email: helena.marjaranta(at)metso.com     Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.     Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com, x.com/metsoofficial